Selected CGRP antagonists, processes for preparing them and their use as pharmaceutical compositions

ABSTRACT

The present invention relates to the CGRP antagonists of general formula I 
                         
wherein R 1 , R 2 , R 3  and R 4  are as defined in claim  1 , the tautomers, the isomers, the diastereomers, the enantiomers, the hydrates thereof, the mixtures thereof and the salts thereof and the hydrates of the salts thereof, particularly the physiologically acceptable salts thereof with inorganic or organic acids or bases, as well as those compounds of general formula I wherein one or more hydrogen atoms are replaced by deuterium, pharmaceutical compositions containing these compounds, their use and processes for preparing them.

The present invention relates to the CGRP antagonists of general formulaI

wherein R¹, R², R³ and R⁴ are as defined herein, the tautomers, theisomers, the diastereomers, the enantiomers, the hydrates thereof, themixtures thereof and the salts thereof and the hydrates of the saltsthereof, particularly the physiologically acceptable salts thereof withinorganic or organic acids or bases, as well as those compounds ofgeneral formula I wherein one or more hydrogen atoms are replaced bydeuterium, pharmaceutical compositions containing these compounds, theiruse and processes for preparing them.

PRIOR ART

CGRP antagonists for the treatment of migraine have already beendescribed in International Patent Applications PCT/EP97/04862 andPCT/EP03/11762.

DETAILED DESCRIPTION OF THE INVENTION

In the above general formula I in a first embodiment

-   R¹ denotes a group selected from

wherein

-   -   R^(1.1) denotes H or H₃C—O,

-   R² denotes a group selected from

-   R³ denotes a group of general formula II

wherein

-   -   X denotes N or C,    -   R^(3.1) denotes H, C₁₋₃-alkyl or R^(3.1.1)—O—C(O),    -   R^(3.1.1) denotes H, C₁₋₆-alkyl, H₂N—C₂₋₄-alkylene,        (C₁₋₃-alkyl)-NH—C₂₋₄-alkylene, (C₁₋₃-alkyl)₂N—C₂₋₄-alkylene,        H₂N—C(O)—C₁₋₃-alkylene, (C₁₋₃-alkyl)-NH—C(O)—C₁₋₃-alkylene,        (C₁₋₃-alkyl)₂N—C(O)—C₁₋₃-alkylene or R^(3.1.1.1)—C₂₋₄-alkylene,    -   R^(3.1.1.1) denotes a group selected from

-   -   R^(3.2) denotes a pair of free electrons, if X=N, or    -   R^(3.2) denotes H, C₁₋₃-alkyl or R^(3.2.1)—O—C(O), if X=C,    -   R^(3.2.1) denotes H, C₁₋₆-alkyl, H₂N—C₂₋₄-alkylene,        (C₁₋₃-alkyl)-NH—C₂₋₄-alkylene, (C₁₋₃-alkyl)₂N—C₂₋₄-alkylene,        H₂N—C(O)—C₁₋₃-alkylene, (C₁₋₃-alkyl)-NH—C(O)—C₁₋₃-alkylene,        (C₁₋₃-alkyl)₂N—C(O)—C₁₋₃-alkylene or R^(3.2.1.1)—C₂₋₄-alkylene,    -   R^(3.2.1.1) denotes a group selected from

-   R⁴ denotes a group of general formulae III

wherein

-   -   Y denotes C and    -   R^(4.1) denotes H or C₁₋₃-alkyl, or    -   Y denotes N and    -   R^(4.1) denotes a pair of free electrons,    -   with the proviso that X and Y do not simultaneously represent N,    -   R^(4.2) denotes H, C₁₋₃-alkyl or R^(4.2.1)—O—C(O),    -   R^(4.2.1) denotes H, C₁₋₆-alkyl, H₂N—C₂₋₄-alkylene,        (C₁₋₃-alkyl)-NH—C₂₋₄-alkylene, (C₁₋₃-alkyl)₂N—C₂₋₄-alkylene,        H₂N—C(O)—C₁₋₃-alkylene, (C₁₋₃-alkyl)-NH—C(O)—C₁₋₃-alkylene,        (C₁₋₃-alkyl)₂N—C(O)—C₁₋₃-alkylene or R^(4.2.1.1)—C₂₋₄-alkylene,    -   R^(4.2.1.1) denotes a group selected from

-   -   and    -   R^(4.3) denotes H, C₁₋₆-alkyl, H₂N—C₂₋₄-alkylene,        (C₁₋₃-alkyl)-NH—C₂₋₄-alkylene, (C₁₋₃-alkyl)₂N—C₂₋₄-alkylene,        H₂N—C(O)—C₁₋₃-alkylene, (C₁₋₃-alkyl)-NH—C(O)—C₁₋₃-alkylene,        (C₁₋₃-alkyl)₂N—C(O)—C₁₋₃-alkylene or R^(4.3.1—C) ₂₋₄-alkylene,    -   R^(4.3.1) denotes a group selected from

-   R^(5.1) denotes H, C₁₋₃-alkyl, R^(5.1.1)—O—C(O),    R^(5.1.1)—O—C(O)—C₁₋₃-alkylene-NH,    R^(5.1.1)—O—C(O)—C₁₋₃-alkylene-N(C₁₋₃-alkyl),    R^(5.1.1)—O—C(O)—C₁₋₃-alkylene-O, R^(5.1.1)—O—C(O)—C₁₋₃-alkylene,    R^(5.1.1)—O—C(O)—C(O), R^(5.1.1)—O—C(O)—C(O)—O,    R^(5.1.1)—O—C(O)—C₁₋₃-alkylene-C(O) or    R^(5.1.1)—O—C(O)—C₁₋₃-alkylene-C(O)—O,    -   R^(5.1.1) denotes H, C₁₋₈-alkyl, phenyl, indanyl,        pyridyl-C₁₋₃-alkylene, HO—C₂₋₄-alkylene,        C₁₋₆-alkyl-O—C₂₋₄-alkylene, H₂N—C₂₋₄-alkylene,        (C₁₋₆-alkyl)-NH—C₂₋₄-alkylene, (C₁₋₆-alkyl)₂N—C₂₋₄-alkylene,        H₂N—C(O)—C₁₋₃-alkylene, (C₁₋₆-alkyl)-NH—C(O)—C₁₋₃-alkylene,        (C₁₋₆-alkyl)₂N—C(O)—C₁₋₃-alkylene,        C₁₋₆-alkyl-C(O)—O—C₁₋₃-alkylene,        C₁₋₆-alkyl-O—C(O)—O—C₁₋₃-alkylene,        R^(5.1.1.1)—C(O)—C₁₋₃-alkylene or R^(5.1.1.2)—C₂₋₄-alkylene,    -   R^(5.1.1.1) denotes a group selected from

-   -   R^(5.1.1.2) denotes a group selected from

-   R^(5.2) denotes H, C₁₋₃-alkyl, R^(5.2.1)—O—C(O)—C₁₋₃-alkylene-NH,    R^(5.2.1)—O—C(O)—C₁₋₃-alkylene-O, R^(5.2.1)—O—C(O)—C₁₋₃-alkylene,    R^(5.2.1)—O—C(O)—C(O) or R^(5.2.1)—O—C(O)—C₁₋₃-alkylene-C(O),    -   R^(5.2.1) denotes H, C₁₋₈-alkyl, phenyl, indanyl,        pyridyl-C₁₋₃-alkylene, HO—C₂₋₄-alkylene,        C₁₋₆-alkyl-O—C₂₋₄-alkylene,        C₁₋₆-alkyl-O—C₂₋₄-alkylene-O—C₂₋₄-alkylene, H₂N—C₂₋₄-alkylene,        (C₁₋₆-alkyl)-NH—C₂₋₄-alkylene, (C₁₋₆-alkyl)₂N—C₂₋₄-alkylene,        H₂N—C(O)—C₁₋₃-alkylene, (C₁₋₆-alkyl)-NH—C(O)—C₁₋₃-alkylene,        (C₁₋₆-alkyl)₂N—C(O)—C₁₋₃-alkylene,        C₁₋₆-alkyl-C(O)—O—C₁₋₃-alkylene,        C₁₋₆-alkyl-O—C(O)—O—C₁₋₃-alkylene,        R^(5.2.1.1)—C(O)—C₁₋₃-alkylene or R^(5.2.1.2)—C₂₋₄-alkylene,    -   R^(5.2.1.1) denotes a group selected from

-   -   R^(5.2.1.2) denotes a group selected from

-   -   R^(5.2.1) denotes a group of formula

-   with the proviso that at least one of the groups R^(3.1), R^(3.2),    R^(4.2), R^(5.1) or R^(5.2) denotes a group other than H or    C₁₋₃-alkyl,    the tautomers, the diastereomers, the enantiomers, the hydrates, the    mixtures thereof and the salts thereof as well as the hydrates of    the salts thereof, particularly the physiologically acceptable salts    thereof with inorganic or organic acids or bases.

A preferred first embodiment of the present invention consists of thecompounds of the above general formula I, wherein

-   R¹ denotes a group selected from

wherein

-   -   R^(1.1) denotes H or H₃C—O,

-   R² denotes a group selected from

-   R³ denotes a group of general formula II

wherein

-   -   X denotes N or C,    -   R^(3.1) denotes H, C₁₋₃-alkyl or HO—C(O),    -   R^(3.2) denotes a pair of free electrons, if X=N, or    -   R^(3.2) denotes H, C₁₋₃-alkyl or HO—C(O), if X=C,

-   R⁴ denotes a group of general formulae III

wherein

-   -   Y denotes C and    -   R^(4.1) denotes H or C₁₋₃-alkyl, or    -   Y denotes N and    -   R^(4.1) denotes a pair of free electrons,    -   with the proviso that X and Y do not simultaneously represent N,    -   R^(4.2) denotes H, C₁₋₃-alkyl or HO—C(O),

-   R^(5.1) denotes H, C₁₋₃-alkyl, HO—C(O), HO—C(O)—C₁₋₃-alkylene-NH,    HO—C(O)—C₁₋₃-alkylene-N(C₁₋₃-alkyl), HO—C(O)—C₁₋₃-alkylene-O,    HO—C(O)—C₁₋₃-alkylene, HO—C(O)—C(O),HO—C(O)—C(O)—O,    HO—C(O)—C₁₋₃-alkylene-C(O) or HO—C(O)—C₁₋₃-alkylene-C(O)—O,

-   R^(5.2) denotes H, C₁₋₃-alkyl, HO—C(O)—C₁₋₃-alkylene-NH,    HO—C(O)—C₁₋₃-alkylene-O, HO—C(O)—C₁₋₃-alkylene, HO—C(O)—C(O) or    HO—C(O)—C₁₋₃-alkylene-C(O),

-   with the proviso that at least one of the groups R^(3.1), R^(3.2),    R^(4.2), R^(5.1) or R^(5.2) denotes a group other than H or    C₁₋₃-alkyl,    the tautomers, the diastereomers, the enantiomers, the hydrates, the    mixtures thereof and the salts thereof as well as the hydrates of    the salts thereof, particularly the physiologically acceptable salts    thereof with inorganic or organic acids or bases.

A second embodiment of the present invention consists of the compoundsof the above general formula I, wherein

-   R¹ denotes a group selected from

wherein

-   -   R^(1.1) denotes H or H₃C—O,

-   R² denotes a group selected from

-   R³ denotes a group of general formula II

wherein

-   -   X denotes N or C,    -   R^(3.1) denotes H, C₁₋₃-alkyl or R^(3.1.1)—(O)C,    -   R^(3.1.1) denotes HO, C₁₋₆-alkyl-O,    -   R^(3.2) denotes a pair of free electrons, if X=N, or    -   R^(3.2) denotes H or C₁₋₃-alkyl, if X=C,

-   R⁴ denotes a group of general formulae III

wherein

-   -   Y denotes C and    -   R^(4.1) denotes H or C₁₋₃-alkyl, or    -   Y denotes N and    -   R^(4.1) denotes a pair of free electrons,    -   with the proviso that X and Y do not simultaneously represent N,    -   R^(4.2) denotes H, C₁₋₃-alkyl or R^(4.2.1)—(O)C,    -   R^(4.2.1) denotes HO, C₁₋₆-alkyl-O, and    -   R^(4.3) denotes H, C₁₋₆-alkyl, H₂N—C₂₋₄-alkylene,        (C₁₋₃-alkyl)-NH—C₂₋₄-alkylene, (C₁₋₃-alkyl)₂N—C₂₋₄-alkylene,        H₂N—C(O)—C₁₋₃-alkylene, (C₁₋₃-alkyl)-NH—C(O)—C₁₋₃-alkylene,        (C₁₋₃-alkyl)₂N—C(O)—C₁₋₃-alkylene or R^(4.3.1)—C₂₋₄-alkylene,    -   R^(4.3.1) denotes a group selected from

-   R^(5.1) denotes R^(5.1.1)—O—C(O), R^(5.1.1)—O—C(O)—C₁₋₃-alkylene-NH,    R^(5.1.1)—O—C(O)—C₁₋₃-alkylene-O, R^(5.1.1)—O—C(O)—C₁₋₃-alkylene,    R^(5.1.1)—O—C(O)—C(O) or R^(5.1.1)—O—C(O)—C₁₋₃-alkylene-C(O),    -   R^(5.1.1) denotes H, C₁₋₈-alkyl, phenyl, indanyl,        pyridyl-C₁₋₃-alkylene, HO—C₂₋₄-alkylene,        C₁₋₆-alkyl-O—C₂₋₄-alkylene, H₂N—C₂₋₄-alkylene,        (C₁₋₆-alkyl)-NH—C₂₋₄-alkylene, (C₁₋₆-alkyl)₂N—C₂₋₄-alkylene,        H₂N—C(O)—C₁₋₃-alkylene, (C₁₋₆-alkyl)-NH—C(O)—C₁₋₃-alkylene,        (C₁₋₆-alkyl)₂N—C(O)—C₁₋₃-alkylene,        C₁₋₆-alkyl-C(O)—O—C₁₋₃-alkylene,        C₁₋₆-alkyl-O—C(O)—O—C₁₋₃-alkylene,        R^(5.1.1.1)—C(O)—C₁₋₃-alkylene or R^(5.1.1.2)—C₂₋₄-alkylene,    -   R^(5.1.1.1) denotes a group selected from

-   -   R^(5.1.1.2) denotes a group selected from

-   R^(5.2) denotes R^(5.2.1)—O—C(O)—C₁₋₃-alkylene-NH,    R^(5.2.1)—O—C(O)—C₁₋₃-alkylene-O, R^(5.2.1)—O—C(O)—C₁₋₃-alkylene,    R^(5.2.1)—O—C(O)—C(O) or R^(5.2.1)—O—C(O)—C₁₋₃-alkylene-C(O),    -   R^(5.2.1) denotes H, C₁₋₈-alkyl, phenyl, indanyl,        pyridyl-C₁₋₃-alkylene, HO—C₂₋₄-alkylene,        C₁₋₆-alkyl-O—C₂₋₄-alkylene, H₂N—C₂₋₄-alkylene,        (C₁₋₆-alkyl)-NH—C₂₋₄-alkylene, (C₁₋₆-alkyl)₂N—C₂₋₄-alkylene,        H₂N—C(O)—C₁₋₃-alkylene, (C₁₋₆-alkyl)-NH—C(O)—C₁₋₃-alkylene,        (C₁₋₆-alkyl)₂N—C(O)—C₁₋₃-alkylene,        C₁₋₆-alkyl-C(O)—O—C₁₋₃-alkylene,        C₁₋₆-alkyl-O—C(O)—O—C₁₋₃-alkylene,        R^(5.2.1.1)—C(O)—C₁₋₃-alkylene or R^(5.2.1.2)—C₂₋₄-alkylene,    -   R^(5.2.1.1) denotes a group selected from

-   -   R^(5.2.1.2) denotes a group selected from

the tautomers, the diastereomers, the enantiomers, the hydrates, themixtures thereof and the salts thereof as well as the hydrates of thesalts thereof, particularly the physiologically acceptable salts thereofwith inorganic or organic acids or bases.

A preferred second embodiment of the present invention consists of thecompounds of the above general formula I, wherein

-   R¹ denotes a group selected from

wherein

-   -   R^(1.1) denotes H or H₃C—O,

-   R² denotes a group selected from

-   R³ denotes a group of general formula II

wherein

-   -   X denotes N or C,    -   R^(3.1) denotes H, C₁₋₃-alkyl or HO—C(O),    -   R^(3.2) denotes a pair of free electrons, if X=N, or    -   R^(3.2) denotes H or C₁₋₃-alkyl, if X=C,

-   R⁴ denotes a group of general formulae III

wherein

-   -   Y denotes C and    -   R^(4.1) denotes H or C₁₋₃-alkyl, or    -   Y denotes N and    -   R^(4.1) denotes a pair of free electrons,    -   with the proviso that X and Y do not simultaneously represent N,    -   R^(4.2) denotes H, C₁₋₃-alkyl or HO—C(O),

-   R^(5.1) denotes HO—C(O), HO—C(O)—C₁₋₃-alkylene-NH,    HO—C(O)—C₁₋₃-alkylene-O, HO—C(O)—C₁₋₃-alkylene, HO—C(O)—C(O) or    HO—C(O)—C₁₋₃-alkylene-C(O),

-   R^(5.2) denotes HO—C(O)—C₁₋₃-alkylene-NH, HO—C(O)—C₁₋₃-alkylene-O,    HO—C(O)—C₁₋₃-alkylene, HO—C(O)—C(O) or HO—C(O)—C₁₋₃-alkylene-C(O),    the tautomers, the diastereomers, the enantiomers, the hydrates, the    mixtures thereof and the salts thereof as well as the hydrates of    the salts thereof, particularly the physiologically acceptable salts    thereof with inorganic or organic acids or bases.

A third embodiment of the present invention consists of the compounds ofthe above general formula I, wherein

-   R¹ denotes a group selected from

wherein

-   -   R^(1.1) denotes H or H₃C—O,

-   R² denotes a group selected from

-   R³—R⁴ together denote a group of general formulae IV

wherein

-   -   R^(3.1) denotes H, H₃C or R^(3.1.1)—O—C(O),    -   R^(3.1.1) denotes H, C₁₋₆-alkyl, (C₁₋₃-alkyl)₂N—C₂₋₄-alkylene,        (C₁₋₃-alkyl)₂N—C(O)—C₁₋₃-alkylene or R^(3.1.1.1)—C₂₋₄-alkylene,    -   R^(3.1.1.1) denotes a group selected from

-   -   R^(3.2) denotes H, C₁₋₃-alkyl or R^(3.2.1)—O—C(O),    -   R^(3.2.1) denotes H, C₁₋₆-alkyl, (C₁₋₃-alkyl)₂N—C₂₋₄-alkylene,        (C₁₋₃-alkyl)₂N—C(O)—C₁₋₃-alkylene or R^(3.2.1.1)—C₂₋₄-alkylene,    -   R^(3.2.1.1) denotes a group selected from

-   -   R^(4.1) denotes H or C₁₋₃-alkyl,    -   R^(4.2) denotes H, C₁₋₃-alkyl or R^(4.2.1)—O—C(O),    -   R^(4.2.1) denotes H, C₁₋₆-alkyl, (C₁₋₃-alkyl)₂N—C₂₋₄-alkylene,        (C₁₋₃-alkyl)₂N—C(O)—C₁₋₃-alkylene or R^(4.2.1.1)—C₂₋₄-alkylene,    -   R^(4.2.1.1) denotes a group selected from

-   -   R^(4.3) denotes H, C₁₋₆-alkyl, H₂N—C₂₋₄-alkylene,        (C₁₋₃-alkyl)-NH—C₂₋₄-alkylene, (C₁₋₃-alkyl)₂N—C₂₋₄-alkylene,        H₂N—C(O)—C₁₋₃-alkylene, (C₁₋₃-alkyl)-NH—C(O)—C₁₋₃-alkylene,        (C₁₋₃-alkyl)₂N—C(O)—C₁₋₃-alkylene or R^(4.3.1)—C₂₋₄-alkylene,    -   R^(4.3.1) denotes a group selected from

-   R^(5.1) denotes H, H₃C, R^(5.1.1)—O—C(O),    R^(5.1.1)—O—C(O)—C₁₋₃-alkylene-NH,    R^(5.1.1)—O—C(O)—C₁₋₃-alkylene-N(C₁₋₃-alkyl),    R^(5.1.1)—O—C(O)—C₁₋₃-alkylene-O, R^(5.1.1)—O—C(O)—C₁₋₃-alkylene,    R^(5.1.1)—O—C(O)—C(O), R^(5.1.1)—O—C(O)—C(O)—O,    R^(5.1.1)—O—C(O)—C₁₋₃-alkylene-C(O) or    R^(5.1.1)—O—C(O)—C₁₋₃-alkylene-C(O)—O,    -   R^(5.1.1) denotes H, C₁₋₈-alkyl, phenyl, indanyl,        pyridyl-C₁₋₃-alkylene, HO—C₂₋₄-alkylene,        C₁₋₆-alkyl-O—C₂₋₄-alkylene, H₂N—C₂₋₄-alkylene,        (C₁₋₆-alkyl)-NH—C₂₋₄-alkylene, (C₁₋₆-alkyl)₂N—C₂₋₄-alkylene,        H₂N—C(O)—C₁₋₃-alkylene, (C₁₋₆-alkyl)-NH—C(O)—C₁₋₃-alkylene,        (C₁₋₆-alkyl)₂N—C(O)—C₁₋₃-alkylene,        C₁₋₆-alkyl-C(O)—O—C₁₋₃-alkylene,        C₁₋₆-alkyl-O—C(O)—O—C₁₋₃-alkylene,        R^(5.1.1.1)—C(O)—C₁₋₃-alkylene or R^(5.1.1.2)—C₂₋₄-alkylene,    -   R^(5.1.1.1) denotes a group selected from

-   -   R^(5.1.1.2) denotes a group selected from

-   R^(5.2) denotes H, H₃C, R^(5.2.1)—O—C(O)—C₁₋₃-alkylene-NH,    R^(5.2.1)—O—C(O)—C₁₋₃-alkylene-O, R^(5.2.1)—O—C(O)—C₁₋₃-alkylene,    R^(5.2.1)—O—C(O)—C(O) or R^(5.2.1)—O—C(O)—C₁₋₃-alkylene-C(O),    -   R^(5.2.1) denotes H, C₁₋₈-alkyl, phenyl, indanyl,        pyridyl-C₁₋₃-alkylene, HO—C₂₋₄-alkylene,        C₁₋₆-alkyl-O—C₂₋₄-alkylene,        C₁₋₆-alkyl-O—C₂₋₄-alkylene-O—C₂₋₄-alkylene, H₂N—C₂₋₄-alkylene,        (C₁₋₆-alkyl)-NH—C₂₋₄-alkylene, (C₁₋₆-alkyl)₂N—C₂₋₄-alkylene,        H₂N—C(O)—C₁₋₃-alkylene, (C₁₋₆-alkyl)-NH—C(O)—C₁₋₃-alkylene,        (C₁₋₆-alkyl)₂N—C(O)—C₁₋₃-alkylene,        C₁₋₆-alkyl-C(O)—O—C₁₋₃-alkylene,        C₁₋₆-alkyl-O—C(O)—O—C₁₋₃-alkylene,        R^(5.2.1.1)—C(O)—C₁₋₃-alkylene or R^(5.2.1.2)—C₂₋₄-alkylene,    -   R^(5.2.1.1) denotes a group selected from

-   -   R^(5.2.1.2) denotes a group selected from

-   -   R^(5.2.1) denotes a group of formula

-   with the proviso that at least one of the groups R^(3.1), R^(3.2),    R^(4.2), R^(5.1) or R^(5.2) denotes a group other than H or    C₁₋₃-alkyl,    the tautomers, the diastereomers, the enantiomers, the hydrates, the    mixtures thereof and the salts thereof as well as the hydrates of    the salts thereof, particularly the physiologically acceptable salts    thereof with inorganic or organic acids or bases.

A preferred third embodiment of the present invention consists of thecompounds of the above general formula I, wherein

-   R¹ denotes a group selected from

wherein

-   -   R^(1.1) denotes H or H₃C—O,

-   R² denotes a group selected from

-   R³—R⁴ together denote a group of general formulae IV

wherein

-   -   R^(3.1) denotes H, H₃C or HO—C(O),    -   R^(3.2) denotes H, C₁₋₃-alkyl or HO—C(O),    -   R^(4.1) denotes H or C₁₋₃-alkyl,    -   R^(4.2) denotes H, C₁₋₃-alkyl or HO—C(O),

-   R^(5.1) denotes H, H₃C, HO—C(O), HO—C(O)—C₁₋₃-alkylene-NH,    HO—C(O)—C₁₋₃-alkylene-N(C₁₋₃-alkyl), HO—C(O)—C₁₋₃-alkylene-O,    HO—C(O)—C₁₋₃-alkylene, HO—C(O)—C(O),    HO—C(O)—C(O)—O—HO—C(O)—C₁₋₃-alkylene-C(O) or    HO—C(O)—C₁₋₃-alkylene-C(O)—O,

-   R^(5.2) denotes H, H₃C, HO—C(O)—C₁₋₃-alkylene-NH,    HO—C(O)—C₁₋₃-alkylene-O, HO—C(O)—C₁₋₃-alkylene, HO—C(O)—C(O) or    HO—C(O)—C₁₋₃-alkylene-C(O),

-   with the proviso that at least one of the groups R^(3.1), R^(3.2),    R^(4.2), R^(5.1) or R^(5.2) denotes a group other than H, H₃C or    C₁₋₃-alkyl,    the tautomers, the diastereomers, the enantiomers, the hydrates, the    mixtures thereof and the salts thereof as well as the hydrates of    the salts thereof, particularly the physiologically acceptable salts    thereof with inorganic or organic acids or bases.

A fourth embodiment of the present invention consists of the compoundsof the above general formula I, wherein

-   R¹ denotes a group selected from

wherein

-   -   R^(1.1) denotes H or H₃C—O,

-   R² denotes a group selected from

-   R³—R⁴ together denote a group of general formulae IV

wherein

-   -   R^(3.1) denotes H,    -   R^(3.2) denotes H or C₁₋₃-alkyl,    -   R^(4.1) denotes H or C₁₋₃-alkyl,    -   R^(4.2) denotes H,    -   R^(4.3) denotes H, C₁₋₆-alkyl, H₂N—C₂₋₄-alkylene,        (C₁₋₃-alkyl)-NH—C₂₋₄-alkylene, (C₁₋₃-alkyl)₂N—C₂₋₄-alkylene,        H₂N—C(O)—C₁₋₃-alkylene, (C₁₋₃-alkyl)-NH—C(O)—C₁₋₃-alkylene,        (C₁₋₃-alkyl)₂N—C(O)—C₁₋₃-alkylene or R^(4.3.1)—C₂₋₄-alkylene,    -   R^(4.3.1) denotes a group selected from

-   R^(5.1) denotes R^(5.1.1)—O—C(O), R^(5.1.1)—O—C(O)—C₁₋₃-alkylene-NH,    R^(5.1.1)—O—C(O)—C₁₋₃-alkylene-O, R^(5.1.1)—O—C(O)—C₁₋₃-alkylene,    R^(5.1.1)—C(O) or R^(5.1.1)—O—C(O)—C₁₋₃-alkylene-C(O),    -   R^(5.1.1) denotes H, C₁₋₈-alkyl, phenyl, indanyl,        pyridyl-C₁₋₃-alkylene, HO—C₂₋₄-alkylene,        C₁₋₆-alkyl-O—C₂₋₄-alkylene, H₂N—C₂₋₄-alkylene,        (C₁₋₆-alkyl)-NH—C₂₋₄-alkylene, (C₁₋₆-alkyl)₂N—C₂₋₄-alkylene,        H₂N—C(O)—C₁₋₃-alkylene, (C₁₋₆-alkyl)-NH—C(O)—C₁₋₃-alkylene,        (C₁₋₆-alkyl)₂N—C(O)—C₁₋₃-alkylene,        C₁₋₆-alkyl-C(O)—O—C₁₋₃-alkylene,        C₁₋₆-alkyl-O—C(O)—O—C₁₋₃-alkylene,        R^(5.1.1.1)—C(O)—C₁₋₃-alkylene or R^(5.1.1.2)—C₂₋₄-alkylene,    -   R^(5.1.1.1) denotes a group selected from

-   -   R^(5.1.1.2) denotes a group selected from

-   R^(5.2) denotes R^(5.2.1)—O—C(O)—C₁₋₃-alkylene-NH,    R^(5.2.1)—O—C(O)—C₁₋₃-alkylene-O, R^(5.2.1)—O—C(O)—C₁₋₃-alkylene,    R^(5.2.1)—O—C(O)—C(O) or R^(5.2.1)—O—C(O)—C₁₋₃-alkylene-C(O),    -   R^(5.2.1) denotes H, C₁₋₈-alkyl, phenyl, indanyl,        pyridyl-C₁₋₃-alkylene, HO—C₂₋₄-alkylene,        C₁₋₆-alkyl-O—C₂₋₄-alkylene, H₂N—C₂₋₄-alkylene,        (C₁₋₆-alkyl)-NH—C₂₋₄-alkylene, (C₁₋₆-alkyl)₂N—C₂₋₄-alkylene,        H₂N—C(O)—C₁₋₃-alkylene, (C₁₋₆-alkyl)-NH—C(O)—C₁₋₃-alkylene,        (C₁₋₆-alkyl)₂N—C(O)—C₁₋₃-alkylene,        C₁₋₆-alkyl-C(O)—O—C₁₋₃-alkylene,        C₁₋₆-alkyl-O—C(O)—O—C₁₋₃-alkylene,        R^(5.2.1.1)—C(O)—C₁₋₃-alkylene or R^(5.2.1.2)—C₂₋₄-alkylene,    -   R^(5.2.1.1) denotes a group selected from

-   -   R^(5.2.1.2) denotes a group selected from

the tautomers, the diastereomers, the enantiomers, the hydrates, themixtures thereof and the salts thereof as well as the hydrates of thesalts thereof, particularly the physiologically acceptable salts thereofwith inorganic or organic acids or bases.

A preferred fourth embodiment of the present invention consists of thecompounds of the above general formula I, wherein

-   R¹ denotes a group selected from

wherein

-   -   R^(1.1) denotes H or H₃C—O,

-   R² denotes a group selected from

-   R³—R⁴ together denote a group of general formulae IV

wherein

-   -   R^(3.1) denotes H,    -   R^(3.2) denotes H or C₁₋₃-alkyl,    -   R^(4.1) denotes H or C₁₋₃-alkyl,    -   R^(4.2) denotes H,

-   R^(5.1) denotes HO—C(O), HO—C(O)—C₁₋₃-alkylene-NH,    HO—C(O)—C₁₋₃-alkylene-O, HO—C(O)—C₁₋₃-alkylene, HO—C(O)—C(O) or    HO—C(O)—C₁₋₃-alkylene-C(O),

-   R^(5.2) denotes HO—C(O)—C₁₋₃-alkylene-NH, HO—C(O)—C₁₋₃-alkylene-O,    HO—C(O)—C₁₋₃-alkylene, HO—C(O)—C(O) or HO—C(O)—C₁₋₃-alkylene-C(O),    the tautomers, the diastereomers, the enantiomers, the hydrates, the    mixtures thereof and the salts thereof as well as the hydrates of    the salts thereof, particularly the physiologically acceptable salts    thereof with inorganic or organic acids or bases.

A fifth embodiment of the present invention consists of the compounds ofthe above general formula I, wherein

-   R¹ denotes a group selected from

wherein

-   -   R^(1.1) denotes H or H₃C—O,

-   R² denotes a group selected from

-   R³—R⁴ together denote a group of general formulae IV

wherein

-   -   R^(3.1) denotes H or R^(3.1.1)—O—C(O),    -   R^(3.1.1) denotes H, C₁₋₆-alkyl, (C₁₋₃-alkyl)₂N—C₂₋₄-alkylene,        (C₁₋₃-alkyl)₂N—C(O)—C₁₋₃-alkylene or R^(3.1.1.1)—C₂₋₄-alkylene,    -   R^(3.1.1.1) denotes a group

-   -   R^(3.2) denotes H, H₃C or R^(3.2.1)—O—C(O),    -   R^(3.2.1) denotes H, C₁₋₆-alkyl, (C₁₋₃-alkyl)₂N—C₂₋₄-alkylene,        (C₁₋₃-alkyl)₂N—C(O)—C₁₋₃-alkylene or R^(3.2.1.1)—C₂₋₄-alkylene,    -   R^(3.2.1.1) denotes a group

-   -   R^(4.2) denotes H or H₃C,    -   R^(4.3) denotes H, C₁₋₆-alkyl, (C₁₋₃-alkyl)₂N—C₂₋₄-alkylene,        (C₁₋₃-alkyl)₂N—C(O)—C₁₋₃-alkylene or R^(4.3.1)—-C₂₋₄-alkylene,    -   R^(4.3.1) denotes a group selected from

-   R^(5.1) denotes H, H₃C, R^(5.1.1)—O—C(O),    R^(5.1.1)—O—C(O)—C₁₋₃-alkylene-NH,    R^(5.1.1)—O—C(O)—C₁₋₃-alkylene-N(C₁₋₃-alkyl),    R^(5.1.1)—O—C(O)—C₁₋₃-alkylene-O, R^(5.1.1)—O—C(O)—C₁₋₃-alkylene,    R^(5.1.1)—O—C(O)—C(O),    R^(5.1.1)—O—C(O)—C(O)—O—R^(5.1.1)—O—C(O)—C₁₋₃-alkylene-C(O) or    R^(5.1.1)—O—C(O)—C₁₋₃-alkylene-C(O)—O,    -   R^(5.1.1) denotes H, C₁₋₈-alkyl, phenyl, indanyl, pyridyl-CH₂,        HO—C₂₋₄-alkylene, C₁₋₆-alkyl-O—C₂₋₄-alkylene, H₂N—C₂₋₄-alkylene,        (C₁₋₆-alkyl)-NH—C₂₋₄-alkylene, (C₁₋₆-alkyl)₂N—C₂₋₄-alkylene,        H₂N—C(O)—C₁₋₃-alkylene, (C₁₋₆-alkyl)-NH—C(O)—C₁₋₃-alkylene,        (C₁₋₆-alkyl)₂N—C(O)—C₁₋₃-alkylene,        C₁₋₆-alkyl-C(O)—O—C₁₋₃-alkylene,        C₁₋₆-alkyl-O—C(O)—O—C₁₋₃-alkylene,        R^(5.1.1.1)—C(O)—C₁₋₃-alkylene or R^(5.1.1.2)—C₂₋₄-alkylene,    -   R^(5.1.1.1) denotes a group selected from

-   -   R^(5.1.1.2) denotes a group selected from

-   R^(5.2) denotes H, H₃C, R^(5.2.1)—O—C(O)—C₁₋₃-alkylene,    R^(5.2.1)—O—C(O)—C(O) or R^(5.2.1)—O—C(O)—C₁₋₃-alkylene-C(O),    -   R^(5.2.1) denotes H, C₁₋₈-alkyl, phenyl, indanyl, pyridyl-CH₂,        HO—C₂₋₄-alkylene, C₁₋₆-alkyl-O—C₂₋₄-alkylene,        C₁₋₆-alkyl-O—C₂₋₄-alkylene-O—C₂₋₄-alkylene, H₂N—C₂₋₄-alkylene,        (C₁₋₆-alkyl)-NH—C₂₋₄-alkylene, (C₁₋₆-alkyl)₂N—C₂₋₄-alkylene,        H₂N—C(O)—C₁₋₃-alkylene, (C₁₋₆-alkyl)-NH—C(O)—C₁₋₃-alkylene,        (C₁₋₆-alkyl)₂N—C(O)—C₁₋₃-alkylene,        C₁₋₆-alkyl-C(O)—O—C₁₋₃-alkylene,        C₁₋₆-alkyl-O—C(O)—O—C₁₋₃-alkylene,        R^(5.2.1.1)—C(O)—C₁₋₃-alkylene or R^(5.2.1.2)—C₂₋₄-alkylene,    -   R^(5.2.1.1) denotes a group selected from

-   -   R^(5.2.1.2) denotes a group selected from

-   -   R^(5.2.1) denotes a group of formula

-   with the proviso that at least one of the groups R^(3.1), R^(3.2),    R^(4.2), R^(5.1) or R^(5.2) denotes a group other than H, H₃C or    C₁₋₃-alkyl,    the tautomers, the diastereomers, the enantiomers, the hydrates, the    mixtures thereof and the salts thereof as well as the hydrates of    the salts thereof, particularly the physiologically acceptable salts    thereof with inorganic or organic acids or bases.

A preferred fifth embodiment of the present invention consists of thecompounds of the above general formula I, wherein

-   R¹ denotes a group selected from

wherein

-   -   R^(1.1) denotes H or H₃C—O,

-   R² denotes a group selected from

-   R³—R⁴ together denote a group of general formulae IV

wherein

-   -   R^(3.1) denotes H or HO—C(O),    -   R^(3.2) denotes H, H₃C or HO—C(O),    -   R^(4.2) denotes H or H₃C,

-   R^(5.1) denotes HO—C(O), HO—C(O)—C₁₋₃-alkylene-NH,    HO—C(O)—C₁₋₃-alkylene-N(C₁₋₃-alkyl), HO—C(O)—C₁₋₃-alkylene-O,    HO—C(O)—C₁₋₃-alkylene, HO—C(O)—C(O), HO—C(O)—C(O)—O,    HO—C(O)—C₁₋₃-alkylene-C(O) or HO—C(O)—C₁₋₃-alkylene-C(O)—O,

-   R^(5.2) denotes HO—C(O)—C₁₋₃-alkylene, HO—C(O)—C(O) or    HO—C(O)—C₁₋₃-alkylene-C(O),

-   with the proviso that at least one of the groups R^(3.1), R^(3.2),    R^(4.2), R^(5.1) or R^(5.2) denotes a group other than H, H₃C or    C₁₋₃-alkyl,    the tautomers, the diastereomers, the enantiomers, the hydrates, the    mixtures thereof and the salts thereof as well as the hydrates of    the salts thereof, particularly the physiologically acceptable salts    thereof with inorganic or organic acids or bases.

A sixth embodiment of the present invention consists of the compounds ofthe above general formula I, wherein

-   R¹ denotes a group selected from

wherein

-   -   R^(1.1) denotes H or H₃C—O,

-   R² denotes a group selected from

-   R³—R⁴ together denote a group of general formulae IV

wherein

-   -   R^(4.3) denotes H, C₁₋₆-alkyl, (C₁₋₃-alkyl)₂N—C₂₋₄-alkylene,        (C₁₋₃-alkyl)₂N—C(O)—C₁₋₃-alkylene or R^(4.3.1)—C₂₋₄-alkylene,    -   R^(4.3.1) denotes a group selected from

-   -   R^(5.1) denotes R^(5.1.1)—O—C(O),        R^(5.1.1)—O—C(O)—C₁₋₃-alkylene-NH,        R^(5.1.1)—O—C(O)—C₁₋₃-alkylene-O,        R^(5.1.1)—O—C(O)—C₁₋₃-alkylene, R^(5.1.1)—O—C(O)—C(O) or        R^(5.1.1)—O—C(O)—C₁₋₃-alkylene-C(O),    -   R^(5.1.1) denotes H, C₁₋₈-alkyl, phenyl, indanyl, pyridyl-CH₂,        HO—C₂₋₄-alkylene, C₁₋₆-alkyl-O—C₂₋₄-alkylene, H₂N—C₂₋₄-alkylene,        (C₁₋₆-alkyl)-NH—C₂₋₄-alkylene, (C₁₋₆-alkyl)₂N—C₂₋₄-alkylene,        H₂N—C(O)—C₁₋₃-alkylene, (C₁₋₆-alkyl)-NH—C(O)—C₁₋₃-alkylene,        (C₁₋₆-alkyl)₂N—C(O)—C₁₋₃-alkylene,        C₁₋₆-alkyl-C(O)—O—C₁₋₃-alkylene,        C₁₋₆-alkyl-O—C(O)—O—C₁₋₃-alkylene,        R^(5.1.1.1)—C(O)—C₁₋₃-alkylene or R^(5.1.1.2)—C₂₋₄-alkylene,    -   R^(5.1.1.1) denotes a group selected from

-   -   R^(5.1.1.2) denotes a group selected from

-   R^(5.2) denotes R^(5.2.1)—O—C(O)—C₁₋₃-alkylene,    R^(5.2.1)—O—C(O)—C(O) or R^(5.2.1)—O—C(O)—C₁₋₃-alkylene-C(O),    -   R^(5.2.1) denotes H, C₁₋₈-alkyl, phenyl, indanyl, pyridyl-CH₂,        HO—C₂₋₄-alkylene, C₁₋₆-alkyl-O—C₂₋₄-alkylene, H₂N—C₂₋₄-alkylene,        (C₁₋₆-alkyl)-NH—C₂₋₄-alkylene, (C₁₋₆-alkyl)₂N—C₂₋₄-alkylene,        H₂N—C(O)—C₁₋₃-alkylene, (C₁₋₆-alkyl)-NH—C(O)—C₁₋₃-alkylene,        (C₁₋₆-alkyl)₂N—C(O)—C₁₋₃-alkylene,        C₁₋₆-alkyl-C(O)—O—C₁₋₃-alkylene,        C₁₋₆-alkyl-O—C(O)—O—C₁₋₃-alkylene,        R^(5.2.1.1)—C(O)—C₁₋₃-alkylene or R^(5.2.1.2)—C₂₋₄-alkylene,    -   R^(5.2.1.1) denotes a group selected from

-   -   R^(5.2.1.2) denotes a group selected from

the tautomers, the diastereomers, the enantiomers, the hydrates, themixtures thereof and the salts thereof as well as the hydrates of thesalts thereof, particularly the physiologically acceptable salts thereofwith inorganic or organic acids or bases.

A preferred sixth embodiment of the present invention consists of thecompounds of the above general formula I, wherein

-   R¹ denotes a group selected from

wherein

-   -   R^(1.1) denotes H or H₃C—O,

-   R² denotes a group selected from

-   R³—R⁴ together denote a group of general formulae IV

-   R^(5.1) denotes HO—C(O), HO—C(O)—C₁₋₃-alkylene-NH,    HO—C(O)—C₁₋₃-alkylene-O, HO—C(O)—C₁₋₃-alkylene, HO—C(O)—C(O) or    HO—C(O)—C₁₋₃-alkylene-C(O),-   R^(5.2) denotes HO—C(O)—C₁₋₃-alkylene, HO—C(O)—C(O) or    HO—C(O)—C₁₋₃-alkylene-C(O),    the tautomers, the diastereomers, the enantiomers, the hydrates, the    mixtures thereof and the salts thereof as well as the hydrates of    the salts thereof, particularly the physiologically acceptable salts    thereof with inorganic or organic acids or bases.

A seventh embodiment of the present invention consists of the compoundsof the above general formula I, wherein

-   R¹ denotes a group selected from

wherein

-   -   R^(1.1) denotes H or H₃C—O,

-   R² denotes a group selected from

-   R³—R⁴ together denote a group of formulae IV

the tautomers, the diastereomers, the enantiomers, the hydrates, themixtures thereof and the salts thereof as well as the hydrates of thesalts thereof, particularly the physiologically acceptable salts thereofwith inorganic or organic acids or bases.

The following compounds are also mentioned as examples of mostparticularly preferred compounds of the above general formula I:

No. Structure (1)

(2)

(3)

(4)

(5)

(6)

(7)

(8)

(9)

(10)

(11)

(12)

(13)

(14)

(15)

(16)

(17)

(18)

(19)

(20)

(21)

(22)

(23)

(24)

(25)

(26)

(27)

(28)

(29)

(30)

(31)

(32)

(33)

(34)

(35)

(36)

(37)

(38)

(39)

(40)

(41)

(42)

(43)

(44)

(45)

(46)

(47)

(48)

(49)

(50)

(51)

(52)

(53)

(54)

(55)

(56)

(57)

(58)

(59)

(60)

(61)

(62)

(63)

(64)

(65)

(66)

(67)

(68)

(69)

(70)

(71)

(72)

(73)

(74)

(75)

(76)

(77)

(78)

(79)

(80)

(81)

(82)

(83)

(84)

(85)

(86)

(87)

(88)

(89)

(90)

(91)

(92)

(93)

(94)

(95)

(96)

(97)

(98)

(99)

(100)

(101)

(102)

(103)

(104)

(105)

(106)

(107)

(108)

(109)

(110)

(111)

(112)

(113)

(114)

(115)

(116)

(117)

(118)

(119)

(120)

(121)

(122)

(123)

(124)

(125)

(126)

(127)

(128)

(129)

(130)

(131)

(132)

(133)

(134)

(135)

(136)

(137)

(138)

(139)

(140)

(141)

(142)

(143)

(144)

(145)

(146)

(147)

(148)

(149)

(150)

(151)

(152)

(153)

(154)

(155)

(156)

(157)

(158)

(159)

(160)

(161)

(162)

(163)

(164)

(165)

(166)

(167)

(168)

(169)

(170)

(171)

(172)

(173)

(174)

(175)

(176)

(177)

(178)

(179)

(180)

(181)

(182)

(183)

(184)

(185)

(186)

(187)

(188)

(189)

(190)

(191)

(192)

(193)

(194)

(195)

(196)

(197)

(198)

(199)

(200)

(201)

(202)

(203)

(204)

(205)

(206)

(207)

(208)

(209)

(210)

(211)

(212)

(213)

(214)

(215)

(216)

(217)

(218)

(219)

(220)

(221)

(222)

(223)

(224)

(225)

(226)

(227)

(228)

(229)

(230)

(231)

(232)

(233)

(234)

(235)

(236)

(237)

(238)

(239)

(240)

(241)

(242)

(243)

(244)

(245)

(246)

(247)

(248)

(249)

(250)

(251)

(252)

(253)

(254)

(255)

(256)

(257)

(258)

(259)

(260)

(261)

(262)

(263)

(264)

(265)

(266)

(267)

(268)

(269)

(270)

(271)

(272)

(273)

(274)

(275)

(276)

(277)

(278)

(279)

(280)

(281)

(282)

(283)

(284)

(285)

(286)

(287)

(288)

(289)

(290)

(291)

(292)

(293)

(294)

(295)

(296)

(297)

(298)

(299)

(300)

(301)

(302)

(303)

(304)

(305)

(306)

(307)

(308)

(309)

(310)

(311)

(312)

(313)

(314)

(315)

(316)

(317)

(318)

(319)

(320)

(321)

(322)

(323)

(324)

(325)

(326)

(327)

(328)

(329)

(330)

(331)

(332)

(333)

(334)

(335)

(336)

(337)

(338)

(339)

(340)

(341)

(342)

(343)

(344)

(345)

(346)

(347)

(348)

(349)

(350)

(351)

(352)

(353)

(354)

(355)

(356)

(357)

(358)

(359)

(360)

(361)

(362)

(363)

(364)

(365)

(366)

(367)

(368)

(369)

(370)

(371)

(372)

(373)

(374)

(375)

(376)

(377)

(378)

(379)

(380)

(381)

(382)

(383)

(384)

(385)

(386)

(387)

(388)

(389)

(390)

(391)

(392)

(393)

(394)

(395)

(396)

(397)

(398)

(399)

(400)

(401)

(402)

(403)

(404)

(405)

(406)

(407)

(408)

(409)

(410)

(411)

(412)

(413)

(414)

(415)

(416)

(417)

(418)

(419)

(420)

(421)

(422)

(423)

(424)

(425)

(426)

(427)

(428)

(429)

(430)

(431)

(432)

(433)

(434)

(435)

(436)

(437)

(438)

(439)

(440)

(441)

(442)

(443)

(444)

(445)

(446)

(447)

(448)

(449)

(450)

(451)

(452)

(453)

(454)

(455)

(456)

(457)

(458)

(459)

(460)

(461)

(462)

(463)

(464)

(465)

(466)

(467)

(468)

(469)

(470)

(471)

(472)

(473)

(474)

(475)

(476)

(477)

(478)

(479)

(480)

(481)

(482)

(483)

(484)

(485)

(486)

(487)

(488)

(489)

(490)

(491)

(492)

(493)

(494)

(495)

(496)

(497)

(498)

(499)

(500)

(501)

(502)

(503)

(504)

(505)

(506)

(507)

(508)

(509)

(510)

(511)

(512)

(513)

(514)

(515)

(516)

(517)

(518)

(519)

(520)

(521)

(522)

(523)

(524)

(525)

(526)

(527)

(528)

(529)

(530)

(531)

(532)

(533)

(534)

(535)

(536)

(537)

(538)

(539)

(540)

(541)

(542)

(543)

(544)

(545)

(546)

(547)

(548)

(549)

(550)

(551)

(552)

(553)

(554)

(555)

(556)

(557)

the tautomers, the diastereomers, the enantiomers, the hydrates, themixtures thereof and the salts thereof as well as the hydrates of thesalts thereof, particularly the physiologically acceptable salts thereofwith inorganic or organic acids or bases.

Terms And Definitions Used

Unless otherwise stated, all the substituents are independent of oneanother. If for example there are a plurality of C₁₋₆-alkyl groups assubstituents in one group, in the case of three C₁₋₆-alkyl substituents,independently of one another, one may represent methyl, one n-propyl andone tert-butyl.

Within the scope of this application, in the definition of possiblesubstituents, these may also be represented in the form of a structuralformula. If present, an asterisk (*) in the structural formula of thesubstituent is to be understood as being the linking point to the restof the molecule.

The subject-matter of this invention also includes the compoundsaccording to the invention, including the salts thereof, wherein one ormore hydrogen atoms, for example one, two, three, four or five hydrogenatoms, are replaced by deuterium.

By the term “C₁₋₃-alkyl” (including those which are part of othergroups) are meant branched and unbranched alkyl groups with 1 to 3carbon atoms, by the term “C₁₋₆-alkyl” are meant branched and unbranchedalkyl groups with 1 to 6 carbon atoms and by the term “C₁₋₈-alkyl” aremeant branched and unbranched alkyl groups with 1 to 8 carbon atoms.Examples include: methyl, ethyl, n-propyl, iso-propyl, n-butyl,iso-butyl, sec-butyl, tert-butyl, n-pentyl, iso-pentyl, neo-pentyl,hexyl, heptyl and octyl. The following abbreviations may optionally alsobe used for the above-mentioned groups: Me, Et, n—Pr, i—Pr, n-Bu, i-Bu,t-Bu, etc. Unless stated otherwise, the definitions propyl, butyl,pentyl, hexyl, heptyl or octyl include all the possible isomeric formsof the groups in question. Thus, for example, propyl includes n-propyland iso-propyl, butyl includes iso-butyl, sec-butyl and tert-butyl etc.

By the term “C₁₋₃-alkylene” (including those which are part of othergroups) are meant branched and unbranched alkylene groups with 1 to 3carbon atoms and by the term “C₂₋₄-alkylene” are meant branched andunbranched alkylene groups with 2 to 4 carbon atoms. Examples include:methylene, ethylene, ethane-1,1-diyl, propylene, propane-2,2-diyl,1-methylethylene, butylene, 1-methylpropylene, 1,1-dimethylethylene,1,2-dimethylethylene. Unless stated otherwise, the definitions propyleneand butylene include all the possible isomeric forms with the samenumber of carbons. Thus, for example, propyl also includes1-methylethylene and butylene includes 1-methylpropylene,1,1-dimethylethylene, 1,2-dimethylethylene.

It should also be mentioned that within the scope of the presentinvention the terms “alkylene” and “alkylenyl” are used synonymously.

Compounds of general formula I may have acid groups, mainly carboxylgroups, and/or basic groups such as e.g. amino functions. Compounds ofgeneral formula I may therefore be present as internal salts, as saltswith pharmaceutically useable inorganic acids such as for examplehydrobromic acid, phosphoric acid, nitric acid, hydrochloric acid,sulphuric acid, methanesulphonic acid, ethanesulphonic acid,benzenesulphonic acid, p-toluenesulphonic acid or organic acids such asfor example malic acid, succinic acid, acetic acid, fumaric acid, maleicacid, mandelic acid, lactic acid, tartaric acid, citric acid or as saltswith pharmaceutically useable bases such as alkali or alkaline earthmetal hydroxides, e.g. sodium hydroxide or potassium hydroxide, orcarbonates, ammonia, zinc or ammonium hydroxides or organic amines suchas e.g. diethylamine, triethylamine, ethanolamine, diethanolamine,triethanolamine, cyclohexylamine, dicyclohexylamine, inter alia.

The invention relates to the compounds in question, optionally in theform of the individual optical isomers, mixtures of the individualenantiomers or racemates, in the form of the tautomers as well as in theform of the free bases or the corresponding acid addition salts withpharmacologically acceptable acids—such as for example acid additionsalts with hydrohalic acids—for example hydrochloric or hydrobromicacid—or organic acids—such as for example oxalic, fumaric, diglycolic ormethanesulphonic acid.

Methods of Preparation

The compounds of general formula I are prepared by methods known inprinciple. The following methods have proved particularly useful forpreparing the compounds of general formula I according to the invention:

(a) For preparing compounds of general formula I wherein all the groupsare as hereinbefore defined:

-   coupling a carboxylic acid of general formula V

-   wherein R¹ and R² are as hereinbefore defined, with an amine of    general formula VI    H—R³—R⁴-   wherein R³ and R⁴ are as hereinbefore defined, the linking taking    place via the nitrogen atom of R³.

Before the reaction is carried out any carboxylic acid functions,primary or secondary amino functions or hydroxy functions present in thegroups of the amine of formula H—R³—R⁴ may be protected by conventionalprotective groups and after the reaction has taken place any protectivegroups used may be cleaved again using methods familiar to those skilledin the art.

The coupling is preferably carried out using methods known from peptidechemistry (cf. e.g. Houben-Weyl, Methoden der Organischen Chemie, Vol.15/2), for example using carbodiimides such as e.g.dicyclohexylcarbodiimide (DCC), diisopropyl carbodiimide (DIC) orethyl-(3-dimethylaminopropyl)-carbodiimide,O-(1H-benzotriazol-1-yl)-N,N-N′,N′-tetramethyluroniumhexafluorophosphate (HBTU) or tetrafluoroborate (TBTU) or1H-benzotriazol-1-yl-oxy-tris-(dimethylamino)-phosphoniumhexafluorophosphate (BOP). By adding 1-hydroxybenzotriazole (HOBt) or3-hydroxy-4-oxo-3,4-dihydro-1,2,3-benzotriazine (HOObt) the reactionspeed can be increased. The couplings are normally carried out withequimolar amounts of the coupling components as well as the couplingreagent in solvents such as dichloromethane, tetrahydrofuran,acetonitrile, dimethyl formamide (DMF), dimethyl acetamide (DMA),N-methylpyrrolidone (NMP) or mixtures thereof and at temperaturesbetween −30° C. and +30° C., preferably −20° C. and +25° C. Ifnecessary, N-ethyl-diisopropylamine (Hünig base) is preferably used asan additional auxiliary base.

The so-called “anhydride process” is used as a further coupling methodfor synthesising compounds of general formula I (cf. also: M. Bodanszky,“Peptide Chemistry”, Springer-Verlag 1988, p. 58-59; M. Bodanszky,“Principles of Peptide Synthesis”, Springer-Verlag 1984, p. 21-27). TheVaughan variant of the “mixed anhydride process” is preferred (J. R.Vaughan Jr., J. Amer. Chem. Soc. 73, 3547 (1951)), in which the mixedanhydride of the carboxylic acid of general formula V which is to becoupled and monoisobutyl carbonate is obtained, using isobutylchlorocarbonate in the presence of bases such as 4-methylmorpholine or4-ethylmorpholine. The preparation of this mixed anhydride and thecoupling with the amines of general formula VI are carried out in aone-pot process, using the above-mentioned solvents and at temperaturesbetween −20° C. and +25° C., preferably 0° C. and +25° C.

(b) For preparing compounds of general formula I wherein all the groupsare as hereinbefore defined:

-   coupling a compound of general formula VII

-   wherein R¹ and R² are as hereinbefore defined and Nu denotes a    leaving group, for example a halogen atom, such as the chlorine,    bromine or iodine atom, an alkylsulphonyloxy group with 1 to 10    carbon atoms in the alkyl moiety, a phenyl-sulphonyloxy or    naphthylsulphonyloxy group optionally mono-, di- or trisubstituted    by chlorine or bromine atoms, by methyl or nitro groups, wherein the    substituents may be identical or different, a 1H-imidazol-1-yl, a    1H-pyrazol-1-yl optionally substituted by one or two methyl groups    in the carbon skeleton, a 1H-1,2,4-triazol-1-yl,    1H-1,2,3-triazol-1-yl, 1H-1,2,3,4-tetrazol-1-yl, a vinyl, propargyl,    p-nitrophenyl, 2,4-dinitrophenyl, trichlorophenyl,    pentachlorophenyl, pentafluorophenyl, pyranyl or pyridinyl, a    dimethylaminyloxy, 2(1H)-oxopyridin-1-yl-oxy,    2,5-dioxo-pyrrolidin-1-yloxy, phthalimidyloxy,    1H-benzotriazol-1-yloxy or azide group, with an amine of general    formula VI    H—R³—R⁴-   wherein all the groups are as hereinbefore defined and the link is    effected via the nitrogen atom of the amine R³.

Before the reaction is carried out any carboxylic acid functions,primary or secondary amino functions or hydroxy functions present in thegroups of the amine of general formula VI may be protected byconventional protective groups and after the reaction has taken placeany protective groups used may be cleaved again using methods familiarto those skilled in the art.

The reaction is carried out under Schotten-Baumann or Einhornconditions, i.e. the components are reacted in the presence of at leastone equivalent of an auxiliary base at temperatures between −50° C. and+120° C., preferably −10° C. and +30° C., and optionally in the presenceof solvents. The auxiliary bases used are preferably alkali metal andalkaline earth metal hydroxides, e.g. sodium hydroxide, potassiumhydroxide or barium hydroxide, alkali metal carbonates, e.g. sodiumcarbonate, potassium carbonate or caesium carbonate, alkali metalacetates, e.g. sodium or potassium acetate, as well as tertiary amines,e.g. pyridine, 2,4,6-trimethylpyridine, quinoline, triethylamine,N-ethyl-diisopropylamine, N-ethyl-dicyclohexylamine,1,4-diazabicyclo[2,2,2]octane or 1,8-diazabicyclo[5,4,0]undec-7-ene, thesolvents used may be, for example, dichloromethane, tetrahydrofuran,1,4-dioxane, acetonitrile, dimethyl formamide, dimethyl acetamide,N-methyl-pyrrolidone or mixtures thereof; if alkali metal or alkalineearth metal hydroxides, alkali metal carbonates or acetates are used asthe auxiliary bases, water may also be added to the reaction mixture ascosolvent.

The new compounds of general formula I according to the inventioncontain one or more chiral centres. If for example there are two chiralcentres present, the compounds may occur in the form of twodiastereomeric pairs of antipodes. The invention includes the individualisomers as well as the mixtures thereof.

The diastereomers may be separated on the basis of their differentphysico-chemical properties, e.g. by fractional crystallisation fromsuitable solvents, by high pressure liquid or column chromatography,using chiral or preferably non-chiral stationary phases.

Racemates covered by general formula I may be separated for example byHPLC on suitable chiral stationary phases (e.g. Chiral AGP, ChiralpakAD). Racemates which contain a basic or acidic function can also beseparated via the diastereomeric, optically active salts which areproduced on reacting with an optically active acid, for example (+) or(−)-tartaric acid, (+) or (−)-diacetyl tartaric acid, (+) or(−)-monomethyl tartrate or (+) or (−)-camphorsulphonic acid, or anoptically active base, for example with (R)—(+)-1-phenylethylamine,(S)—(−)-1-phenylethylamine or (S)-brucine.

According to a conventional method of separating isomers, the racemateof a compound of general formula I is reacted with one of theabovementioned optically active acids or bases in equimolar amounts in asolvent and the resulting crystalline, diastereomeric, optically activesalts thereof are separated using their different solubilities. Thisreaction may be carried out in any type of solvent provided that it issufficiently different in terms of the solubility of the salts.Preferably, methanol, ethanol or mixtures thereof, for example in aratio by volume of 50:50, are used. Then each of the optically activesalts is dissolved in water, carefully neutralised with a base such assodium carbonate or potassium carbonate, or with a suitable acid, e.g.with dilute hydrochloric acid or aqueous methanesulphonic acid, and inthis way the corresponding free compound is obtained in the (+) or (−)form.

The (R) or (S) enantiomer alone or a mixture of two optically activediastereomeric compounds covered by general formula I may also beobtained by performing the syntheses described above with a suitablereaction component in the (R) or (S) configuration.

The hydroxycarboxylic acids of general formula V needed as startingcompounds may be obtained by reacting piperidines of general formulaVIII

wherein R¹ is as hereinbefore defined, with carbonic acid derivatives ofgeneral formula IX

wherein Y¹ and Y² represent nucleofugic groups, which may be identicalor different, preferably the chlorine atom, the p-nitrophenoxy ortrichloromethoxy group,and with compounds of general formula X

wherein R² is as hereinbefore defined and Z¹ denotes a protective groupfor a carboxy group, for example a C₁₋₆-alkyl or an optionallysubstituted benzyl group, wherein the alkyl groups may be straight-chainor branched and the benzyl group may be substituted by one or twomethoxy groups.

Preferably Z¹ denotes the methyl, ethyl, tert-butyl or benzyl group.Before the reaction is carried out any hydroxy functions present in thegroup R² of a compound of formula (VI) may be protected by conventionalprotective groups and after the reaction is complete any protectivegroups used may be cleaved again using methods familiar to the skilledman.

In a first step the compounds of general formula VIII are reacted withthe carbonic acid derivatives of general formula IX in a solvent, forexample in dichloromethane, THF, pyridine or mixtures thereof, at atemperature between −20° C. to 50° C. in the presence of a base, forexample triethylamine, pyridine or ethyldiisopropylamine. Theintermediate thus formed may be purified or reacted further withoutpurification. The reaction of these intermediates with compounds ofgeneral formula X also takes place in one of the above-mentionedsolvates and at the temperatures specified above, in the presence of abase, such as triethylamine or pyridine, with or without the addition ofan activating reagent, such as e.g. 4-dimethylaminopyridine. To activatethem the compounds of general formula X may also be deprotonated using ametal hydride, such as e.g. NaH or KH, while in this case there is noneed for the base or the activating reagent to be present.

The starting compounds of formula VIII and IX are either commerciallyobtainable, known from the literature or may be prepared using methodsknown from the literature.

One way of obtaining compounds of general formula X comprises reactingaldehydes of general formula XI

wherein R² is as hereinbefore defined, with N-acetylglycine in aceticanhydride as solvent in the presence of alkali metal acetate, preferablysodium or potassium acetate, at suitable temperatures, preferably at 80to 130° C.

The azlactones obtained as primary product are hydrolysed without beingisolated to form the compounds of general formula XII

wherein R² is as hereinbefore defined. By further reaction in thepresence of aqueous inorganic acids, such as sulphuric, phosphoric orhydrochloric acid, but preferably hydrochloric acid, compounds ofgeneral formula XIII are obtained

wherein R² is as hereinbefore defined.

These are then converted with suitable reducing agents into thecompounds of general formula XIV

wherein R² is as hereinbefore defined.

Suitable reducing agents are alkali metal borohydrides, such as sodiumor potassium borohydride. Other suitable reducing agents arechlorodialkylboranes, such as chlorodicyclohexylborane. If chiralchlorodialkylboranes, such as e.g. B-chlorodiisopinocampheylborane, areused, the compounds of general formula XIV may be isolated inenantiomerically pure form. The further reaction of compounds of generalformula XIV to form compounds of general formula X is carried out in analcoholic medium, preferably in methanol or ethanol, in the presence ofa suitable acid, such as hydrochloric acid. Alternatively, the reactionmay be carried out by reacting with thionyl chloride in alcoholicsolvents, preferably methanol.

All the compounds of general formula I which contain primary orsecondary amino, hydroxy or hydroxycarbonyl functions are preferablyobtained from precursors with protective groups. Examples of protectivegroups for amino functions include a benzyloxycarbonyl, 2-nitrobenzyloxycarbonyl, 4-nitro-benzyloxycarbonyl,4-methoxy-benzyloxycarbonyl, 2-chloro-benzyloxycarbonyl,3-chloro-benzyloxycarbonyl, 4-chloro-benzyloxycarbonyl,4-biphenylyl-α,α-dimethyl-benzyl-oxycarbonyl or3,5-dimethoxy-α,α-dimethyl-benzyloxycarbonyl group, an alkoxycarbonylgroup with a total of 1 to 5 carbon atoms in the alkyl moiety, forexample the methoxycarbonyl, ethoxycarbonyl, n-propoxycarbonyl,iso-propoxycarbonyl, n-butoxycarbonyl, 1-methyl propoxycarbonyl,2-methyl propoxy-carbonyl or tert-butyloxycarbonyl group, theallyloxycarbonyl, 2,2,2-trichloro-(1,1-dimethylethoxy)carbonyl or9-fluorenylmethoxycarbonyl group or a formyl, acetyl or trifluoracetylgroup.

Examples of protective groups for hydroxy functions include atrimethylsilyl, triethylsilyl, triisopropyl, tert-butyldimethylsilyl ortert-butyldiphenylsilyl group, a tert-butyl, benzyl, 4-methoxybenzyl or3,4-dimethoxybenzyl group.

Examples of protective groups for hydroxycarbonyl functions include analkyl group with a total of 1 to 5 carbon atoms, for example the methyl,ethyl, n-propyl, isopropyl, n-butyl, tert-butyl, allyl,2,2,2-trichloroethyl, benzyl or 4-methoxybenzyl group.

The compounds of general formula I obtained may, if they containsuitable basic functions, be converted, particularly for pharmaceuticaluse, into their physiologically acceptable salts with inorganic ororganic acids. Suitable acids include for example hydrochloric acid,hydrobromic acid, phosphoric acid, nitric acid, sulphuric acid,methanesulphonic acid, ethanesulphonic acid, benzenesulphonic acid,p-toluenesulphonic acid, acetic acid, fumaric acid, succinic acid,lactic acid, mandelic acid, malic acid, citric acid, tartaric acid ormaleic acid.

Moreover, if they contain a carboxylic acid function, the new compoundsof formula I may be converted into the addition salts thereof withinorganic or organic bases, particularly, for pharmaceutical use, intotheir physiologically acceptable addition salts. Suitable bases for thisinclude for example sodium hydroxide, potassium hydroxide, ammonia,cyclohexylamine, dicyclohexylamine, ethanolamine, diethanolamine andtriethanolamine.

The present invention relates to racemates if the compounds of generalformula I have only one chiral element. However, the application alsoincludes the individual diastereomeric pairs of antipodes or mixturesthereof which are obtained if there is more than one chiral element inthe compounds of general formula I, as well as the individual opticallyactive enantiomers of which the above-mentioned racemates are made up.

Also included in the subject matter of this invention are the compoundsaccording to the invention, including the salts thereof, in which one ormore hydrogen atoms, for example one, two, three, four or five hydrogenatoms, are replaced by deuterium.

The new compounds of general formula I and the physiologicallyacceptable salts thereof have valuable pharmacological properties, basedon their selective CGRP-antagonistic properties. The invention furtherrelates to pharmaceutical compositions containing these compounds, theiruse and the preparation thereof. The new compounds mentioned above andthe physiologically acceptable salts thereof have CGRP-antagonisticproperties and exhibit good affinities in CGRP receptor binding studies.The compounds display CGRP-antagonistic properties in thepharmacological test systems described hereinafter.

The following experiments were carried out to demonstrate the affinityof the above-mentioned compounds for human CGRP-receptors and theirantagonistic properties:

A. Binding Studies with SK-N-MC Cells (Expressing the Human CGRPReceptor)

SK-N-MC cells are cultivated in “Dulbecco's modified Eagle medium”. Themedium is removed from confluent cultures. The cells are washed twicewith PBS buffer (Gibco 041-04190 M), detached by the addition of PBSbuffer mixed with 0.02% EDTA, and isolated by centrifuging. Afterresuspension in 20 ml of “Balanced Salts Solution” [BSS (in mM): NaCl120, KCl 5.4, NaHCO₃ 16.2, MgSO₄ 0.8, NaHPO₄ 1.0, CaCl₂ 1.8, D-glucose5.5, HEPES 30, pH 7.40] the cells are centrifuged twice at 100×g andresuspended in BSS. After the number of cells has been determined, thecells are homogenised using an Ultra-Turrax and centrifuged for 10minutes at 3000×g. The supernatant is discarded and the pellet isrecentrifuged in Tris buffer (10 mM Tris, 50 mM NaCl, 5 mM MgCl₂, 1 mMEDTA, pH 7.40) enriched with 1% bovine serum albumin and 0.1%bacitracin, and resuspended (1 ml/1000000 cells). The homogenisedproduct is frozen at −80° C. The membrane preparations are stable formore than 6 weeks under these conditions.

After thawing, the homogenised product is diluted 1:10 with assay buffer(50 mM Tris, 150 mM NaCl, 5 mM MgCl₂, 1 mM EDTA, pH 7.40) andhomogenised for 30 seconds with an Ultra-Turrax. 230 μl of thehomogenised product are incubated for 180 minutes at ambient temperaturewith 50 pM ¹²⁵I-iodotyrosyl-Calcitonin-Gene-Related Peptide (Amersham)and increasing concentrations of the test substances in a total volumeof 250 μl. The incubation is ended by rapid filtration throughGF/B-glass fibre filters treated with polyethyleneimine (0.1%) using acell harvester. The protein-bound radioactivity is measured using agamma counter. Non-specific binding is defined as the boundradioactivity after the presence of 1 μM human CGRP-alpha duringincubation.

The concentration binding curves are analysed using computer-aidednon-linear curve fitting.

The compounds mentioned hereinbefore show IC₅₀ values≦10000 nM in thetest described.

B. CGRP Antagonism in SK-N-MC Cells

SK-N-MC cells (1 million cells) are washed twice with 250 μl incubationbuffer (Hanks' HEPES, 1 mM 3-isobutyl-1-methylxanthine, 1% BSA, pH 7.4)and pre-incubated at 37° C. for 15 minutes. After the addition of CGRP(10 μl) as agonist in increasing concentrations (10⁻¹¹ to 10⁻⁶ M), oradditionally the substance in 3 to 4 different concentrations, themixture is incubated for another 15 minutes.

Intracellular cAMP is then extracted by the addition of 20 μl of 1 M HCland centrifugation (2000×g, 4° C., for 15 minutes). The supernatants arefrozen in liquid nitrogen and stored at −20° C.

The cAMP contents of the samples are determined by radioimmunoassay(Messrs. Amersham) and the pA₂ values of antagonistically actingsubstances are determined graphically.

The compounds according to the invention exhibit CGRP-antagonisticproperties in the in vitro test model described, in a dosage rangebetween 10⁻¹² and 10⁻⁵ M.

Indications

In view of their pharmacological properties the compounds according tothe invention and the salts thereof with physiologically acceptableacids are thus suitable for the acute and prophylactic treatment ofheadaches, particularly migraine or cluster headaches and tensionheadaches. Moreover, the compounds according to the invention also havea positive effect on the following diseases: non-insulin-dependentdiabetes mellitus (“NIDDM”), cardiovascular diseases, morphinetolerance, diarrhoea caused by clostridium toxin, skin diseases,particularly thermal and radiation-induced skin damage includingsunburn, lichen, pruritis, pruritic toxidermies and severe itching,inflammatory diseases, e.g. inflammatory diseases of the joints(osteoarthritis, rheumatoid arthritis, neurogenic arthritis),generalised soft-tissue rheumatism (fibromyalgia), neurogenicinflammation of the oral mucosa, inflammatory lung diseases, allergicrhinitis, asthma, COPD, diseases accompanied by excessive vasodilatationand resultant reduced blood supply to the tissues, e.g. shock andsepsis, chronic pain, e.g. diabetic neuropathies, neuropathies inducedby chemotherapy, HIV-induced neuropathies, postherpetic neuropathies,neuropathies induced by tissue trauma, trigeminal neuralgias,temporomandibular dysfunctions, CRPS (complex regional pain syndrome),back pain, and visceral complaints, such as e.g. irritable bowelsyndrome (IBS) and inflammatory bowel syndrome. In addition, thecompounds according to the invention have a general pain-relievingeffect. The symptoms of menopausal hot flushes caused by vasodilatationand increased blood flow in oestrogen-deficient women andhormone-treated patients with prostate carcinoma and castrated men arefavourably affected by the CGRP antagonists of the present applicationin a preventive and acute-therapeutic capacity, this therapeuticapproach being distinguished from hormone replacement by the absence ofside effects.

Preferably, the compounds according to the invention are suitable forthe acute and prophylactic treatment of migraine and cluster headaches,for treating irritable bowel syndrome (IBS) and for the preventive andacute-therapeutic treatment of hot flushes in oestrogen-deficient women.

The dosage required to achieve a corresponding effect is conveniently0.0001 to 3 mg/kg of body weight, preferably 0.01 to 1 mg/kg of bodyweight, when administered intravenously or subcutaneously, and 0.01 to10 mg/kg of body weight, preferably 0.1 to 10 mg/kg of body weight whenadministered orally, nasally or by inhalation, 1 to 3× a day in eachcase.

If the treatment with CGRP antagonists and/or CGRP release inhibitors isgiven as a supplement to conventional hormone replacement, it isadvisable to reduce the doses specified above, in which case the dosagemay be from 1/5 of the lower limits mentioned above up to 1/1 of theupper limits specified.

CGRP is released by sensory nerves, e.g. the trigeminal nerve, whichinnervates part of the skin of the face. It has already been shown thatirritation of the trigeminal ganglion in humans leads to an increase inthe CGRP plasma level and causes redness of the face ([4]: P. J. Goadsbyet al., Annals of Neurology, Vol. 23, No. 2, 1988, 193-196).

To demonstrate that hot flushes can be successfully treated with CGRPantagonists of general formula I, an increased release of endogenousCGRP was produced in marmosets by stimulating the trigeminal ganglion,leading to increased bloodflow through the blood vessels in the skin.The effectiveness was characterised by determining the particular dose,administered i.v., which reduces the increased blood flow through thefacial skin caused by endogenous CGRP by 50%. A detailed description ofthe method is disclosed in European Patent EP 1 207 884 B1.

The CGRP antagonists according to the invention are also active in amodel for visceral pain in rodents. In this model, hypersensitivity ofthe visceral system is achieved by irritating the gut by instillingchemical substances such as e.g. butyrate, trinitrobenzenesulphonic acidor acetic acid. The hypersensitivity of the gut is determined, forexample, by means of the number of abdominal contractions. These occurafter the expansion of a balloon introduced into the gut and areincreased in a hypersensitive gut (Bourdu et al., Gastroenterology 2005,128, 1996-2008; Diop et al., J. Phamacol. Exp. Ther. 2002, 302,1013-1022; Plourde et al. Am. J. Physiol. 1997, 273, G191-G196).

As they reverse the hypersensitivity of the gut in the model described,the CGRP antagonists according to the invention may be used for thetreatment of IBS (irritable bowel syndrome).

The invention further relates to the use of the compounds according tothe invention as valuable adjuvants for the production and purification(by affinity chromatography) of antibodies as well as in RIA and ELISAassays, after suitable radioactive labelling, for example by tritiationof suitable precursors, for example by catalytic hydrogenation withtritium or replacing halogen atoms with tritium, and as a diagnostic oranalytical adjuvant in neurotransmitter research.

Combinations

Categories of active substance which may be used in combination includee.g. antiemetics, prokinetics, neuroleptics, antidepressants, neurokininantagonists, anticonvulsants, histamine-H1-receptor antagonists,β-blockers, α-agonists and α-antagonists, ergot alkaloids, mildanalgesics, non-steroidal antiphlogistics, corticosteroids, calciumantagonists, 5-HT_(1B/1D)-agonists or other anti-migraine agents whichmay be formulated together with one or more inert conventional carriersand/or diluents, e.g. with corn starch, lactose, glucose,microcrystalline cellulose, magnesium stearate, polyvinyl pyrrolidone,citric acid, tartaric acid, water, water/ethanol, water/glycerol,water/sorbitol, water/polyethylene glycol, propylene glycol,cetylstearyl alcohol, carboxymethylcellulose or fatty substances such ashard fat or suitable mixtures thereof, into conventional galenicpreparations such as plain or coated tablets, capsules, powders,suspensions, solutions, metered dose aerosols or suppositories.

Thus other active substances which may be used for the combinationsmentioned above include for example the non-steroidal antiinflammatoriesaceclofenac, acemetacin, acetylsalicylic acid, acetaminophen(paracetamol), azathioprine, diclofenac, diflunisal, fenbufen,fenoprofen, flurbiprofen, ibuprofen, indometacin, ketoprofen,leflunomide, lornoxicam, mefenamic acid, naproxen, phenylbutazone,piroxicam, sulphasalazine, zomepirac or the pharmaceutically acceptablesalts thereof as well as meloxicam and other selective COX2-inhibitors,such as for example rofecoxib, valdecoxib, parecoxib, etoricoxib andcelecoxib, as well as substances that inhibit earlier or later stages ofprostaglandin synthesis or prostaglandin receptor antagonists such ase.g. EP2-receptor antagonists and IP-receptor antagonists.

It is also possible to use ergotamine, dihydroergotamine,metoclopramide, domperidone, diphenhydramine, cyclizine, promethazine,chlorpromazine, vigabatrin, timolol, isometheptene, pizotifen, botox,gabapentin, pregabalin, duloxetine, topiramate, riboflavin, montelukast,lisinopril, micardis, prochloroperazine, dexamethasone, flunarizine,dextropropoxyphene, meperidine, metoprolol, propranolol, nadolol,atenolol, clonidine, indoramin, carbamazepine, phenytoin, valproate,amitryptiline, imipramine, venlafaxine, lidocaine or diltiazem and other5-HT_(1B/1D)-agonists such as, for example, almotriptan, avitriptan,eletriptan, frovatriptan, naratriptan, rizatriptan, sumatriptan andzolmitriptan.

Furthermore, CGRP antagonists with vanilloid receptor antagonists, suchas e.g. VR-1 antagonists, glutamate receptor antagonists, such as e.g.mGlu5 receptor antagonists, mGlu1 receptor antagonists, iGlu5 receptorantagonists, AMPA receptor antagonists, purine receptor blockers, suchas e.g. P2X3 antagonists, NO-synthase inhibitors, such as e.g. iNOSinhibitors, calcium channel blockers, such as e.g. PQ-type blockers,N-type blockers, potassium channel openers, such as e.g. KCNQ channelopeners, sodium channel blockers, such as e.g. PN3 channel blockers,NMDA receptor antagonists, acid-sensing ion channel antagonists, such ase.g. ASIC3 antagonists, bradykinin receptor antagonists such as e.g. B1receptor antagonists, cannabinoid receptor agonists, such as e.g. CB2agonists, CB1 agonists, somatostatin receptor agonists, such as e.g.sst2 receptor agonists may be added.

The dosage of these active substances is expediently 1/5 of the lowestusually recommended dose to 1/1 of the normally recommended dose, i.e.for example 20 to 100 mg of sumatriptan.

Formulations

The compounds prepared according to the invention may be administeredeither on their own or optionally in combination with other activesubstances for the treatment of migraine by intravenous, subcutaneous,intramuscular, intraarticular, intrarectal, intranasal route, byinhalation, topically, transdermally or orally, while aerosolformulations are particularly suitable for inhalation. The combinationsmay be administered either simultaneously or sequentially.

Suitable forms for administration are for example tablets, capsules,solutions, syrups, emulsions or inhalable powders or aerosols. Thecontent of the pharmaceutically effective compound(s) in each caseshould be in the range from 0.1 to 90 wt. %, preferably 0.5 to 50 wt. %of the total composition, i.e. in amounts which are sufficient toachieve the dosage range specified hereinafter.

The preparations may be administered orally in the form of a tablet, asa powder, as a powder in a capsule (e.g. a hard gelatine capsule), as asolution or suspension. When administered by inhalation the activesubstance combination may be given as a powder, as an aqueous oraqueous-ethanolic solution or using a propellant gas formulation.

Preferably, therefore, pharmaceutical formulations are characterised bythe content of one or more compounds of formula I according to thepreferred embodiments above.

It is particularly preferable if the compounds of formula I areadministered orally, and it is also particularly preferable if they areadministered once or twice a day. Suitable tablets may be obtained, forexample, by mixing the active substance(s) with known excipients, forexample inert diluents such as calcium carbonate, calcium phosphate orlactose, disintegrants such as corn starch or alginic acid, binders suchas starch or gelatine, lubricants such as magnesium stearate or talcand/or agents for delaying release, such as carboxymethyl cellulose,cellulose acetate phthalate, or polyvinyl acetate. The tablets may alsocomprise several layers.

Coated tablets may be prepared accordingly by coating cores producedanalogously to the tablets with substances normally used for tabletcoatings, for example collidone or shellac, gum arabic, talc, titaniumdioxide or sugar. To achieve delayed release or preventincompatibilities the core may also consist of a number of layers.Similarly the tablet coating may consist of a number of layers toachieve delayed release, possibly using the excipients mentioned abovefor the tablets.

Syrups containing the active substances or combinations thereofaccording to the invention may additionally contain a sweetener such assaccharine, cyclamate, glycerol or sugar and a flavour enhancer, e.g. aflavouring such as vanillin or orange extract. They may also containsuspension adjuvants or thickeners such as sodium carboxymethylcellulose, wetting agents such as, for example, condensation products offatty alcohols with ethylene oxide, or preservatives such asp-hydroxybenzoates.

Capsules containing one or more active substances or combinations ofactive substances may for example be prepared by mixing the activesubstances with inert carriers such as lactose or sorbitol and packingthem into gelatine capsules. Suitable suppositories may be made forexample by mixing with carriers provided for this purpose, such asneutral fats or polyethyleneglycol or the derivatives thereof.

Excipients which may be used include, for example, water,pharmaceutically acceptable organic solvents such as paraffins (e.g.petroleum fractions), vegetable oils (e.g. groundnut or sesame oil),mono- or polyfunctional alcohols (e.g. ethanol or glycerol), carrierssuch as e.g. natural mineral powders (e.g. kaolins, clays, talc, chalk),synthetic mineral powders (e.g. highly dispersed silicic acid andsilicates), sugars (e.g. cane sugar, lactose and glucose), emulsifiers(e.g. lignin, spent sulphite liquors, methylcellulose, starch andpolyvinylpyrrolidone) and lubricants (e.g. magnesium stearate, talc,stearic acid and sodium lauryl sulphate).

For oral administration the tablets may, of course, contain, apart fromthe abovementioned carriers, additives such as sodium citrate, calciumcarbonate and dicalcium phosphate together with various additives suchas starch, preferably potato starch, gelatine and the like. Moreover,lubricants such as magnesium stearate, sodium lauryl sulphate and talcmay be used at the same time for the tabletting process. In the case ofaqueous suspensions the active substances may be combined with variousflavour enhancers or colourings in addition to the excipients mentionedabove.

It is also preferred if the compounds of formula I are administered byinhalation, particularly preferably if they are administered once ortwice a day. For this purpose, the compounds of formula I have to bemade available in forms suitable for inhalation. Inhalable preparationsinclude inhalable powders, propellant-containing metered-dose aerosolsor propellant-free inhalable solutions, which are optionally present inadmixture with conventional physiologically acceptable excipients.

Within the scope of the present invention, the term propellant-freeinhalable solutions also includes concentrates or sterile ready-to-useinhalable solutions. The preparations which may be used according to theinvention are described in more detail in the next part of thespecification.

Inhalable Powders

If the compounds of formula I are present in admixture withphysiologically acceptable excipients, the following physiologicallyacceptable excipients may be used to prepare the inhalable powdersaccording to the invention: monosaccharides (e.g. glucose or arabinose),disaccharides (e.g. lactose, saccharose, maltose), oligo- andpolysaccharides (e.g. dextrans), polyalcohols (e.g. sorbitol, mannitol,xylitol), salts (e.g. sodium chloride, calcium carbonate) or mixtures ofthese excipients with one another. Preferably, mono- or disaccharidesare used, while the use of lactose or glucose is preferred,particularly, but not exclusively, in the form of their hydrates. Forthe purposes of the invention, lactose is the particularly preferredexcipient, while lactose monohydrate is most particularly preferred.Methods of preparing the inhalable powders according to the invention bygrinding and micronising and by finally mixing the components togetherare known from the prior art.

Propellant-Containing Inhalable Aerosols

The propellant-containing inhalable aerosols which may be used accordingto the invention may contain I dissolved in the propellant gas or indispersed form. The propellant gases which may be used to prepare theinhalation aerosols are known from the prior art. Suitable propellantgases are selected from among hydrocarbons such as n-propane, n-butaneor isobutane and halohydrocarbons such as preferably fluorinatedderivatives of methane, ethane, propane, butane, cyclopropane orcyclobutane. The propellant gases mentioned above may be used on theirown or in mixtures thereof. Particularly preferred propellant gases arefluorinated alkane derivatives selected from TG134a(1,1,1,2-tetrafluoroethane), TG227 (1,1,1,2,3,3,3-heptafluoropropane)and mixtures thereof. The propellant-driven inhalation aerosols usedwithin the scope of the use according to the invention may also containother ingredients such as co-solvents, stabilisers, surfactants,antioxidants, lubricants and pH adjusters. All these ingredients areknown in the art.

Propellant-Free Inhalable Solutions

The compounds of formula I according to the invention are preferablyused to prepare propellant-free inhalable solutions and inhalablesuspensions. Solvents used for this purpose include aqueous oralcoholic, preferably ethanolic solutions. The solvent may be water onits own or a mixture of water and ethanol. The solutions or suspensionsare adjusted to a pH of 2 to 7, preferably 2 to 5, using suitable acids.The pH may be adjusted using acids selected from inorganic or organicacids. Examples of particularly suitable inorganic acids includehydrochloric acid, hydrobromic acid, nitric acid, sulphuric acid and/orphosphoric acid. Examples of particularly suitable organic acids includeascorbic acid, citric acid, malic acid, tartaric acid, maleic acid,succinic acid, fumaric acid, acetic acid, formic acid and/or propionicacid etc. Preferred inorganic acids are hydrochloric and sulphuricacids. It is also possible to use the acids which have already formed anacid addition salt with one of the active substances. Of the organicacids, ascorbic acid, fumaric acid and citric acid are preferred. Ifdesired, mixtures of the above acids may also be used, particularly inthe case of acids which have other properties in addition to theiracidifying qualities, e.g. as flavourings, antioxidants or complexingagents, such as citric acid or ascorbic acid, for example. According tothe invention, it is particularly preferred to use hydrochloric acid toadjust the pH.

Co-solvents and/or other excipients may be added to the propellant-freeinhalable solutions used for the purpose according to the invention.Preferred co-solvents are those which contain hydroxyl groups or otherpolar groups, e.g. alcohols—particularly isopropyl alcohol,glycols—particularly propyleneglycol, polyethyleneglycol,polypropyleneglycol, glycolether, glycerol, polyoxyethylene alcohols andpolyoxyethylene fatty acid esters. The terms excipients and additives inthis context denote any pharmacologically acceptable substance which isnot an active substance but which can be formulated with the activesubstance or substances in the pharmacologically suitable solvent inorder to improve the qualitative properties of the active substanceformulation. Preferably, these substances have no pharmacological effector, in connection with the desired therapy, no appreciable or at leastno undesirable pharmacological effect. The excipients and additivesinclude, for example, surfactants such as soya lecithin, oleic acid,sorbitan esters, such as polysorbates, polyvinylpyrrolidone, otherstabilisers, complexing agents, antioxidants and/or preservatives whichguarantee or prolong the shelf life of the finished pharmaceuticalformulation, flavourings, vitamins and/or other additives known in theart. The additives also include pharmacologically acceptable salts suchas, for example, sodium chloride as isotonic agents. The preferredexcipients include antioxidants such as ascorbic acid, for example,provided that it has not already been used to adjust the pH, vitamin A,vitamin E, tocopherols and similar vitamins or provitamins occurring inthe human body. Preservatives may be used to protect the formulationfrom contamination with pathogens. Suitable preservatives are thosewhich are known in the art, particularly cetyl pyridinium chloride,benzalkonium chloride or benzoic acid or benzoates such as sodiumbenzoate in the concentration known from the prior art.

Experimental Section

As a rule ¹H-NMR and mass spectra have been obtained for the compoundsprepared. Unless stated otherwise, R_(f) values are determined usingready-made TLC silica gel plates 60 F254 (E. Merck, Darmstadt, Item no.1.05714) without chamber saturation.

The Rf values determined under the name Polygram silica gel are obtainedusing ready-made Polygram SIL G/UV254 TLC films (coated with 0.2 mmsilica gel) made by Macherey-Nagel (Düren, Item no. 805 021).

The Rf values determined under the name Polygram Alox are obtained usingready-made Polygram Alox N/UV254 TLC films (coated with 0.2 mm aluminiumoxide) made by Macherey-Nagel (Düren, Item no. 802 021).

The ratios given for the eluants relate to units by volume of theparticular solvents. The units by volume given for NH₃ relate to aconcentrated solution of NH₃ in water.

Unless stated otherwise, the acid, base and salt solutions used inworking up the reaction solutions are aqueous systems of the specifiedconcentrations. Silica gel made by Millipore (MATREX™, 35-70 μm) is usedfor chromatographic purifications.

Aluminium oxide (Alox) made by ICN Biomedicals (Eschwege, Item no.02090) is used for chromatographic purifications. The required activitystage (activity stage II-III) is generated before use according to themanufacturer's instructions. The HPLC data provided are measured underthe parameters listed below:

Method A:

Analytical column: Merck Chromolith Speed ROD, RP18e; 4.6×50 mm; columntemperature: 30° C.; flow: 1.5 mL/min; injection volume: 5 μL; detectionat 254 nm

time Percent of water by volume Percent of acetonitrile by [min] (with0.1% formic acid) volume (with 0.1% formic acid) 0 90 10 4.5 10 90 5 1090 5.5 90 10Method B:

Analytical column: Zorbax column (Agilent Technologies), SB (StableBond)-C18; 3.5 μm; 4.6×75 mm; column temperature: 30° C.; flow: 1.6mL/min; injection volume: 5 μL; detection at 254 nm

time Percent of water by volume Percent of acetonitrile by [min] (with0.1% formic acid) volume (with 0.1% formic acid) 0 95 5 4.5 10 90 5.0 1090 5.5 90 10Method C:

Analytical column: Zorbax column (Agilent Technologies), SB (StableBond)-C18; 3.5 μm; 4.6×75 mm; column temperature: 30° C.; flow: 0.8mL/min; injection volume: 5 μL; detection at 254 nm

time Percent of water by volume Percent of acetonitrile by [min] (with0.1% formic acid) volume (with 0.1% formic acid) 0 95 5 9 10 90 10 10 9011 90 10

In preparative HPLC purifications as a rule the same gradients are usedas were used to obtain the analytical HPLC data.

The products are collected under mass control, the fractions containingproduct are combined and freeze-dried.

In the absence of any more information regarding the configuration, itis unclear whether there are pure enantiomers involved or whetherpartial or even total racemisation has taken place.

The following abbreviations are used in the test descriptions:

Boc tert-butoxycarbonyl Cyc cyclohexane DCM dichloromethane DIPEdiisopropylether DMF N,N-dimethylformamide EtOAc ethyl acetate EtOHethanol h hour HCl hydrochloric acid HOAc acetic acid i. vac. in vacuo(under vacuum) min minute MeOH methanol MTBE methyl-tert-butylether NaOHsodium hydroxide PE petroleum ether RT ambient temperature TBTU2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium tetrafluoro- borateTFA trifluoroacetic acid THF tetrahydrofuran

The preparation of starting compounds is described below:

Amine 1 Ethyl 3-[4,4′]bipiperidinyl-1-yl-propionate

A1a) tert-butyl1′-(2-ethoxycarbonyl-ethyl)-[4,4′]bipiperidinyl-1-carboxylate

4.4 mL (40.6 mmol) ethyl acrylate were added to a solution of 10.0 g(37.3 mmol) tert-butyl[4,4′]bipiperidinyl-1-carboxylate in 100 mL EtOHand the reaction mixture was refluxed for 2 h. To complete the reactiona further 1 mL (9.2 mmol) of ethyl acrylate were added, the mixture wasrefluxed for 1 h and left overnight at RT. The solvent was eliminated i.vac. and the crude product was further reacted without being purified.

Yield: 14.0 g (100% of theory)

ESI-MS: (M+H)⁺=369

A1 b) ethyl 3-[4,4′]bipiperidinyl-1-yl-propionate

28 mL TFA were added dropwise to a solution of 14.0 g of the crudeproduct of Example A1a in 250 mL DCM and the reaction mixture wasstirred for 4 h at RT. The mixture was evaporated down i. vac., theresidue was taken up in 200 mL DCM and this solution was added batchwiseto a solution of 20 g Na₂CO₃ in 120 mL water. The organic phase wasseparated off, the aqueous phase was extracted twice more with DCM andthe combined organic phases were dried over Na₂SO₄. After elimination ofthe desiccant and solvent the residue was dried and reacted withoutfurther purification.

Yield: 8.8 g (88% of theory)

ESI-MS: (M+H)⁺=269

Amine 2 Ethyl 3-(4-piperazin-1-yl-piperidin-1-yl)-propionate

A2a) ethyl 3-[4-(4-benzyl-piperazin-1-yl)-piperidin-1-yl]-propionate

5.5 mL (50.8 mmol) ethyl acrylate were added to a solution of 11.7 g(44.9 mmol) 1-benzyl-4-piperidin-4-yl-piperazine in 120 mL dry EtOH andthe reaction mixture was refluxed for 1 h and then stirred overnight atRT. The solvent was eliminated i. vac. and the residue was dried for 1 hunder an oil pump vacuum. The crude product was reacted further withoutpurification.

Yield: 16.5 g (99% of theory)

ESI-MS: (M+H)⁺=360

A2b) ethyl 3-(4-piperazin-1-yl-piperidin-1-yl)-propionate

A suspension of 16.5 g of the crude product of Example A2a and 1.6 g of10% Pd/C in 200 mL EtOH and was hydrogenated for 4 h at 50° C. and 50psi hydrogen pressure. The catalyst was removed by suction filtering,the filtrate was evaporated down to about 120 mL and combined with 72 mLethanolic HCl (1.3 M). The precipitate formed was suction filtered anddried i. vac. The product was obtained as the bis-hydrochloride salt.

Yield: 12.6 g (83% of theory)

ESI-MS: (M+H)⁺=270

Amine 3 Ethyl 3-(4-piperidin-4-yl-piperazin-1-yl)-propionate

A3a) ethyl 3-[4-(1-benzyl-piperidin-4-yl)-piperazin-1-yl]-propionate

12.5 mL (73.0 mmol) ethyldiisopropylamine and 5.0 mL (46.1 mmol) ethylacrylate were added to a solution of 11.0 g (33.2 mmol)1-(1-benzyl-piperidin-4-yl)-piperazine (used as the bis-hydrochloridesalt) in 40 mL EtOH and the reaction mixture was heated to 90° C. (bathtemperature) for 3 h. After cooling, water was added, the mixture wasexhaustively extracted with EtOAc and the combined organic phases weredried over Na₂SO₄. After elimination of the desiccant and solvent theresidue was purified by chromatography (silica gel, DCM/EtOH/NH₃100:10:1).

Yield: 6.8 g (56% of theory)

ESI-MS: (M+H)⁺=360

R_(f)=0.64 (silica gel, DCM/MeOH/NH₃ 90:9:1)

A3b) ethyl 3-(4-piperidin-4-yl-piperazin-1-yl)-propionate

A suspension of 5.13 g (14.3 mmol) ethyl3-[4-(1-benzyl-piperidin-4-yl)-piperazin-1-yl]-propionate and 1.0 g 10%Pd/C in 100 mL EtOH was hydrogenated for 2 h at 50° C. and 50 psihydrogen pressure. The catalyst was filtered off and the filtrate wasevaporated to dryness. The oily product was reacted further withoutpurification.

Yield: 3.6 g (93% of theory)

ESI-MS: (M+H)⁺=270

Amine 4 Ethyl[4,4′]bipiperidinyl-1-yl-oxo-acetate

A4a) tert-butyl 1′-ethoxyoxalyl-[4,4′]bipiperidinyl-1-carboxylate

1.68 mL (15.0 mmol) ethyl chloro-oxo-acetate were added dropwise to asolution of 4.0 g (14.9 mmol)tert-butyl[4,4′]bipiperidinyl-1-carboxylate and 2.15 mL (15.4 mmol)triethylamine in 80 mL DCM, cooled to 0° C. After the addition had endedthe cooling bath was removed and the mixture was stirred for 1 h at RT.The reaction mixture was mixed with water, the organic phase wasseparated off and dried over Na₂SO₄. After elimination of the desiccantand solvent the residue was taken up in EtOAc, the solution was filteredthrough silica gel and evaporated down i. vac.

Yield: 3.1 g (57% of theory)

ESI-MS: (M+H)⁺=386

A4b) ethyl[4,4′]bipiperidinyl-1-yl-oxo-acetate

5.0 mL TFA were added dropwise to a solution of 3.1 g (8.36 mmol)tert-butyl 1′-ethoxyoxalyl-[4,4′]bipiperidinyl-1-carboxylate in 40 mLDCM and the reaction mixture was stirred for 4 h at RT. The mixture wasevaporated down i. vac., the residue was taken up in 50 mL DCM and thissolution was added batchwise to an ice-cold solution of 4.0 g Na₂CO₃ in20 mL water. The organic phase was separated off, the aqueous phase wasextracted twice more with DCM and the combined organic phases were driedover Na₂SO₄. After elimination of the desiccant and solvent the productwas obtained as an oil, which was reacted further without purification.

Yield: 2.3 g (84% of theory)

ESI-MS: (M+H)⁺=269

Amine 5 Ethyl 4-[4,4′]bipiperidinyl-1-yl-4-oxo-butyrate

A5a) tert-butyl1′-(3-carboxy-propionyl)-[4,4′]bipiperidinyl-1-carboxylate

A solution of 4.1 g (40.7 mmol) succinic acid anhydride in 50 mL THF wasadded dropwise at RT to a solution of 10.0 g (37.3 mmol)tert-butyl[4,4′]bipiperidinyl-1-carboxylate in 100 mL THF and thereaction mixture was stirred overnight at RT. To complete the reactionanother 2.0 g (19.9 mmol) succinic acid anhydride were added, themixture was stirred for 4 h at 50° C. and stirred overnight at RT. 200mL of 7.5% K₂CO₃ solution was added and the aqueous phase was washedwith 200 mL EtOAc. The organic phase was extracted with 200 mL 7.5%K₂CO₃ solution and the combined aqueous phases were acidified withcitric acid. The mixture was extracted exhaustively with EtOAc and thecombined organic phases were evaporated down i. vac.

Yield: 11.7 g (85% of theory)

ESI-MS: (M+H)⁺=369

A5b) ethyl 4-[4,4′]bipiperidinyl-1-yl-4-oxo-butyrate

A solution of 11.7 g (31.7 mmol) tert-butyl1′-(3-carboxy-propionyl)-[4,4′]bipiperidinyl-1-carboxylate in 250 mLethanolic HCl (1.25 M) was stirred overnight at RT. The solvent waseliminated i. vac. and the product was obtained as the hydrochloridesalt, which was reacted further without purification.

Yield: 4.3 g (46% of theory)

ESI-MS: (M+H)⁺=297

Amine 6Ethyl([1,4′]bipiperidinyl-4-yl-tert-butoxycarbonyl-amino)-acetate

A6a) tert-butyl(1′-benzyl-[1,4′]bipiperidinyl-4-yl)-carbamate

A solution of 5.0 g (25.0 mmol) tert-butyl piperidin-4-yl-carbamate and4.46 mL (25.0 mmol) 1-benzyl-piperidin-4-one in 150 mL THF was adjustedwith AcOH to a pH of 5 and then combined batchwise with 5.61 g (26.5mmol) NaBH(OAc)₃ within 3 h while cooling with ice. The reaction mixturewas stirred overnight at RT, then made alkaline with 500 mL 30% K₂CO₃solution, stirred for 1 h at RT, extracted three times with 100 mL EtOAcand the combined organic phases were dried over Na₂SO₄. Afterelimination of the desiccant and solvent the residue was reacted furtherwithout purification.

Yield: 7.0 g (75% of theory)

A6b) 1′-benzyl-[1,4′]bipiperidinyl-4-ylamine

A solution of 7.0 g (18.7 mmol)tert-butyl(1′-benzyl-[1,4′]bipiperidinyl-4-yl)-carbamate and 14.3 mL(185 mmol) TFA in 80 mL DCM was refluxed overnight. The mixture wasevaporated down i. vac., the residue was combined with 200 mL 30% K₂CO₃solution and extracted three times with 100 mL EtOAc, discarding thefirst 100 mL of extract. The combined organic phases were dried overNa₂SO₄, filtered and evaporated down. The product was reacted furtherwithout purification.

Yield: 5.1 g (100% of theory)

A6c) ethyl(1′-benzyl-[1,4′]bipiperidinyl-4-ylamino)-acetate

2.79 g (13.17 mmol) NaBH(OAc)₃ were added batchwise to a solution of 1.8g (6.58 mmol) of 1′-benzyl-[1,4′]bipiperidinyl-4-ylamine, 2.69 mL (13.0mmol) ethyl oxo-acetate (used as a 50% solution in toluene) and 1 mL(17.45 mmol) of AcOH in 250 mL THF, cooled to 0° C., and the reactionmixture was stirred overnight at RT. It was evaporated down i. vac., theresidue was taken up in EtOAc, the organic phase was washed withsaturated K₂CO₃ solution and dried over Na₂SO₄. After elimination of thedesiccant and solvent the residue was purified by HPLC. The fractionscontaining the product were combined, the organic solvent (acetonitrile)was eliminated i. vac., the aqueous residue was extracted exhaustivelywith DCM and the combined organic phases were dried over MgSO₄. Afterelimination of the desiccant and solvent the product was obtained as ayellow oil.

Yield: 1.25 g (53% of theory)

ESI-MS: (M+H)⁺=360

R_(f)=0.35 (silica gel, DCM/MeOH/NH₃ 90:10:1)

A6d) ethyl[(1′-benzyl-[1,4′]bipiperidinyl-4-yl)-tert-butoxycarbonyl-amino]-acetate

3.34 mL (30.0 mmol) triethylamine were added dropwise to a solution of1.20 g (3.34 mmol)ethyl(1′-benzyl-[1,4′]bipiperidinyl-4-ylamino)-acetate in 15 mL DCM andthen 0.73 g (3.34 mmol) Boc-anhydride were added batchwise. The reactionmixture was stirred for 70 h at RT and then evaporated down i. vac. Theresidue was taken up in EtOAc, washed with 15% K₂CO₃ solution and driedover Na₂CO₃. After elimination of the desiccant and solvent the residuewas reacted further without purification.

Yield: 1.3 g (85% of theory)

A6e) ethyl([1,4′]bipiperidinyl-4-yl-tert-butoxycarbonyl-amino)-acetate

A suspension of 1.30 g (2.83 mmol) ethyl[(1′-benzyl-[1,4′]bipiperidinyl-4-yl)-tert-butoxycarbonyl-amino]-acetateand 0.16 g 10% Pd/C in 25 mL EtOH was hydrogenated for 5 h at 50° C. and50 psi hydrogen pressure. The catalyst was removed by suction filteringand the filtrate was evaporated to dryness. The product was obtained asa colourless oil, which was reacted further without purification.

Yield: 1.00 g (96% of theory)

ESI-MS: (M+H)⁺=370

Amine 7 Ethyl(4-methyl-4-piperazin-1-yl-piperidin-1-yl)-acetate

A7a) 1-benzyl-4-piperazin-1-yl-piperidine-4-carbonitrile

A mixture of 11.0 g (49.8 mmol)1-benzyl-4-hydroxy-piperidine-4-carbonitrile and 22.0 g (255 mmol)piperazine in 200 mL MeOH was refluxed for 2 h. The precipitate wassuction filtered, the filtrate was evaporated down i. vac., the residuewas taken up in a little water, extracted exhaustively with DCM and thecombined organic phases were dried over Na₂SO₄. After elimination of thedesiccant and solvent the residue was purified by chromatography (Alox,DCM/MeOH 30:1).

Yield: 2.38 g (16% of theory)

ESI-MS: (M+H)⁺=285

R_(f)=0.37 (Polygram-Alox, DCM/MeOH 25:1)

A7b) 1-(1-benzyl-4-methyl-piperidin-4-yl)-piperazine

15 mL methylmagnesium chloride solution (45 mmol, 3 M in THF) were addedat RT to 2.37 g (7.92 mmol)1-benzyl-4-piperazin-1-yl-piperidine-4-carbonitrile in 100 mL dry THFand the reaction mixture was stirred for 3 h. Saturated NH₄Cl solutionwas added, the mixture was stirred for another 10 min, the aqueous phasewas washed with EtOAc, combined with 4 M NaOH solution until an alkalinereaction was obtained, extracted exhaustively with DCM and the combinedorganic phases were dried over Na₂SO₄. After elimination of thedesiccant and solvent the residue was further reacted without anyfurther purification.

Yield: 0.64 g (30% of theory)

ESI-MS: (M+H)⁺=274

A7c) tert-butyl4-(1-benzyl-4-methyl-piperidin-4-yl)-Piperazine-1-carboxylate

1.35 g (6.00 mmol) Boc-anhydride were added to 1.63 g (5.66 mmol)1-(1-benzyl-4-methyl-piperidin-4-yl)-piperazine in 50 mL THF and thereaction mixture was stirred for 3 h at RT. Then it was evaporated todryness i. vac. and the residue was further reacted without anypurification.

Yield: 2.10 g (100% of theory)

ESI-MS: (M+H)⁺=374

A7d) tert-butyl 4-(4-methyl-piperidin-4-yl)-piperazine-1-carboxylate

A suspension of 2.28 g (5.62 mmol) tert-butyl4-(1-benzyl-4-methyl-piperidin-4-yl)-piperazine-1-carboxylate and 300 mg10% Pd/C in 50 mL MeOH was hydrogenated for 3 h at 50° C. and 3447 hPahydrogen pressure. To complete the reaction 0.47 mL conc. HCl were addedand the mixture was hydrogenated for another 3 h at 50° C. and 3447 hPahydrogen pressure. The catalyst was filtered off, the filtrate wasevaporated down i. vac., the residue was stirred with diethyl ether,suction filtered and dried.

Yield: 1.54 g (86% of theory)

ESI-MS: (M+H)⁺=284

A7e) tert-butyl4-(1-ethoxycarbonylmethyl-4-methyl-piperidin-4-yl)-piperazine-1-carboxylate

A mixture of 1.53 g (4.78 mmol) tert-butyl4-(4-methyl-piperidin-4-yl)-piperazine-1-carboxylate and 1.1 mL (5.55mmol) ethyl oxo-acetate (50% in toluene) in 50 mL THF was stirred for 1h at RT. The reaction mixture was cooled to 0° C., 1.25 g (5.90 mmol)sodium triacetoxyborohydride was added batchwise and after eliminationof the cooling bath the mixture was stirred overnight at RT. It wascombined with 10 mL 20% NaHCO₃ solution, extracted exhaustively withEtOAc and the combined organic phases were dried over Na₂SO₄. Afterelimination of the desiccant and solvent the residue was purified bychromatography (Alox, DCM/EtOH 100:1).

Yield: 0.47 g (27% of theory)

ESI-MS: (M+H)⁺=370

A7f) ethyl(4-methyl-4-piperazin-1-yl-piperidin-1-yl)-acetate

At 0° C. 2 mL TFA were added to 0.46 g (1.25 mmol) tert-butyl4-(1-ethoxycarbonylmethyl-4-methyl-piperidin-4-yl)-piperazine-1-carboxylatein 5 mL DCM and the reaction mixture was stirred for 2 h at RT. This wasevaporated down i. vac. and the crude product, which was obtained as thebis-trifluoroacetate salt, was further reacted without any purification.

Yield: 0.65 g (100% of theory)

ESI-MS: (M+H)⁺=270

Amine 8 Ethyl[4-(4-methyl-piperidin-4-yl)-piperazin-1-yl]-acetate

A8a) ethyl[4-(1-benzyl-4-methyl-piperidin-4-yl)-piperazin-1-yl]-acetate

Prepared analogously to Example A7e from 0.62 g (2.27 mmol)1-(1-benzyl-4-methyl-piperidin-4-yl)-piperazine (Example A7b) and 0.55mL (2.77 mmol) ethyl oxo-acetate (50% in toluene). The crude product waspurified by chromatography (Alox, gradient PE/EtOAc 2:1 to 1:1).

Yield: 0.45 g (50% of theory)

ESI-MS: (M+H)⁺=360

R_(f)=0.56 (Polygram-Alox, PE/EtOAc 1:1)

A8b) ethyl[4-(4-methyl-piperidin-4-yl)-piperazin-1-yl]-acetate

A suspension of 0.44 g (1.10 mmol)ethyl[4-(1-benzyl-4-methyl-piperidin-4-yl)-piperazin-1-yl]-acetate and100 mg 10% Pd/C in 20 mL EtOH was hydrogenated for 12 h at 50° C. and3447 hPa hydrogen pressure. The catalyst was filtered off and thefiltrate was evaporated to dryness. The product was reacted furtherwithout purification.

Yield: 0.29 g (97% of theory)

ESI-MS: (M+H)⁺=270

Amine 9 Ethyl(S)-4-methyl-1-piperidin-4-yl-piperazine-2-carboxylate

A9a) 1-benzyl-4-tert-butyl-2-ethyl(S)-piperazine-1,2,4-tricarboxylate

11.2 g (34.9 mmol) TBTU and 5.5 mL (39.6 mmol) triethylamine were addedto a mixture, cooled to 0° C., of 12.2 g (32.8 mmol)1-benzyl-4-tert-butyl(S)-piperazine-1,2,4-tricarboxylate and 30 mL EtOHin 150 mL THF, stirred for another 30 min at this temperature and thenstirred for 68 h at RT. 600 mL diethyl ether were added to the reactionmixture, it was combined with 200 mL saturated NaHCO₃ solution, theaqueous phase was separated off, the organic phase was washed withsaturated NaCl solution and dried over Na₂SO₄. After elimination of thedesiccant and solvent the residue was purified by chromatography (silicagel, gradient PE/EtOAc 4:1 to 7:3).

Yield: 11.35 g (88% of theory)

ESI-MS: (M+H)⁺=393

R_(f)=0.38 (Polygram-silica gel, PE/EtOAc 3:1)

A9b) 1-benzyl-2-ethyl(S)-piperazine-1,2-dicarboxylate

10 mL TFA were added to a mixture, cooled to 0° C., of 3.27 g (8.33mmol) 1-benzyl-4-tert-butyl-2-ethyl(S)-piperazine-1,2,4-tricarboxylateand 30 mL DCM, the mixture was stirred for 10 min while cooling with iceand for 2 h at RT. The mixture was evaporated down i. vac. at 30° C.,the residue was taken up again in EtOAc and evaporated down again i.vac. The crude product, which was obtained as the trifluoroacetate salt,was reacted further without purification.

A9c) 1-benzyl-2-ethyl(S)-4-methyl-piperazine-1,2-dicarboxylate

1.00 g (12.2 mmol) NaOAc and 10 g molecular sieve A3 were added to amixture of 4.4 g of the crude product from A9b) and 1.2 mL (16.0 mmol)formaldehyde (37% in water) in 80 mL THF and the reaction mixture wasstirred for 2 h at RT. After cooling to 0° C., 3.39 g (16.0 mmol) sodiumtriacetoxyborohydride was added batchwise, the mixture was stirred for30 min at this temperature and for 68 h at RT. The insoluble componentswere filtered off, saturated K₂CO₃ solution was added to the filtrate,it was stirred for 15 min, combined with EtOAc, the organic phase wasseparated off and dried over Na₂SO₄. After elimination of the desiccantand solvent the residue was purified by chromatography (Alox, PE/EtOAc2:1).

Yield: 2.04 g (81% of theory)

ESI-MS: (M+H)⁺=307

R_(f)=0.73 (Polygram-Alox, PE/EtOAc 1:1)

A9d) ethyl(S)-4-methyl-piperazine-2-carboxylate

A suspension of 2.04 (6.66 mmol)1-benzyl-2-ethyl(S)-4-methyl-piperazine-1,2-dicarboxylate and 200 mg 10%Pd/C in 100 mL EtOH was hydrogenated at 50° C. and 3447 hPa hydrogenpressure for 6 h. The catalyst was filtered off, the filtrate wasevaporated to dryness i. vac. and the residue was further reactedwithout any purification.

Yield: 1.06 g (92% of theory)

ESI-MS: (M+H)⁺=173

A9e)ethyl(S)-1-(1-tert-butoxycarbonyl-piperidin-4-yl)-4-methyl-piperazine-2-carboxylate

A mixture of 0.90 g (5.23 mmol)ethyl(S)-4-methyl-piperazine-2-carboxylate and 1.20 g (6.02 mmol)tert-butyl 4-oxo-piperidine-1-carboxylate in 20 mL EtOH was combinedwith 50 μL formic acid and 3 g molecular sieve A3 and the reactionmixture was left for 66 h at RT. The molecular sieve was filtered off,the mixture was combined with 100 mg 10% Pd/C and hydrogenated at 50° C.and 3447 hPa hydrogen pressure for 4 h. The catalyst was removed bysuction filtering, the filtrate was evaporated down i. vac. and theresidue was purified by chromatography (silica gel, gradient DCM/EtOH98:2 to 75:25).

Yield: 0.35 g (19% of theory)

ESI-MS: (M+H)⁺=356

R_(f)=0.5 (Polygram-Alox, DCM/MeOH 50:1)

A9f) ethyl(S)-4-methyl-1-piperidin-4-yl-piperazine-2-carboxylate

A mixture of 0.34 g (0.96 mmol)ethyl(S)-1-(1-tert-butoxycarbonyl-piperidin-4-yl)-4-methyl-piperazine-2-carboxylatein 6 mL ethanolic HCl (1.25 M) was refluxed for 1 hour. After cooling ofthe reaction mixture the precipitate was suction filtered and dried. Theproduct was obtained as the tris-hydrochloride salt.

Yield: 0.33 g (95% of theory)

ESI-MS: (M+H)⁺=256

Amine 10 Ethyl(S)-1-(1-methyl-piperidin-4-yl)-piperazine-2-carboxylate

A10a) 1-tert-butyl-3-ethyl(S)-piperazine-1,3-dicarboxylate

A suspension of 4.00 g (10.2 mmol)1-benzyl-4-tert-butyl-2-ethyl(S)-piperazine-1,2,4-tricarboxylate(Example A9a) and 200 mg 10% Pd/C in 100 mL EtOH was hydrogenated for 2h at 50° C. and 3447 hPa hydrogen pressure. The catalyst was filteredoff, the filtrate was evaporated down i. vac. and the residue wasfurther reacted without any purification.

Yield: 2.61 g (98% of theory)

ESI-MS: (M+H)⁺=259

A10b)1-tert-butyl-3-ethyl(S)-4-(1-methyl-piperidin-4-yl)-piperazine-1,3-dicarboxylate

A mixture of 2.65 g (10.05 mmol)1-tert-butyl-3-ethyl(S)-piperazine-1,3-dicarboxylate and 1.36 mL (11.06mmol) 1-methyl-piperidin-4-one in 100 mL THF was stirred for 1 h at RT.After cooling to 0° C., 3.00 g (14.16 mmol) sodium triacetoxyborohydridewere added batchwise and the reaction mixture was stirred overnight atRT. To complete the reaction a further 1.00 g (4.72 mmol) sodiumtriacetoxyborohydride and 0.3 mL AcOH were added and the mixture wasstirred for another 48 h at RT. 40 mL saturated K₂CO₃ solution wereadded, the mixture was stirred for 15 min, extracted exhaustively withEtOAc and the combined organic phases were dried over Na₂SO₄. Afterelimination of the desiccant and solvent the residue was purified bychromatography (Alox, DCM/EtOH 100:1).

Yield: 1.93 g (53% of theory)

ESI-MS: (M+H)⁺=356

A10c) ethyl(S)-1-(1-methyl-piperidin-4-yl)-piperazine-2-carboxylate

A mixture of 1.88 (5.18 mmol)1-tert-butyl-3-ethyl(S)-4-(1-methyl-piperidin-4-yl)-piperazine-1,3-dicarboxylate,3 mL EtOH and 15 mL ethanolic HCl (1.25 M) was stirred overnight at RT.To complete the reaction the mixture was refluxed for 1 hour. Aftercooling of the reaction mixture the precipitate was suction filtered anddried. The product was obtained as the bis-hydrochloride salt.

Yield: 1.35 g (79% of theory)

ESI-MS: (M+H)⁺=256

Amine 11 Ethyl(S)-4-(1-methyl-piperidin-4-yl)-piperazine-2-carboxylate

A11a)1-benzyl-2-ethyl(S)-4-(1-methyl-piperidin-4-yl)-piperazine-1,2-dicarboxylate

A mixture of 4.20 g (10.13 mmol)1-benzyl-2-ethyl(S)-piperazine-1,2-dicarboxylate (Example A9b, used asthe trifluoroacetate salt) and 1.37 mL 1-methyl-piperidin-4-one in 100mL THF was stirred for 1 h at RT. After cooling to 0° C. 3.00 g (14.16mmol) sodium triacetoxyborohydride were added batchwise and the reactionmixture was stirred overnight at RT. It was combined with 40 mLsaturated K₂CO₃ solution, stirred for another 15 min, extractedexhaustively with EtOAc and the combined organic phases were dried overNa₂SO₄. After elimination of the desiccant and solvent the residue waspurified by chromatography (Alox, DCM/EtOH 100:1).

Yield: 2.17 g (55% of theory)

ESI-MS: (M+H)⁺=390

R_(f)=0.43 (Polygram-Alox, DCM/MeOH 50:1)

A11b) ethyl(S)-4-(1-methyl-piperidin-4-yl)-piperazine-2-carboxylate

A suspension of 2.15 g (5.52 mmol)1-benzyl-2-ethyl(S)-4-(1-methyl-piperidin-4-yl)-piperazine-1,2-dicarboxylateand 100 mg 10% Pd/C in 50 mL EtOH was hydrogenated for 2 h at 50° C. and3447 hPa hydrogen pressure. The catalyst was filtered off and thefiltrate was evaporated to dryness. The product was reacted furtherwithout purification.

Yield: 1.35 g (96% of theory)

ESI-MS: (M+H)⁺=256

Amine 12 Ethyl(3-piperazin-1-yl-8-aza-bicyclo[3.2.1]oct-8-yl)-acetate

A12a) tert-butyl3-(4-benzyloxycarbonyl-piperazin-1-yl)-8-aza-bicyclo[3.2.1]octane-8-carboxylate

A mixture of 5.00 g (22.2 mmol) tert-butyl3-oxo-8-aza-bicyclo[3.2.1]octan-8-carboxylate and benzylpiperazine-1-carboxylate in 60 mL THF was adjusted with AcOH to a pH of5 and stirred for 1 h at RT. The mixture was combined batchwise with5.64 g (26.6 mmol) sodium triacetoxyborohydride while cooling with iceand the reaction mixture was stirred overnight at RT. It was combinedwith 150 mL 15% K₂CO₃ solution, the organic phase was separated off, theaqueous phase was exhaustively extracted with EtOAc and the combinedorganic phases were dried over Na₂SO₄. After elimination of thedesiccant and solvent the residue was purified by chromatography (silicagel, EtOAc).

2 isomeric products were able to be isolated:

Isomer A:

Yield: 2.10 g (22% of theory)

ESI-MS: (M+H)⁺=430

R_(f)=0.55 (silica gel, EtOAc)

Retention time (HPLC): 3.2 min (method B)

Isomer B:

Yield: 2.20 g (23% of theory)

ESI-MS: (M+H)⁺=430

R_(f)=0.68 (silica gel, EtOAc)

A12b) benzyl 4-(8-aza-bicyclo[3.2.1]oct-3-yl)-piperazine-1-carboxylate

6.01 mL (78.0 mmol) TFA were slowly added to a mixture of 2.10 g (4.89mmol) tert-butyl3-(4-benzyloxycarbonyl-piperazin-1-yl)-8-aza-bicyclo[3.2.1]octane-8-carboxylate(isomer A) in 60 mL DCM and the reaction mixture was stirred for 2 atRT. It was evaporated down i. vac., the residue was taken up in 15%K₂CO₃ solution, extracted exhaustively with DCM and the combined organicphases were dried over Na₂SO₄. After elimination of the desiccant andsolvent the product was further reacted without any purification.

Yield: 1.50 g (93% of theory)

ESI-MS: (M+H)⁺=330

R_(f)=0.16 (silica gel, DCM/Cyc/MeOH/NH₃ 70:15:15:2)

A12c) benzyl4-(8-ethoxycarbonylmethyl-8-aza-bicyclo[3.2.1]oct-3-yl)-piperazine-1-carboxylate

1.29 g (9.30 mmol) K₂CO₃ were added to 1.50 g (4.55 mmol) benzyl4-(8-aza-bicyclo[3.2.1]oct-3-yl)-piperazine-1-carboxylate (A12b) in 10mL DMF, then 0.56 mL (5.00 mmol) ethyl bromoacetate were slowly addeddropwise and the reaction mixture was stirred for a further 4 h at RT.The insoluble components were filtered off, combined with EtOAc, theorganic phase was washed twice with saturated NaHCO₃ solution and driedover Na₂SO₄. After elimination of the desiccant and solvent the residuewas further reacted without any further purification.

Yield: 1.75 g (92% of theory)

ESI-MS: (M+H)⁺=416

R_(f)=0.72 (silica gel, DCM/Cyc/MeOH/NH₃ 70:15:15:2)

A12d) ethyl(3-piperazin-1-yl-8-aza-bicyclo[3.2.1]oct-8-yl)-acetate

A suspension of 1.70 g (4.09 mmol) benzyl4-(8-ethoxycarbonylmethyl-8-aza-bicyclo[3.2.1]oct-3-yl)-piperazine-1-carboxylate(A12c) and 200 mg 10% Pd/C in 30 mL EtOH was shaken for 3 h at RT and3000 hPa hydrogen pressure. The catalyst was removed by suctionfiltering and the filtrate was evaporated to dryness. The product wasreacted further without purification.

Yield: 1.10 g (96% of theory)

ESI-MS: (M+H)⁺=282

R_(f)=0.21 (silica gel, DCM/MeOH/NH₃ 80:20:2)

Amine 13 Ethyl([1,4′]bipiperidinyl-4-yloxy)-acetate

A13a) benzyl4-tert-butoxycarbonylmethoxy-[1,4′]bipiperidinyl-1′-carboxylate

2.90 g (13.27 mmol) sodium triacetoxyborohydride were added batchwise toa mixture of 2.58 g (11.06 mmol) benzyl 4-oxo-piperidine-1-carboxylateand 2.80 g (12.36 mmol) tert-butyl(piperidin-4-yloxy)-acetate in 30 mLTHF and the reaction mixture was stirred overnight at RT. It wascombined with 50 mL 1 M NaOH, the mixture was stirred for 1 h at RT,combined with EtOAc, the organic phase was separated off and dried overNa₂SO₄. After elimination of the desiccant and solvent the residue waspurified by chromatography (Alox, DCM/MeOH 100:1).

Yield: 3.10 g (65% of theory)

ESI-MS: (M+H)⁺=433

A13b) tert-butyl([1,4′]bipiperidinyl-4-yloxy)-acetate

A suspension of 3.08 g (7.12 mmol) benzyl4-tert-butoxycarbonylmethoxy-[1,4′]bipiperidinyl-1′-carboxylate and 300mg 10% Pd/C in 60 mL MeOH was hydrogenated for 2 h at 50° C. and 3447hPa hydrogen pressure. The catalyst was removed by suction filtering andthe filtrate was evaporated to dryness. The product was reacted furtherwithout purification.

Yield: 2.15 g (99% of theory)

ESI-MS: (M+H)⁺=299

A13c) ethyl([1,4′]bipiperidinyl-4-yloxy)-acetate

20 mL ethanolic HCl (1.25M) were added to 2.02 g (6.63 mmol) tert-butyl([1,4′]bipiperidinyl-4-yloxy)-acetate in 20 mL EtOH and the reactionmixture was refluxed for 3 h. After cooling to 0° C. the precipitateformed was suction filtered and dried under a high vacuum. The product,which was obtained as the bis-hydrochloride salt, was reacted furtherwithout purification.

Yield: 1.74 g (76% of theory)

ESI-MS: (M+H)⁺=271

Amine 14 Ethyl[1,4′]bipiperidinyl-4-yl-acetate

A14a) ethyl(1′-benzyl-[1,4′]bipiperidinyl-4-yl)-acetate

50 mL DCM and 11.7 mL (62.5 mmol) 1-benzyl-piperidin-4-one were added to11.8 g (56.8 mmol) ethyl piperidin-4-yl-acetate in 100 mL of THF and thereaction mixture was stirred for 2 h at RT. The mixture was combinedbatchwise with 13.7 g (62.5 mmol) sodium triacetoxyborohydride andstirred for another 36 h at RT. 100 mL 10% NaOH were added to thereaction mixture, this was extracted twice with 100 mL MTBE and thecombined organic phases were dried over Na₂SO₄. After elimination of thedesiccant and solvent the residue was purified by HPLC.

Yield: 3.27 g (17% of theory)

ESI-MS: (M+H)⁺=345

R_(f)=0.55 (silica gel, EtOAc/MeOH/NH₃ 90:10:1)

A14b) ethyl[1,4′]bipiperidinyl-4-yl-acetate

a suspension of 3.24 g (9.41 mmol)ethyl(1′-benzyl-[1,4′]bipiperidinyl-4-yl)-acetate and 300 mg 10% Pd/C in50 mL EtOH was hydrogenated at RT and 3000 hPa hydrogen pressure untilthe theoretical amount of hydrogen has been taken up.

The catalyst was removed by suction filtering, the filtrate wasevaporated to dryness, the residue was combined with 50 mL EtOH andethanolic HCl (1.25 M). The mixture was evaporated to dryness i. vac.,the residue was stirred with 100 mL DIPE/isopropanol (2:1), theprecipitate was filtered off and dried at 35° C. in the circulating airdryer. The product was obtained as the bis-hydrochloride salt.

Yield: 2.90 g (94% of theory)

ESI-MS: (M+H)⁺=255

R_(f)=0.05 (silica gel, EtOAc/MeOH/NH₃ 70:30:3)

Amine 15 Ethyl 3-[1,4′]bipiperidinyl-4-yl-propionate

A15a) tert-butyl4-(2-methoxycarbonyl-ethyl)-[1,4′]bipiperidinyl-1′-carboxylate

Under a nitrogen atmosphere a mixture of 4.00 g (19.3 mmol) methyl3-piperidin-4-yl-propionate and 3.85 g (19.3 mmol) tert-butyl4-oxo-piperidine-1-carboxylate in 50 mL THF was adjusted to a pH of 5with AcOH and the mixture was stirred for 1 h at RT. After cooling to 0°C. the mixture was combined batchwise with 5.15 g (24.3 mmol) sodiumtriacetoxyborohydride and the reaction mixture was stirred overnight atRT. Within 10 min, 90 mL of 30% K₂CO₃ solution were added, the mixturewas extracted three times with EtOAc and the combined organic phaseswere dried over Na₂SO₄. After elimination of the desiccant and solventthe residue was further reacted without any further purification.

Yield: 5.40 g (79% of theory)

ESI-MS: (M+H)⁺=355

R_(f)=0.63 (silica gel, DCM/MeOH/NH₃ 80:20:2)

A15b) ethyl 3-[1,4′]bipiperidinyl-4-yl-propionate

5.40 g (15.2 mmol) tert-butyl4-(2-methoxycarbonyl-ethyl)-[1,4′]bipiperidinyl-1′-carboxylate in 150 mLethanolic HCl (1.25 M) was stirred overnight at RT. The solvent waslargely removed i. vac., the precipitate formed was filtered off anddried. The product, which was obtained as the bis-hydrochloride salt,was reacted further without purification.

Yield: 2.30 g (79% of theory)

ESI-MS: (M+H)⁺=269

Retention time (HPLC): 1.2 min (method B)

Amine 16 Ethyl 4-(4-piperazin-1-yl-piperidin-1-yl)-butyrate

A16a) ethyl 4-[4-(4-benzyl-piperazin-1-yl)-piperidin-1-yl]-butyrate

Under a nitrogen atmosphere a mixture of 3.11 g (12.0 mmol)1-benzyl-4-piperidin-4-yl-piperazine and 7.50 mL (12.0 mmol, 15% inwater) 4-oxo-butyric acid in 70 mL THF was adjusted to a pH of 5 withAcOH and stirred for 1 h at RT. After cooling to 0° C., 5.35 g (24.0mmol) sodium triacetoxyborohydride were added batchwise and the reactionmixture was stirred overnight at RT. Within 15 min 80 mL of 30% K₂CO₃solution were added dropwise, the aqueous phase was washed twice withEtOAc and evaporated down by half i. vac. 1 M KHSO₄ solution was added,the precipitate formed was removed by suction filtering, the filtratewas washed with EtOAc and the aqueous phase was evaporated to dryness i.vac. The residue was taken up in 150 mL ethanolic HCl (1.25 M) and thereaction mixture was stirred overnight at RT. It was evaporated down i.vac., the residue was taken up in a little 15% K₂CO₃ solution, extractedexhaustively with EtOAc and the combined organic phases were dried overNa₂SO₄. After elimination of the desiccant and solvent the residue wasfurther reacted without any further purification.

Yield: 2.90 g (65% of theory)

ESI-MS: (M+H)⁺=374

A16b) ethyl 4-(4-piperazin-1-yl-piperidin-1-yl)-butyrate

A suspension of 2.90 g (7.76 mmol) ethyl4-[4-(4-benzyl-piperazin-1-yl)-piperidin-1-yl]-butyrate and 300 mg 10%Pd/C in 60 mL MeOH was hydrogenated for 24 h at RT and 3447 hPa hydrogenpressure. The catalyst was removed by suction filtering, the filtratewas evaporated to dryness, the residue was taken up in DIPE and a littleisopropanol and combined with 4 M HCl in 1,4-dioxane. The precipitatewas suction filtered and dried. The product was obtained as thebis-hydrochloride salt.

Yield: 2.50 g (90% of theory)

ESI-MS: (M+H)⁺=284

Retention time (HPLC): 0.7 min (method B)

Amine 17 Benzyl 4-piperazin-1-yl-piperidine-1-carboxylate

A17a) tert-butyl4-(1-benzyloxycarbonyl-piperidin-4-yl)-piperazine-1-carboxylate

A solution of 7.18 mL (48.0 mmol) benzyl chloroformate in 50 mL DCM wasadded dropwise to 12.3 g (45.7 mmol) tert-butyl4-piperidin-4-yl-piperazine-1-carboxylate and 8.2 mL (50 mmol)N-ethyldiisopropylamine in 200 mL DCM while cooling with ice and thereaction mixture was stirred overnight at RT. It was washed with 200 mLof 15% K₂CO₃ solution, the organic phase was separated off and driedover Na₂SO₄. After elimination of the desiccant and solvent the residuewas further reacted without any further purification.

Yield: 16.0 g (87% of theory)

A17b) benzyl 4-piperazin-1-yl-piperidine-1-carboxylate

25 mL TFA were added at RT to 16.0 g (39.7 mmol) tert-butyl4-(1-benzyloxycarbonyl-piperidin-4-yl)-piperazine-1-carboxylate in 200mL DCM and the reaction mixture was stirred overnight at RT. It wasevaporated down i. vac., the residue was taken up in 200 mL water and200 mL EtOAc, the aqueous phase was separated off, combined with 50 mL15% K₂CO₃ solution, extracted twice with 200 mL EtOAc and the combinedorganic phases were dried over Na₂SO₄. After elimination of thedesiccant and solvent the residue was reacted with any furtherpurification.

Yield: 4.00 g (33% of theory)

ESI-MS: (M+H)⁺=304

The preparation of the final compounds is described hereinafter:

EXAMPLE 1 Ethyl1′-{(R)-3-(4-amino-3-chloro-5-trifluoromethyl-phenyl)-2-[4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidine-1-carbonyloxy]-propionyl}-1,4′-bipiperidinyl-4-carboxylate

1a)(Z,E)-2-acetylamino-3-(4-amino-3-chloro-5-trifluoromethyl-phenyl)-acrylicacid

39.7 g (335 mmol) N-acetylglycine were added to a suspension of 50.0 g(224 mmol) 4-amino-3-chloro-5-trifluoromethyl-benzaldehyde and 27.5 g(335 mmol) NaOAc in 202 mL acetic anhydride and the reaction mixture washeated to 115° C. for 1 h. After cooling to 80° C. 100 mL water wereadded dropwise, while the temperature of the mixture was maintained at80° C. The suspension was heated to 95° C. for a further 40 min and thenadded to a mixture of 250 mL toluene and 500 mL water. The suspensionwas stirred at RT, the precipitate was suction filtered and dried at 60°C. in the circulating air dryer.

Yield: 48.8 g (68% of theory)

ESI-MS: (M+H)⁺=321/323 (Cl)

R_(f)=0.37 (silica gel, DCM/MeOH/AcOH 90:10:1)

1 b) 3-(4-amino-3-chloro-5-trifluoromethyl-phenyl)-2-oxo-propionic acid

A suspension of 97.0 g (300 mmol)(Z,E)-2-acetylamino-3-(4-amino-3-chloro-5-tri-fluoromethyl-phenyl)-acrylicacid in 900 mL 1,4-dioxane and 1050 mL 4 M HCl was heated to 100° C. for8 h. The mixture was evaporated down to about 600 mL i. vac., cooled toRT, the substance precipitated was filtered off, washed twice with 100mL water and dried at 50° C. The residue was taken up in 850 mL toluene,refluxed and then cooled in the ice bath. The precipitate formed wasfiltered, washed with PE and dried in the circulating air dryer at 50°C.

Yield: 63.0 g (74% of theory)

ESI-MS: (M−H)⁻=280/282 (Cl)

R_(f)=0.21 (silica gel, DCM/MeOH/NH₃ 80:20:2)

1c)(R)-3-(4-amino-3-chloro-5-trifluoromethyl-phenyl)-2-hydroxy-propionicacid

A solution of 100.0 g (312 mmol) (1R)—B-chlorodiisopinocampheylborane in150 mL THF was added dropwise to a solution of 63.0 g (224 mmol)3-(4-amino-3-chloro-5-trifluoromethyl-phenyl)-2-oxo-propionic acid and31.2 mL (224 mmol) triethylamine in 300 mL THF cooled to about −30° C.and the reaction mixture was kept for 1.5 h at this temperature and thenheated to RT within a further hour with 80 mL 4 M NaOH were added to thereaction mixture, it was stirred for 5 min, cooled to 0° C., combinedwith 300 mL MTBE, stirred for another 20 min at this temperature andthen the phases were separated. The organic phase was exhaustivelyextracted with water, the combined aqueous phases were acidified with 4M HCl, exhaustively extracted with MTBE and the combined organic phaseswere dried over Na₂SO₄.

The THF/MTBE/NaOH phase was acidified with 4 M HCl, the phases wereseparated and the organic phase was evaporated down i. vac. The tworesidues were combined and reacted further without purification.

R_(f)=0.20 (silica gel, DCM/MeOH/NH₃ 80:20:2)

1 d)methyl(R)-3-(4-amino-3-chloro-5-trifluoromethyl-phenyl)-2-hydroxy-propionate

The crude product of Example 1c (62 g) was dissolved in 300 mL MeOH and3.65 mL (50 mmol) SOCl₂ were slowly added dropwise to this solution. Thereaction mixture was stirred for a further 3 h at RT, then evaporateddown i. vac., the residue was taken up in DCM and filtered throughsilica gel. The solution was evaporated down i. vac. and the residue waspurified by chromatography (silica gel, DCM/MeOH/NH₃ 80:20:2). Thefractions containing the product were combined, evaporated down i. vac.,the residue was combined with PE, suction filtered and dried.

Yield: 43.1 g (65% of theory over 2 steps)

ESI-MS: (M+H)⁺=298/300 (Cl)

R_(f)=0.86 (silica gel, DCM/MeOH/NH₃ 80:20:2)

1 e)(R)-2-(4-amino-3-chloro-5-trifluoromethyl-phenyl)-1-methoxycarbonyl-ethyl4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidine-1-carboxylate

Under a nitrogen atmosphere a solution of 13.5 g (65.0 mmol)4-nitrophenyl chloroformate in 40 mL THF were metered into 100 mLpyridine at 60° C. (bath temperature) within 10 min, the mixture wasstirred for 10 min, then a solution of 18.0 g (60.5 mmol)methyl(R)-3-(4-amino-3-chloro-5-trifluoromethyl-phenyl)-2-hydroxy-propionatein 50 ml of pyridine was added dropwise and the reaction mixture waskept for 1.5 h at this temperature. Then 15.9 g (65.0 mmol)3-piperidin-4-yl-1,3,4,5-tetrahydro-1,3-benzodiazepin-2-one was addedbatchwise. The temperature of the reaction mixture was increased to 100°C., the mixture was kept at this temperature for 6 h and then stirredovernight at RT. The mixture was evaporated down i. vac., the residuewas taken up in 200 mL EtOAc, the organic phase was washed twice with100 mL of 1 M KHSO₄ solution, ten times with 50 mL of 15% K₂CO₃ solutionand dried over Na₂SO₄. After elimination of the desiccant and solventthe residue was reacted further without purification.

Yield: 33.1 g (96% of theory)

ESI-MS: (M+H)⁺=569/571 (Cl)

R_(f)=0.72 (silica gel, DCM/Cyc/MeOH/NH₃ 70:15:15:2)

1 f) (R)-2-(4-amino-3-chloro-5-trifluoromethyl-phenyl)-1-carboxy-ethyl4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidine-1-carboxylate

A solution of 2.11 g (88.0 mmol) LiOH in 100 mL water was added to asolution of 33.0 g (58.0 mmol)(R)-2-(4-amino-3-chloro-5-trifluoromethyl-phenyl)-1-methoxy-carbonyl-ethyl4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidine-1-carboxylatein 200 mL THF and the reaction solution was stirred for 3.5 h at RT. THFwas eliminated i. vac., the aqueous residue was washed twice with MTBE,acidified with 2 M HCl, exhaustively extracted with DCM and the combinedorganic phases were dried over Na₂SO₄. After elimination of thedesiccant and solvent the residue was dissolved at 65° C. in 80 mLisopropanol and slowly cooled to RT overnight. The suspension was cooledin the ice bath, suction filtered, washed with a little isopropanol andDIPE and dried.

Yield: 26.2 g (81% of theory)

ESI-MS: (M+H)⁺=555/557 (Cl)

R_(f)=0.18 (silica gel, DCM/Cyc/MeOH/NH₃ 70:15:15:2)

Retention time (HPLC): 4.0 min (Method B)

1g)(R)-1-(4-amino-3-chloro-5-trifluoromethyl-benzyl)-2-oxo-2-(4-oxo-piperidin-1-yl)-ethyl4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidine-1-carboxylate

7.40 g (23.0 mmol) TBTU and 5.84 mL (40.0 mmol) triethylamine were addedto a solution of 10.0 g (18.0 mmol)(R)-2-(4-amino-3-chloro-5-trifluoromethyl-phenyl)-1-carboxy-ethyl4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidine-1-carboxylatein 50 mL DMF and stirred for 10 min at RT. 2.77 g (18.0 mmol)piperidin-4-one (used as the hydrate of the hydrochloride salt) wereadded to the reaction mixture and this was stirred overnight at RT. Thereaction solution was poured onto 1 L of 7% K₂CO₃ solution, theprecipitated substance was filtered off, washed with water and dried at60° C. for 6 h. Further purification was carried out by columnchromatography (silica gel, EtOAc).

Yield: 7.5 g (65% of theory)

ESI-MS: (M+H)⁺=636/638 (Cl)

R_(f)=0.25 (silica gel, EtOAc)

1 h) ethyl1′-{(R)-3-(4-amino-3-chloro-5-trifluoromethyl-phenyl)-2-[4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidine-1-carbonyloxy]-propionyl}-1,4′-bipiperidinyl-4-carboxylate

62.9 mg (0.4 mmol) ethyl piperidine-4-carboxylate and 11 μL (0.2 mmol)AcOH were added to a solution of 127 mg (0.2 mmol)(R)-1-(4-amino-3-chloro-5-trifluoromethyl-benzyl)-2-oxo-2-(4-oxo-piperidin-1-yl)-ethyl4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidine-1-carboxylatein 2 mL THF/MeOH (2:1) and the reaction mixture was stirred for 2 h atRT. Then it was cooled to 0° C., combined with 10.6 mg (0.16 mmol)NaBH₃CN after 2 h and stirred at 0° C. overnight. The solvent wasallowed to evaporate, the residue was taken up in 2 mL DMF and the crudeproduct was purified by HPLC. The fractions containing the product werecombined and freeze-dried.

Yield: 68 mg (44% of theory)

ESI-MS: (M+H)⁺=777/779 (Cl)

Retention time (HPLC): 7.0 min (Method C)

EXAMPLE 1.11′-{(R)-3-(4-amino-3-chloro-5-trifluoromethyl-phenyl)-2-[4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidine-1-carbonyloxy]-propionyl}-1,4′-bipiperidinyl-4-carboxylicacid

A solution of 7.2 mg (0.3 mmol) LiOH in 1 mL water was added to asolution of 140 mg (0.18 mmol) ethyl1′-{(R)-3-(4-amino-3-chloro-5-trifluoromethyl-phenyl)-2-[4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidine-1-carbonyloxy]-propionyl}-1,4′-bipiperidinyl-4-carboxylatein 1 mL THF and the reaction mixture was stirred for 3 h at RT. 1 mL HCl(1 M) was added and the crude product was purified by HPLC. Thefractions containing the product were combined and freeze-dried.

Yield: 53 mg (39% of theory)

ESI-MS: (M+H)⁺=749/751 (Cl)

Retention time (HPLC): 3.4 min (Method B)

EXAMPLE 2(R)-1-(4-amino-3-chloro-5-trifluoromethyl-benzyl)-2-[4-(ethoxycarbonylmethyl-amino)-1,4′-bipiperidinyl-1′-yl]-2-oxo-ethyl4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidine-1-carboxylate

2a)(R)-1-(4-amino-3-chloro-5-trifluoromethyl-benzyl)-2-[4-(tert-butoxycarbonyl-ethoxycarbonyl-methylamino)-1,4′-bipiperidinyl-1′-yl]-2-oxo-ethyl4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidine-1-carboxylate

128 mg (0.40 mmol) TBTU and 56 μL (0.40 mmol) triethylamine were addedto a solution of 200 mg (0.36 mmol)(R)-2-(4-amino-3-chloro-5-trifluoromethyl-phenyl)-1-carboxy-ethyl4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidine-1-carboxylatein 2 mL DMF and stirred for 10 min at RT. 148 mg (0.40 mmol) ethyl([1,4′]bipiperidinyl-4-yl-tert-butoxycarbonyl-amino)-acetate (Amine A6)were added to the reaction mixture and this was stirred overnight at RT.The reaction solution was evaporated down i. vac., the residue was takenup in EtOAc, the precipitate formed was suction filtered and dried. Theproduct was reacted further without purification.

Yield: 330 mg (100% of theory)

2b)(R)-1-(4-amino-3-chloro-5-trifluoromethyl-benzyl)-2-[4-(ethoxycarbonylmethyl-amino)-1,4′-bipiperidinyl-1′-yl]-2-oxo-ethyl4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidine-1-carboxylate

0.5 mL TFA were added to a solution of 330 mg (0.36 mmol)(R)-1-(4-amino-3-chloro-5-trifluoromethyl-benzyl)-2-[4-(tert-butoxycarbonyl-ethoxycarbonyl-methylamino)-1,4′-bipiperidinyl-1′-yl]-2-oxo-ethyl4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidine-1-carboxylatein 5 mL DCM cooled to 0° C. and the reaction mixture was stirredovernight at RT. It was evaporated down i. vac. and the residue waspurified by HPLC. The fractions containing the product were combined andfreeze-dried.

Yield: 263 mg (90% of theory)

ESI-MS: (M+H)⁺=806/808 (Cl)

Retention time (HPLC): 2.6 min (Method A)

EXAMPLE 2.1(R)-1-(4-amino-3-chloro-5-trifluoromethyl-benzyl)-2-[4-(carboxymethyl-amino)-1,4′-bipiperidinyl-1′-yl]-2-oxo-ethyl4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidine-1-carboxylate

A solution of 9.4 mg (0.39 mmol) LiOH was added to a solution of 212 mg(0.26 mmol)(R)-1-(4-amino-3-chloro-5-trifluoromethyl-benzyl)-2-[4-(ethoxy-carbonylmethylamino)-1,4′-bipiperidinyl-1′-yl]-2-oxo-ethyl4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidine-1-carboxylatein 9 mL THF and the reaction mixture was stirred overnight at RT. Tocomplete the reaction 6.3 mg (0.26 mmol) LiOH were also added and themixture was again stirred overnight at RT. The reaction mixture waspurified by HPLC without further working up. The fractions containingthe product were combined and freeze-dried, the product being obtainedas the trifluoroacetate salt.

Yield: 130 mg (55% of theory)

ESI-MS: (M+H)⁺=778/780 (Cl)

Retention time (HPLC): 2.7 min (Method A)

EXAMPLE 3(R)-1-(4-amino-3-chloro-5-trifluoromethyl-benzyl)-2-(1′-ethoxycarbonylmethyl-4,4′-bipiperidinyl-1-yl)-2-oxo-ethyl4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidine-1-carboxylate

632 mg (1.97 mmol) TBTU and 0.34 mL (1.97 mmol) ethyldiisopropylaminewere added to a solution of 1.0 g (1.80 mmol)(R)-2-(4-amino-3-chloro-5-trifluoromethyl-phenyl)-1-carboxy-ethyl4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidine-1-carboxylatein 10 mL THF and the mixture was stirred for 10 min at RT. 500 mg (1.97mmol) ethyl[4,4′]bipiperidinyl-1-yl-acetate were added to the reactionmixture and this was stirred overnight at RT. The mixture was evaporateddown i. vac., the residue was taken up in DCM, the organic phase waswashed with 1 M KHSO₄ solution and 15% K₂CO₃ solution and dried overNa₂SO₄. After elimination of the desiccant and solvent the residue waspurified by HPLC. The fractions containing the product were combined,evaporated down i. vac., the residue was triturated with DIPE, suctionfiltered and dried.

Yield: 150 mg (11% of theory)

ESI-MS: (M+H)⁺=791/793 (Cl)

R_(f)=0.46 (silica gel, DCM/Cyc/MeOH/NH₃ 70:15:15:2)

EXAMPLE 3.1(R)-1-(4-amino-3-chloro-5-trifluoromethyl-benzyl)-2-(1′-carboxymethyl-4,4′-bipiperidinyl-1-yl)-2-oxo-ethyl4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidine-1-carboxylate

A solution of 1 mg (0.04 mmol) LiOH in 1 mL water was added to asolution of 30 mg (0.04 mmol)(R)-1-(4-amino-3-chloro-5-trifluoromethyl-benzyl)-2-(1′-ethoxy-carbonylmethyl-4,4′-bi-piperidinyl-1-yl)-2-oxo-ethyl4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidine-1-carboxylatein 2 mL THF and the reaction mixture was stirred overnight at RT. Themixture was evaporated down i. vac., the residue was combined with alittle water and 1 M HCl until an acidic reaction was obtained. Theprecipitate formed was suction filtered and dried.

Yield: 20 mg (66% of theory)

ESI-MS: (M+H)⁺=763/765 (Cl)

R_(f)=0.31 (silica gel, DCM/Cyc/MeOH/NH₃ 70:15:15:2)

EXAMPLE 3.2(R)-1-(4-amino-3-chloro-5-trifluoromethyl-benzyl)-2-(1′-methoxycarbonylmethyl-4,4′-bipiperidinyl-1-yl)-2-oxo-ethyl4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidine-1-carboxylate

100 mg (0.31 mmol) TBTU and 0.06 mL (0.34 mmol) ethyldiisopropylaminewere added to a solution of 200 mg (0.26 mmol)(R)-1-(4-amino-3-chloro-5-trifluoromethyl-benzyl)-2-(1′-carboxymethyl-4,4′-bipiperidinyl-1-yl)-2-oxo-ethyl4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidine-1-carboxylatein 15 mL THF and the mixture was stirred for 10 min at RT. 1 mL (24.6mmol) MeOH was added to the reaction mixture and this was stirredovernight at RT. It was evaporated down i. vac., the residue was takenup in 2 mL DMF and the crude product was purified by HPLC. The fractionscontaining the product were combined and freeze-dried.

Yield: 80 mg (39% of theory)

ESI-MS: (M+H)⁺=777/779 (Cl)

R_(f)=0.60 (silica gel, DCM/Cyc/MeOH/NH₃ 70:15:15:2)

The following compounds were prepared analogously from in each case 200mg of(R)-1-(4-amino-3-chloro-5-trifluoromethyl-benzyl)-2-(1′-carboxymethyl-4,4′-bipiperidinyl-1-yl)-2-oxo-ethyl4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidine-1-carboxylateand 1 mL of the respective alcohol:

R_(f) (silica gel, Mass DCM/MeOH/Cyc/NH₃ Example R Yield (%) spectrum70:15:15:2) 3.3

33 805/807 [M + H]⁺ 0.59 3.4

30 819/821 [M + H]⁺ 0.61 3.5

47 821/823 [M + H]⁺ 0.58 3.6

39 875/877 [M + H]⁺ 0.70

EXAMPLE 3.7(R)-1-(4-amino-3-chloro-5-trifluoromethyl-benzyl)-2-oxo-2-(1′-phenoxycarbonylmethyl-4,4′-bipiperidinyl-1-yl)-ethyl4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidine-1-carboxylate

50 mg (0.16 mmol) TBTU and 37 μL (0.26 mmol) triethylamine were added toa solution of 100 mg (0.13 mmol)(R)-1-(4-amino-3-chloro-5-trifluoromethyl-benzyl)-2-(1′-carboxymethyl-4,4′-bipiperidinyl-1-yl)-2-oxo-ethyl4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidine-1-carboxylatein 1.5 mL DMF and stirred for 1 h at RT. 14.8 mg (0.16 mmol) phenol wereadded and the reaction mixture was stirred overnight at RT. The reactionsolution was filtered through a syringe filter and the crude product waspurified by HPLC. The fractions containing the product were combined andfreeze-dried. The residue was dissolved in DCM, evaporated down i. vac.,triturated with DIPE, suction filtered and dried.

Yield: 48 mg (44% of theory)

ESI-MS: (M+H)⁺=839/841 (Cl)

R_(f)=0.47 (silica gel, DCM/MeOH/NH₃ 90:10:1)

Retention time (HPLC): 3.2 min (Method B)

The following compounds were prepared analogously from in each case 100mg (Examples 3.8 to 3.12), 120 mg (Example 3.13) or 90 mg (Examples 3.14and 3.15)(R)-1-(4-amino-3-chloro-5-trifluoromethyl-benzyl)-2-(1′-carboxymethyl-4,4′-bipiperidinyl-1-yl)-2-oxo-ethyl4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidine-1-carboxylateand the amount of the alcohol component needed in each case:

retention time Mass HPLC Example R Yield (%) spectrum (Method) 3.8

69 879/881 [M + H]⁺ 3.1 min (B) 3.9

57 876/878 [M + H]⁺ 2.5 min (B) 3.10

59 834/836 [M + H]⁺ 2.9 min (B) 3.11

52 888/890 [M + H]⁺ 3.0 min (B) 3.12

31 854/856 [M + H]⁺ 2.4 min (B) 3.13

57 874/876 [M + H]⁺ 3.0 min (B) 3.14

17 890/892 [M + H]⁺ 3.0 min (B) 3.15

63 848/850 [M + H]⁺ 3.0 min (B)

EXAMPLE 3.16(R)-1-(4-amino-3-chloro-5-trifluoromethyl-benzyl)-2-[1′-(2,2-dimethylpropionyloxy-methoxycarbonyl-methyl)-4,4′-bipiperidinyl-1-yl]-2-oxo-ethyl4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidine-1-carboxylate

27 mg (0.20 mmol) K₂CO₃ and 28 μL (0.20 mmol) chloromethyl2,2-dimethyl-propionate were added to a solution of 100 mg (0.13 mmol)(R)-1-(4-amino-3-chloro-5-trifluoromethyl-benzyl)-2-(1′-carboxymethyl-4,4′-bipiperidinyl-1-yl)-2-oxo-ethyl4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidine-1-carboxylatein 2 mL DMF and the reaction mixture was stirred for 2 h at RT. Themixture was evaporated down i. vac., the residue was taken up in 50 mLDCM, the organic phase was washed with 20 mL water and dried overNa₂SO₄. After elimination of the desiccant and solvent the residue waspurified by chromatography (silica gel, DCM/MeOH/NH₃ 97:3:0.3). Thefractions containing the product were combined, evaporated down, theresidue was triturated with a little diethyl ether/DIPE, suctionfiltered and dried.

Yield: 39 mg (34% of theory)

ESI-MS: (M+H)⁺=877/879 (Cl)

R_(f)=0.47 (silica gel, DCM/MeOH/NH₃ 90:10:1)

Retention time (HPLC): 3.3 min (Method B)

EXAMPLE 3.17(R)-1-(4-amino-3-chloro-5-trifluoromethyl-benzyl)-2-(1′-dimethylcarbamoylmethoxy-carbonylmethyl-4,4′-bipiperidinyl-1-yl)-2-oxo-ethyl4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidine-1-carboxylate

48 mg (0.15 mmol) TBTU, 21 μL (0.15 mmol) triethylamine and 15 mg (0.15mmol) 2-hydroxy-N,N-dimethyl-acetamide were added to a solution of 100mg (0.13 mmol)(R)-1-(4-amino-3-chloro-5-trifluoromethyl-benzyl)-2-(1′-carboxymethyl-4,4′-bipiperidinyl-1-yl)-2-oxo-ethyl4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidine-1-carboxylatein 1 mL DMF and the reaction mixture was stirred overnight at RT. Thereaction solution was filtered through a syringe filter and the crudeproduct was purified by HPLC. The fractions containing the product werecombined and evaporated down i. vac.

Yield: 23 mg (21% of theory)

ESI-MS: (M+H)⁺=848/850 (Cl)

Retention time (HPLC): 2.9 min (Method B)

EXAMPLE 4(R)-1-(4-amino-3-chloro-5-trifluoromethyl-benzyl)-2-[4-(1-ethoxycarbonylmethyl-piperidin-4-yl)-piperazin-1-yl]-2-oxo-ethyl4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidine-1-carboxylate

0.52 g (1.62 mmol) TBTU and 0.28 mL (1.61 mmol) ethyldiisopropylaminewere added to a solution of 0.80 g (1.44 mmol)(R)-2-(4-amino-3-chloro-5-trifluoromethyl-phenyl)-1-carboxy-ethyl4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidine-1-carboxylatein 30 mL THF and stirred for 10 min at RT. 0.40 g (1.57 mmol)ethyl(4-piperazin-1-yl-piperidin-1-yl)-acetate were added to thereaction mixture and this was stirred overnight at RT. 40 mL EtOAc wereadded, the organic phase was washed with 15% K₂CO₃ solution and driedover MgSO₄. After elimination of the desiccant and solvent the residuewas purified by chromatography (silica gel, gradient DCM to DCM/EtOH/NH₃70:30:3).

Yield: 0.68 g (60% of theory)

ESI-MS: (M+H)⁺=792/794 (Cl)

R_(f)=0.70 (silica gel, DCM/Cyc/MeOH/NH₃ 70:15:15:2)

EXAMPLE 4.1(R)-1-(4-amino-3-chloro-5-trifluoromethyl-benzyl)-2-[4-(1-carboxymethyl-piperidin-4-yl)-piperazin-1-yl]-2-oxo-ethyl4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidine-1-carboxylate

A solution of 25 mg (1.02 mmol) LiOH in 20 mL water was added to asolution of 380 mg (0.48 mmol)(R)-1-(4-amino-3-chloro-5-trifluoromethyl-benzyl)-2-[4-(1-ethoxycarbonylmethyl-piperidin-4-yl)-piperazin-1-yl]-2-oxo-ethyl4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidine-1-carboxylatein 20 mL THF and the reaction mixture was stirred overnight at RT. Theorganic solvent was eliminated i. vac. and 20 mL water and 1.1 mL 1 MHCl were added. The mixture was evaporated down i. vac., the residue wastaken up in 5 mL DMF and the crude product was purified by HPLC. Thefractions containing the product were combined and freeze-dried.

Yield: 114 mg (31% of theory)

ESI-MS: (M+H)⁺=764/766 (Cl)

R_(f)=0.07 (silica gel, DCM/Cyc/MeOH/NH₃ 70:15:15:2)

EXAMPLE 4.2(R)-1-(4-amino-3-chloro-5-trifluoromethyl-benzyl)-2-[4-(1-butoxycarbonylmethyl-piperidin-4-yl)-piperazin-1-yl]-2-oxo-ethyl4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidine-1-carboxylate

51 mg (0.16 mmol) TBTU and 29 μL (0.34 mmol) triethylamine were added toa solution of 80 mg (0.11 mmol)(R)-1-(4-amino-3-chloro-5-trifluoromethyl-benzyl)-2-[4-(1-carboxymethyl-piperidin-4-yl)-piperazin-1-yl]-2-oxo-ethyl4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidine-1-carboxylatein 1.5 mL DMF and the mixture was shaken for 30 min at RT. 100 μL (1.09mmol) 1-butanol were added to the reaction mixture and this was shakenovernight at RT. After filtration through a syringe filter the crudeproduct was purified by HPLC. The fractions containing the product werecombined and freeze-dried.

Yield: 46 mg (54% of theory)

ESI-MS: (M+H)⁺=820/822 (Cl)

R_(f)=0.67 (silica gel, DCM/Cyc/MeOH/NH₃ 70:15:15:2)

The following compounds were prepared analogously from in each case 80mg(R)-1-(4-amino-3-chloro-5-trifluoromethyl-benzyl)-2-[4-(1-carboxymethyl-piperidin-4-yl)-piperazin-1-yl]-2-oxo-ethyl4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidine-1-carboxylateand 100 μL of the respective alcohol component:

R_(f) (silica gel, Mass DCM/MeOH/Cyc/NH₃ Example R Yield (%) spectrum70:15:15:2) 4.3

52 834/836 [M + H]⁺ 0.63 4.4

52 848/850 [M + H]⁺ 0.61

The following compounds were prepared analogously from in each case 80mg(R)-1-(4-amino-3-chloro-5-trifluoromethyl-benzyl)-2-[4-(1-carboxymethyl-piperidin-4-yl)-piperazin-1-yl]-2-oxo-ethyl4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidine-1-carboxylateand 1.5 equivalents (Examples 4.5 and 4.6) and 1.6 equivalents (Examples4.7 and 4.8) of the respective alcohol component:

R_(f) (silica gel, Mass DCM/MeOH/Cyc/NH₃ Example R Yield (%) spectrum70:15:15:2) 4.5

44 840/842 [M + H]⁺ 0.71 4.6

57 889/891 [M + H]⁺ 0.70 4.7

33 880/882 [M + H]⁺ 0.51 4.8

49 855/857 [M + H]⁺ 0.67

EXAMPLE 4.9(R)-1-(4-amino-3-chloro-5-trifluoromethyl-benzyl)-2-{4-[1-(2-morpholin-4-yl-ethoxycarbonylmethyl)-piperidin-4-yl]-piperazin-1-yl}-2-oxo-ethyl4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidine-1-carboxylate

50 mg (0.16 mmol) TBTU and 37 μL (0.34 mmol) triethylamine were added toa solution of 100 mg (0.13 mmol)(R)-1-(4-amino-3-chloro-5-trifluoromethyl-benzyl)-2-[4-(1-carboxymethyl-piperidin-4-yl)-piperazin-1-yl]-2-oxo-ethyl4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidine-1-carboxylatein 5 mL THF and stirred for 30 min at RT. 19 μL (0.16 mmol)2-morpholin-4-yl-ethanol were added to the reaction mixture and thesuspension was stirred for 1.5 h at RT. 3 mL of DMF were added and themixture was stirred for another 4 h at RT. The reaction mixture wasevaporated down i. vac., the residue was dissolved in 1.5 mL MeOH,filtered through a syringe filter and purified by HPLC. The fractionscontaining the product were evaporated down i. vac., the residue wastriturated with DIPE, suction filtered and dried at 50° C. in vacuo.

Yield: 47 mg (41% of theory)

ESI-MS: (M+H)⁺=877/879 (Cl)

R_(f)=0.31 (silica gel, DCM/MeOH/NH₃ 90:10:1)

Retention time (HPLC): 2.7 min (Method B)

EXAMPLE 4.10(R)-1-(4-amino-3-chloro-5-trifluoromethyl-benzyl)-2-oxo-2-(4-{1-[2-(2-oxo-pyrrolidin-1-yl)-ethoxycarbonylmethyl]-piperidin-4-yl}-piperazin-1-yl)-ethyl4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidine-1-carboxylate

Prepared analogously to Example 4.9 from 80 mg (0.11 mmol)(R)-1-(4-amino-3-chloro-5-trifluoromethyl-benzyl)-2-[4-(1-carboxymethyl-piperidin-4-yl)-piperazin-1-yl]-2-oxo-ethyl4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidine-1-carboxylateand 18 μL (0.16 mmol) 1-(2-hydroxy-ethyl)-pyrrolidin-2-one, using 1.5 mLDMF as solvent.

Yield: 39 mg (43% of theory)

ESI-MS: (M+H)⁺=875/877 (Cl)

R_(f)=0.40 (silica gel, DCM/MeOH/NH₃ 90:10:1)

Retention time (HPLC): 2.9 min (Method B)

EXAMPLE 4.11(R)-1-(4-amino-3-chloro-5-trifluoromethyl-benzyl)-2-{4-[1-(3-morpholin-4-yl-propoxycarbonyl-methyl)-piperidin-4-yl]-piperazin-1-yl}-2-oxo-ethyl4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidine-1-carboxylate

Prepared analogously to Example 4.9 from 90 mg (0.12 mmol)(R)-1-(4-amino-3-chloro-5-trifluoromethyl-benzyl)-2-[4-(1-carboxymethyl-piperidin-4-yl)-piperazin-1-yl]-2-oxo-ethyl4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidine-1-carboxylateand 22 mg (0.15 mmol) 3-morpholin-4-yl-propan-1-ol, using 1.5 mL DMF assolvent. After purification by HPLC the product was taken up in DCM, theorganic phase was extracted with 5% NaHCO₃ solution and dried overNa₂SO₄. After elimination of the desiccant and solvent the residue wasstirred with DIPE, suction filtered and dried in the air.

Yield: 48 mg (46% of theory)

ESI-MS: (M+H)⁺=891/893 (Cl)

R_(f)=0.17 (silica gel, DCM/MeOH/NH₃ 90:10:1)

Retention time (HPLC): 2.7 min (Method B)

EXAMPLE 4.12(R)-1-(4-amino-3-chloro-5-trifluoromethyl-benzyl)-2-{4-[1-(2,2-dimethyl-propionyloxymethoxycarbonyl-methyl)-piperidin-4-yl]-piperazin-1-yl}-2-oxo-ethyl4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidine-1-carboxylate

42 mg (0.30 mmol) K₂CO₃ and 43 μL (0.30 mmol) chloromethyl2,2-dimethyl-propionate were added to a solution of 150 mg (0.20 mmol)(R)-1-(4-amino-3-chloro-5-trifluoromethyl-benzyl)-2-[4-(1-carboxymethyl-piperidin-4-yl)-piperazin-1-yl]-2-oxo-ethyl4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidine-1-carboxylatein 5 mL DMF and the reaction mixture was stirred overnight at RT. It wasevaporated down i. vac., the residue was combined with 30 mL 15% K₂CO₃solution, the product precipitated was suction filtered and purified bycolumn chromatography (silica gel, gradient DCM to DCM/MeOH/NH₃50:47:3).

Yield: 50 mg (29% of theory)

ESI-MS: (M+H)⁺=878/880 (Cl)

R_(f)=0.63 (silica gel, DCM/Cyc/MeOH/NH₃ 70:15:15:2)

EXAMPLE 4.13(R)-1-(4-amino-3-chloro-5-trifluoromethyl-benzyl)-2-{4-[1-(1-ethoxycarbonyloxy-ethoxycarbonyl-methyl)-piperidin-4-yl]-piperazin-1-yl}-2-oxo-ethyl4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidine-1-carboxylate

Prepared analogously to Example 4.12 from 150 mg (0.20 mmol)(R)-1-(4-amino-3-chloro-5-trifluoromethyl-benzyl)-2-[4-(1-carboxymethyl-piperidin-4-yl)-piperazin-1-yl]-2-oxo-ethyl4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidine-1-carboxylateand 40 μL (0.30 mmol) 1-chloroethyl-ethylcarbonate.

Yield: 50 mg (29% of theory)

ESI-MS: (M+H)⁺=880/882 (Cl)

R_(f)=0.68 (silica gel, DCM/Cyc/MeOH/NH₃ 70:15:15:2)

EXAMPLE 4.14(R)-1-(4-amino-3-chloro-5-trifluoromethyl-benzyl)-2-[4-(1-diethylcarbamoylmethoxy-carbonylmethyl-piperidin-4-yl)-piperazin-1-yl]-2-oxo-ethyl4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidine-1-carboxylate

50 mg (0.16 mmol) TBTU, 25 μL (0.18 mmol) triethylamine and 30 mg (0.23mmol) N,N-diethyl-2-hydroxy-acetamide were added to a solution of 100 mg(0.13 mmol)(R)-1-(4-amino-3-chloro-5-trifluoro-methyl-benzyl)-2-[4-(1-carboxymethyl-piperidin-4-yl)-piperazin-1-yl]-2-oxo-ethyl4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidine-1-carboxylatein 1 mL DMF and the reaction mixture was stirred for 20 h at RT. Thereaction solution was poured onto saturated NaHCO₃ solution, theprecipitate formed was suction filtered and dried. The crude product waspurified by HPLC. The fractions containing the product were combined andfreeze-dried.

Yield: 36 mg (31% of theory)

ESI-MS: (M+H)⁺=877/879 (Cl)

Retention time (HPLC): 3.2 min (Method B)

The following compounds were prepared analogously from in each case 100mg(R)-1-(4-amino-3-chloro-5-trifluoromethyl-benzyl)-2-[4-(1-carboxymethyl-piperidin-4-yl)-piperazin-1-yl]-2-oxo-ethyl4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidine-1-carboxylateand the corresponding amount of the respective alcohol component:

Mass Retention time Example R Yield (%) spectrum HPLC (Method) 4.15

76 849/851 [M + H]⁺ 3.1 min (B) 4.16

25 889/891 [M + H]⁺ 3.2 min (B)

EXAMPLE 5(R)-1-(4-amino-3-chloro-5-trifluoromethyl-benzyl)-2-[4-(4-ethoxycarbonylmethyl-piperazin-1-yl)-piperidin-1-yl]-2-oxo-ethyl4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidine-1-carboxylate

64 mg (0.20 mmol) TBTU and 28 μL (0.20 mmol) triethylamine were added toa solution of 100 mg (0.18 mmol)(R)-2-(4-amino-3-chloro-5-trifluoromethyl-phenyl)-1-carboxy-ethyl4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidine-1-carboxylatein 1 mL DMF and stirred for 10 min at RT. 51 mg (0.20 mmol)ethyl(4-piperidin-4-yl-piperazin-1-yl)-acetate were added to thereaction mixture and this was shaken overnight at RT. After filtrationthrough a syringe filter the reaction solution was purified by HPLCwithout further working up. The fractions containing the product werecombined and freeze-dried.

Yield: 91 mg (64% of theory)

ESI-MS: (M+H)⁺=792/794 (Cl)

R_(f)=0.48 (silica gel, DCM/MeOH/NH₃ 90:10:1)

EXAMPLE 5.1(R)-1-(4-amino-3-chloro-5-trifluoromethyl-benzyl)-2-[4-(4-carboxymethyl-piperazin-1-yl)-piperidin-1-yl]-2-oxo-ethyl4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidine-1-carboxylate

A solution of 3.6 mg (0.15 mmol) LiOH in 1 mL water was added to asolution of 70 mg (0.09 mmol)(R)-1-(4-amino-3-chloro-5-trifluoromethyl-benzyl)-2-[4-(4-ethoxy-carbonylmethyl-piperazin-1-yl)-piperidin-1-yl]-2-oxo-ethyl4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidine-1-carboxylatein 10 mL THF and the reaction mixture was stirred overnight at RT. TheTHF was eliminated in a nitrogen stream, then a little water was added,followed by formic acid until an acidic reaction was obtained and thenacetonitrile and the product was subjected to freeze-drying.

Yield: 52 mg (76% of theory)

ESI-MS: (M−H)⁻=762/764 (Cl)

R_(f)=0.14 (silica gel, DCM/MeOH/NH₃ 90:10:1)

EXAMPLE 5.2(R)-1-(4-amino-3-chloro-5-trifluoromethyl-benzyl)-2-[4-(4-dimethylcarbamoylmethoxycarbonyl-methyl-piperazin-1-yl)-piperidin-1-yl]-2-oxo-ethyl4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidine-1-carboxylate

90 mg (0.28 mmol) TBTU, 39 μL (0.15 mmol) triethylamine and 29 mg (0.28mmol) 2-hydroxy-N,N-dimethyl-acetamide were added to a solution of 190mg (0.25 mmol)(R)-1-(4-amino-3-chloro-5-trifluoromethyl-benzyl)-2-[4-(4-carboxymethyl-piperazin-1-yl)-piperidin-1-yl]-2-oxo-ethyl4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidine-1-carboxylatein 5 mL DMF and the reaction mixture was stirred overnight at RT. Thereaction solution was filtered through a syringe filter and the crudeproduct was purified by HPLC. The fractions containing the product werecombined and freeze-dried.

Yield: 106 mg (50% of theory)

ESI-MS: (M+H)⁺=849/851 (Cl)

Retention time (HPLC): 3.3 min (Method B)

EXAMPLE 6(R)-1-(4-amino-3-chloro-5-trifluoromethyl-benzyl)-2-[1′-(2-ethoxycarbonyl-ethyl)-4,4′-bipiperidinyl-1-yl]-2-oxo-ethyl4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidine-1-carboxylate

64 mg (0.20 mmol) TBTU and 28 μL (0.20 mmol) triethylamine were added toa solution of 100 mg (0.18 mmol)(R)-2-(4-amino-3-chloro-5-trifluoromethyl-phenyl)-1-carboxy-ethyl4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidine-1-carboxylatein 1 mL DMF and stirred for 10 min at RT. 54 mg (0.20 mmol) ethyl3-[4,4′]bipiperidinyl-1-yl-propionate (Amine A1) were added to thereaction mixture and this was shaken overnight at RT. After filtrationthrough a syringe filter the reaction solution was purified by HPLCwithout further working up. The fractions containing the product werecombined and freeze-dried.

Yield: 42 mg (29% of theory)

ESI-MS: (M+H)⁺=805/807 (Cl)

R_(f)=0.58 (silica gel, DCM/MeOH/NH₃ 90:10:1)

EXAMPLE 6.1(R)-1-(4-amino-3-chloro-5-trifluoromethyl-benzyl)-2-[1′-(2-carboxy-ethyl)-4,4′-bipiperidinyl-1-yl]-2-oxo-ethyl4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidine-1-carboxylate

A solution of 1.4 mg (0.06 mmol) LiOH in 1 mL water was added to asolution of 30 mg (0.04 mmol)(R)-1-(4-amino-3-chloro-5-trifluoromethyl-benzyl)-2-[1′-(2-ethoxy-carbonyl-ethyl)-4,4′-bipiperidinyl-1-yl]-2-oxo-ethyl4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidine-1-carboxylatein 10 mL THF and the reaction mixture was stirred overnight at RT. TheTHF was eliminated in a nitrogen stream, then a little water was added,followed by formic acid until an acidic reaction was obtained and thenacetonitrile and the crude product was purified by HPLC. The fractionscontaining the product were combined and freeze-dried.

Yield: 28 mg (97% of theory)

ESI-MS: (M+H)⁺=777/779 (Cl)

R_(f)=0.15 (silica gel, DCM/MeOH/NH₃ 90:10:1)

EXAMPLE 7(R)-1-(4-amino-3-chloro-5-trifluoromethyl-benzyl)-2-{4-[1-(2-ethoxycarbonyl-ethyl)-piperidin-4-yl]-piperazin-1-yl}-2-oxo-ethyl4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidine-1-carboxylate

64 mg (0.20 mmol) TBTU and 111 μL (0.80 mmol) triethylamine were addedto a solution of 100 mg (0.18 mmol)(R)-2-(4-amino-3-chloro-5-trifluoromethyl-phenyl)-1-carboxy-ethyl4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidine-1-carboxylatein 1 mL DMF and stirred for 10 min at RT. 122 mg (0.20 mmol) ethyl3-(4-piperazin-1-yl-piperidin-1-yl)-propionate (Amine A2, used as thetris-trifluoroacetate salt) were added to the reaction mixture and thiswas shaken overnight at RT. After filtration through a syringe filterthe reaction solution was purified by HPLC without further working up.The fractions containing the product were combined and freeze-dried.

Yield: 45 mg (31% of theory)

ESI-MS: (M+H)⁺=806/808 (Cl)

R_(f)=0.57 (silica gel, DCM/MeOH/NH₃ 90:10:1)

EXAMPLE 7.1(R)-1-(4-amino-3-chloro-5-trifluoromethyl-benzyl)-2-{4-[1-(2-carboxy-ethyl)-piperidin-4-yl]-piperazin-1-yl}-2-oxo-ethyl4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidine-1-carboxylate

Prepared analogously to Example 6.1 from 30 mg (0.04 mmol)(R)-1-(4-amino-3-chloro-5-trifluoromethyl-benzyl)-2-{4-[1-(2-ethoxycarbonyl-ethyl)-piperidin-4-yl]-piperazin-1-yl}-2-oxo-ethyl4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidine-1-carboxylateand 1.4 mg (0.06 mmol) LiOH.

Yield: 15 mg (51% of theory)

ESI-MS: (M−H)⁻=776/778 (Cl)

R_(f)=0.13 (silica gel, DCM/MeOH/NH₃ 90:10:1)

EXAMPLE 7.2(R)-1-(4-amino-3-chloro-5-trifluoromethyl-benzyl)-2-(4-{1-[2-(2-dimethylamino-ethoxycarbonyl)-ethyl]-piperidin-4-yl}-piperazin-1-yl)-2-oxo-ethyl4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidine-1-carboxylate

48 mg (0.15 mmol) TBTU and 21 μL (0.15 mmol) triethylamine were added toa solution of 100 mg (0.13 mmol)(R)-1-(4-amino-3-chloro-5-trifluoromethyl-benzyl)-2-{4-[1-(2-carboxy-ethyl)-piperidin-4-yl]-piperazin-1-yl}-2-oxo-ethyl4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidine-1-carboxylatein 1 mL DMF and stirred for 10 min at RT. 15 μL (0.15 mmol)2-dimethylamino-ethanol were added to the reaction mixture and this wasshaken overnight at RT. After filtration through a syringe filter thereaction solution was purified by HPLC without further working up. Thefractions containing the product were combined and freeze-dried.

Yield: 22 mg (20% of theory)

ESI-MS: (M+H)⁺=849/851 (Cl)

Retention time (HPLC): 2.8 min (Method B)

The following compounds were prepared analogously from in each case 100mg (Examples 7.3 and 7.4) or from 95 mg (Example 7.5)(R)-1-(4-amino-3-chloro-5-trifluoromethyl-benzyl)-2-{4-[1-(2-carboxy-ethyl)-piperidin-4-yl]-piperazin-1-yl}-2-oxo-ethyl4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidine-1-carboxylateand the corresponding amount of the respective alcohol component:

Mass Retention time Example R Yield (%) spectrum HPLC (Method) 7.3

17 891/893 [M + H]⁺ 2.1 min (B) 7.4

39 889/891 [M + H]⁺ 2.7 min (B) 7.5

16 863/865 [M + H]⁺ 3.1 min (B)

EXAMPLE 8(R)-1-(4-amino-3-chloro-5-trifluoromethyl-benzyl)-2-{4-[4-(2-ethoxycarbonyl-ethyl)-piperazin-1-yl]-piperidin-1-yl}-2-oxo-ethyl4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidine-1-carboxylate

64 mg (0.20 mmol) TBTU and 28 μL (0.20 mmol) triethylamine were added toa solution of 100 mg (0.18 mmol)(R)-2-(4-amino-3-chloro-5-trifluoromethyl-phenyl)-1-carboxy-ethyl4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidine-1-carboxylatein 1 mL DMF and stirred for 10 min at RT. 54 mg (0.20 mmol) ethyl3-(4-piperidin-4-yl-piperazin-1-yl)-propionate (Amine A3) were added tothe reaction mixture and this was shaken overnight at RT. Afterfiltration through a syringe filter the reaction solution was purifiedby HPLC without further working up. The fractions containing the productwere combined and freeze-dried.

Yield: 77 mg (53% of theory)

ESI-MS: (M+H)⁺=806/808 (Cl)

R_(f)=0.58 (silica gel, DCM/MeOH/NH₃ 90:10:1)

EXAMPLE 8.1(R)-1-(4-amino-3-chloro-5-trifluoromethyl-benzyl)-2-{4-[4-(2-carboxy-ethyl)-piperazin-1-yl]-piperidin-1-yl}-2-oxo-ethyl4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidine-1-carboxylate

Prepared analogously to Example 6.1 from 60 mg (0.07 mmol)(R)-1-(4-amino-3-chloro-5-trifluoromethyl-benzyl)-2-{4-[4-(2-ethoxycarbonyl-ethyl)-piperazin-1-yl]-piperidin-1-yl}-2-oxo-ethyl4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidine-1-carboxylateand 2.9 mg (0.12 mmol) LiOH.

Yield: 40 mg (70% of theory)

ESI-MS: (M−H)⁻=776/778 (Cl)

R_(f)=0.14 (silica gel, DCM/MeOH/NH₃ 90:10:1)

EXAMPLE 9(R)-1-(4-amino-3-chloro-5-trifluoromethyl-benzyl)-2-[4-((R)-2-ethoxycarbonyl-pyrrolidin-1-yl)-piperidin-1-yl]-2-oxo-ethyl4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidine-1-carboxylate

64 mg (0.20 mmol) TBTU and 28 μL (0.20 mmol) triethylamine were added toa solution of 100 mg (0.18 mmol)(R)-2-(4-amino-3-chloro-5-trifluoromethyl-phenyl)-1-carboxy-ethyl4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidine-1-carboxylatein 1 mL DMF and stirred for 10 min at RT. 45 mg (0.20 mmol) ethyl(R)-1-piperidin-4-yl-pyrrolidine-2-carboxylate were added to thereaction mixture and this was shaken overnight at RT. After filtrationthrough a syringe filter the reaction solution was purified by HPLCwithout further working up. The fractions containing the product werecombined and freeze-dried.

Yield: 77 mg (56% of theory)

ESI-MS: (M+H)⁺=763/765 (Cl)

Retention time (HPLC): 3.4 min (Method B)

EXAMPLE 9.1(R)-1-(4-amino-3-chloro-5-trifluoromethyl-benzyl)-2-[4-((R)-2-carboxy-pyrrolidin-1-yl)-piperidin-1-yl]-2-oxo-ethyl4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidine-1-carboxylate

Prepared analogously to Example 6.1 from 60 mg (0.08 mmol)(R)-1-(4-amino-3-chloro-5-trifluoromethyl-benzyl)-2-[4-((R)-2-ethoxycarbonyl-pyrrolidin-1-yl)-piperidin-1-yl]-2-oxo-ethyl4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidine-1-carboxylateand 2.9 mg (0.12 mmol) LiOH.

Yield: 42 mg (73% of theory)

ESI-MS: (M+H)⁺=735/737 (Cl)

Retention time (HPLC): 3.3 min (Method B)

EXAMPLE 9.2(R)-1-(4-amino-3-chloro-5-trifluoromethyl-benzyl)-2-[4-((R)-2-dimethylcarbamoylmethoxycarbonyl-pyrrolidin-1-yl)-piperidin-1-yl]-2-oxo-ethyl4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidine-1-carboxylate

25 mg (0.08 mmol) TBTU and 11 μL (0.08 mmol) triethylamine were added toa solution of 50 mg (0.07 mmol)(R)-1-(4-amino-3-chloro-5-trifluoromethyl-benzyl)-2-[4-((R)-2-carboxy-pyrrolidin-1-yl)-piperidin-1-yl]-2-oxo-ethyl4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidine-1-carboxylatein 1 mL DMF and stirred for 10 min at RT. 8.1 mg (0.08 mmol)2-hydroxy-N,N-dimethyl-acetamide were added to the reaction mixture andthis was shaken overnight at RT. After filtration through a syringefilter the reaction solution was purified by HPLC without furtherworking up. The fractions containing the product were combined andfreeze-dried.

Yield: 38 mg (68% of theory)

ESI-MS: (M+H)⁺=820/822 (Cl)

Retention time (HPLC): 2.9 min (Method A)

EXAMPLE 9.3(R)-1-(4-amino-3-chloro-5-trifluoromethyl-benzyl)-2-{4-[(R)-2-(2-morpholin-4-yl-ethoxycarbonyl)-pyrrolidin-1-yl]-piperidin-1-yl}-2-oxo-ethyl4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidine-1-carboxylate

Prepared analogously to Example 9.2 from 50 mg (0.07 mmol)(R)-1-(4-amino-3-chloro-5-trifluoromethyl-benzyl)-2-[4-((R)-2-carboxy-pyrrolidin-1-yl)-piperidin-1-yl]-2-oxo-ethyl4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidine-1-carboxylateand 10.3 mg (0.08 mmol) 2-morpholin-4-yl-ethanol.

Yield: 35 mg (61% of theory)

ESI-MS: (M+H)⁺=848/850 (Cl)

Retention time (HPLC): 2.6 min (Method A)

EXAMPLE 10(R)-1-(4-amino-3-chloro-5-trifluoromethyl-benzyl)-2-[4-((S)-2-methoxycarbonyl-pyrrolidin-1-yl)-piperidin-1-yl]-2-oxo-ethyl4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidine-1-carboxylate

Prepared analogously to Example 9 from 100 mg (0.18 mmol)(R)-2-(4-amino-3-chloro-5-trifluoromethyl-phenyl)-1-carboxy-ethyl4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidine-1-carboxylateand 42 mg (0.20 mmol)methyl(S)-1-piperidin-4-yl-pyrrolidine-2-carboxylate.

Yield: 80 mg (59% of theory)

ESI-MS: (M+H)⁺=749/751 (Cl)

Retention time (HPLC): 3.3 min (Method B)

EXAMPLE 10.1(R)-1-(4-amino-3-chloro-5-trifluoromethyl-benzyl)-2-[4-((S)-2-carboxy-pyrrolidin-1-yl)-piperidin-1-yl]-2-oxo-ethyl4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidine-1-carboxylate

A solution of 2.9 mg (0.12 mmol) LiOH in 1 mL water was added to asolution of 60 mg (0.08 mmol)(R)-1-(4-amino-3-chloro-5-trifluoromethyl-benzyl)-2-[4-((S)-2-methoxycarbonyl-pyrrolidin-1-yl)-piperidin-1-yl]-2-oxo-ethyl4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidine-1-carboxylatein 3 mL THF and the reaction mixture was stirred overnight at RT. Thesolvent was eliminated in the nitrogen stream, the residue was taken upin 1 mL water, formic acid was added until an acidic reaction wasobtained and the mixture was exhaustively extracted with EtOAc. Thecombined organic extracts were dried over Na₂SO₄, filtered andevaporated down i. vac. The residue was taken up in a little water andacetonitrile and freeze-dried.

Yield: 51 mg (87% of theory)

ESI-MS: (M+H)⁺=735/737 (Cl)

Retention time (HPLC): 3.3 min (Method B)

EXAMPLE 10.2(R)-1-(4-amino-3-chloro-5-trifluoromethyl-benzyl)-2-[4-((S)-2-dimethylcarbamoylmethoxycarbonyl-pyrrolidin-1-yl)-piperidin-1-yl]-2-oxo-ethyl4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidine-1-carboxylate

Prepared analogously to Example 9.2 from 70 mg (0.10 mmol)(R)-1-(4-amino-3-chloro-5-trifluoromethyl-benzyl)-2-[4-((S)-2-carboxy-pyrrolidin-1-yl)-piperidin-1-yl]-2-oxo-ethyl4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidine-1-carboxylateand 11 mg (0.11 mmol) 2-hydroxy-N,N-dimethyl-acetamide.

Yield: 45 mg (58% of theory)

ESI-MS: (M+H)⁺=820/822 (Cl)

Retention time (HPLC): 3.0 min (Method A)

EXAMPLE 10.3(R)-1-(4-amino-3-chloro-5-trifluoromethyl-benzyl)-2-{4-[(S)-2-(2-morpholin-4-yl-ethoxycarbonyl)-pyrrolidin-1-yl]-piperidin-1-yl}-2-oxo-ethyl4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidine-1-carboxylate

Prepared analogously to Example 9.2 from 70 mg (0.10 mmol)(R)-1-(4-amino-3-chloro-5-trifluoromethyl-benzyl)-2-[4-((S)-2-carboxy-pyrrolidin-1-yl)-piperidin-1-yl]-2-oxo-ethyl4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidine-1-carboxylateand 13.2 mg (0.11 mmol) 2-morpholin-4-yl-ethanol.

Yield: 54 mg (59% of theory)

ESI-MS: (M+H)⁺=848/850 (Cl)

Retention time (HPLC): 2.6 min (Method A)

EXAMPLE 11Methyl(R)-1′-{(R)-3-(4-amino-3-chloro-5-trifluoromethyl-phenyl)-2-[4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidine-1-carbonyloxy]-propionyl}-1,4′-bipiperidinyl-2-carboxylate

64 mg (0.20 mmol) TBTU and 56 μL (0.40 mmol) triethylamine were added toa solution of 100 mg (0.18 mmol)(R)-2-(4-amino-3-chloro-5-trifluoromethyl-phenyl)-1-carboxy-ethyl4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidine-1-carboxylatein 1 mL DMF and stirred for 10 min at RT. 57 mg (0.20 mmol) methyl(R)-[1,4′]bipiperidinyl-2-carboxylate (used as the acetate salt) wereadded to the reaction mixture and this was shaken overnight at RT. Afterfiltration through a syringe filter the reaction solution was purifiedby HPLC without further working up. The fractions containing the productwere combined and freeze-dried.

Yield: 59 mg (43% of theory)

ESI-MS: (M+H)⁺=763/765 (Cl)

R_(f)=0.50 (silica gel, DCM/MeOH/NH₃ 90:10:1)

EXAMPLE 11.1(R)-1′-{(R)-3-(4-amino-3-chloro-5-trifluoromethyl-phenyl)-2-[4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidine-1-carbonyloxy]-propionyl}-1,4′-bipiperidinyl-2-carboxylicacid

Prepared analogously to Example 6.1 from 40 mg (0.05 mmol)methyl(R)-1′-{(R)-3-(4-amino-3-chloro-5-trifluoromethyl-phenyl)-2-[4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidine-1-carbonyloxy]-propionyl}-1,4′-bipiperidinyl-2-carboxylateand 1.9 mg (0.08 mmol) LiOH.

Yield: 10 mg (25% of theory)

ESI-MS: (M−H)⁻=747/749 (Cl)

R_(f)=0.27 (silica gel, DCM/MeOH/NH₃ 90:10:1)

EXAMPLE 12Methyl(S)-1′-{(R)-3-(4-amino-3-chloro-5-trifluoromethyl-phenyl)-2-[4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidine-1-carbonyloxy]-propionyl}-1,4′-bipiperidinyl-2-carboxylate

Prepared analogously to Example 11 from 100 mg (0.18 mmol)(R)-2-(4-amino-3-chloro-5-trifluoromethyl-phenyl)-1-carboxy-ethyl4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidine-1-carboxylateand 45 mg (0.20 mmol) methyl(S)-[1,4′]bipiperidinyl-2-carboxylate.

Yield: 33 mg (24% of theory)

ESI-MS: (M+H)⁺=763/765 (Cl)

R_(f)=0.44 (silica gel, DCM/MeOH/NH₃ 90:10:1)

EXAMPLE 12.1(S)-1′-{(R)-3-(4-amino-3-chloro-5-trifluoromethyl-phenyl)-2-[4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidine-1-carbonyloxy]-propionyl}-1,4′-bipiperidinyl-2-carboxylicacid

Prepared analogously to Example 6.1 from 20 mg (0.03 mmol)methyl(S)-1′-{(R)-3-(4-amino-3-chloro-5-trifluoromethyl-phenyl)-2-[4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidine-1-carbonyloxy]-propionyl}-1,4′-bipiperidinyl-2-carboxylateand 1.2 mg (0.05 mmol) LiOH.

Yield: 3 mg (15% of theory)

ESI-MS: (M−H)⁻=747/749 (Cl)

R_(f)=0.29 (silica gel, DCM/MeOH/NH₃ 90:10:1)

EXAMPLE 13(R)-1-(4-amino-3-chloro-5-trifluoromethyl-benzyl)-2-(1′-ethoxyoxalyl-4,4′-bipiperidinyl-1-yl)-2-oxo-ethyl4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidine-1-carboxylate

64 mg (0.20 mmol) TBTU and 70 μL (0.50 mmol) triethylamine were added toa solution of 100 mg (0.18 mmol)(R)-2-(4-amino-3-chloro-5-trifluoromethyl-phenyl)-1-carboxy-ethyl4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidine-1-carboxylatein 2 mL DMF and stirred for 10 min at RT. 54 mg (0.20 mmol) ethyl[4,4′]bipiperidinyl-1-yl-oxo-acetate (Amine A4) were added to thereaction mixture and this was shaken overnight at RT. After filtrationthrough a syringe filter the reaction solution was purified by HPLCwithout further working up. The fractions containing the product werecombined and freeze-dried.

Yield: 88 mg (61% of theory)

ESI-MS: (M+H)⁺=805/807 (Cl)

Retention time (HPLC): 4.5 min (Method B)

EXAMPLE 13.1(R)-1-(4-amino-3-chloro-5-trifluoromethyl-benzyl)-2-(1′-oxalyl-4,4′-bipiperidinyl-1-yl)-2-oxo-ethyl4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidine-1-carboxylate

Prepared analogously to Example 6.1 from 40 mg (0.05 mmol)(R)-1-(4-amino-3-chloro-5-trifluoromethyl-benzyl)-2-(1′-ethoxyoxalyl-4,4′-bipiperidinyl-1-yl)-2-oxo-ethyl4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidine-1-carboxylateand 3.6 mg (0.15 mmol) LiOH.

Yield: 26 mg (67% of theory)

ESI-MS: (M+H)⁺=777/779 (Cl)

Retention time (HPLC): 5.0 min (Method C)

EXAMPLE 13.2(R)-1-(4-amino-3-chloro-5-trifluoromethyl-benzyl)-2-(1′-dimethylcarbamoyl-methoxyoxalyl-4,4′-bipiperidinyl-1-yl)-2-oxo-ethyl4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidine-1-carboxylate

Prepared analogously to Example 7.2 from 100 mg (0.13 mmol)(R)-1-(4-amino-3-chloro-5-trifluoromethyl-benzyl)-2-(1′-oxalyl-4,4′-bipiperidinyl-1-yl)-2-oxo-ethyl4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidine-1-carboxylateand 15 mg (0.15 mmol) 2-hydroxy-N,N-dimethyl-acetamide.

Yield: 70 mg (63% of theory)

ESI-MS: (M+H)⁺=862/864 (Cl)

Retention time (HPLC): 4.1 min (Method B)

EXAMPLE 13.3(R)-1-(4-amino-3-chloro-5-trifluoromethyl-benzyl)-2-[1′-(2-morpholin-4-yl-ethoxyoxalyl)-4,4′-bipiperidinyl-1-yl]-2-oxo-ethyl4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidine-1-carboxylate

Prepared analogously to Example 9.2 from 100 mg (0.13 mmol)(R)-1-(4-amino-3-chloro-5-trifluoromethyl-benzyl)-2-(1′-oxalyl-4,4′-bipiperidinyl-1-yl)-2-oxo-ethyl4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidine-1-carboxylateand 18 μL (0.15 mmol) 2-morpholin-4-yl-ethanol.

Yield: 69 mg (60% of theory)

ESI-MS: (M+H)⁺=890/892 (Cl)

Retention time (HPLC): 3.6 min (Method B)

EXAMPLE 14(R)-1-(4-amino-3-chloro-5-trifluoromethyl-benzyl)-2-[1′-(3-ethoxycarbonyl-propionyl)-4,4′-bipiperidinyl-1-yl]-2-oxo-ethyl4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidine-1-carboxylate

64 mg (0.20 mmol) TBTU and 28 μL (0.50 mmol) triethylamine were added toa solution of 100 mg (0.18 mmol)(R)-2-(4-amino-3-chloro-5-trifluoromethyl-phenyl)-1-carboxy-ethyl4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidine-1-carboxylatein 1 mL DMF and stirred for 10 min at RT. 59 mg (0.20 mmol) ethyl4-[4,4′]bipiperidinyl-1-yl-4-oxo-butyrate (Amine A5) were added to thereaction mixture and this was shaken overnight at RT. After filtrationthrough a syringe filter the reaction solution was purified by HPLCwithout further working up. The fractions containing the product werecombined and freeze-dried.

Yield: 61 mg (41% of theory)

ESI-MS: (M+H)⁺=833/835 (Cl)

R_(f)=0.61 (silica gel, DCM/MeOH/NH₃ 90:10:1)

EXAMPLE 14.1(R)-1-(4-amino-3-chloro-5-trifluoromethyl-benzyl)-2-[1′-(3-carboxy-propionyl)-4,4′-bipiperidinyl-1-yl]-2-oxo-ethyl4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidine-1-carboxylate

A solution of 1.9 mg (0.08 mmol) LiOH in 1 mL water was added to asolution of 40 mg (0.05 mmol)(R)-1-(4-amino-3-chloro-5-trifluoromethyl-benzyl)-2-[1′-(3-ethoxy-carbonyl-propionyl)-4,4′-bipiperidinyl-1-yl]-2-oxo-ethyl4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidine-1-carboxylatein 10 mL THF and the reaction mixture was stirred overnight at RT. Thesolvent was eliminated in a nitrogen stream, the residue was taken up in1 mL water, combined with formic acid until an acidic reaction wasobtained and mixed with 1 mL acetonitrile and freeze-dried.

The residue was taken up in 1 mL DMF and purified by HPLC. The fractionscontaining the product were combined and freeze-dried.

Yield: 19 mg (39% of theory)

ESI-MS: (M+H)⁺=805/807 (Cl)

R_(f)=0.16 (silica gel, DCM/MeOH/NH₃ 90:10:1)

EXAMPLE 14.2(R)-1-(4-amino-3-chloro-5-trifluoromethyl-benzyl)-2-{1′-[3-(2-morpholin-4-yl-ethoxycarbonyl)-propionyl]-4,4′-bipiperidinyl-1-yl}-2-oxo-ethyl4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidine-1-carboxylate

Prepared analogously to Example 9.2 from 100 mg (0.12 mmol)(R)-1-(4-amino-3-chloro-5-trifluoromethyl-benzyl)-2-[1′-(3-carboxy-propionyl)-4,4′-bipiperidinyl-1-yl]-2-oxo-ethyl4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidine-1-carboxylateand 17 μL (0.14 mmol) 2-morpholin-4-yl-ethanol.

Yield: 16 mg (14% of theory)

ESI-MS: (M+H)²⁺=459/460 (Cl)

Retention time (HPLC): 3.7 min (Method B)

EXAMPLE 15

(R)-1-(4-amino-3-chloro-5-trifluoromethyl-benzyl)-2-(1′-ethoxycarbonylmethyl-4,4′-bipiperidinyl-1-yl)-2-oxo-ethyl4-(7-methoxy-2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidine-1-carboxylate

15a)(R)-2-(4-amino-3-chloro-5-trifluoromethyl-phenyl)-1-ethoxycarbonyl-ethyl4-(7-methoxy-2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidine-1-carboxylate

1.29 g (6.42 mmol) 4-nitrophenyl chloroformate were added to a solutionof 0.79 g (6.42 mmol) DMAP in 50 mL pyridine and stirred for 1 h at RT.A solution of 2.00 g (6.42 mmol)ethyl(R)-3-(4-amino-3-chloro-5-trifluoromethyl-phenyl)-2-hydroxy-propionatein 15 mL pyridine was added dropwise and the reaction mixture wasstirred for 2 h at RT. Then 1.77 g (6.42 mmol)7-methoxy-3-piperidin-4-yl-1,3,4,5-tetrahydro-1,3-benzodiazepin-2-onewas added batchwise. The suspension was stirred for 72 h at RT and thenevaporated down i. vac. The residue was combined with 200 mL EtOAc,washed with 200 mL 15% K₂CO₃ solution, the organic phase was separatedoff and evaporated down i. vac. The residue was purified bychromatography (silica gel, gradient DCM to MeOH/NH₃ 95:5).

Yield: 1.80 g (46% of theory)

ESI-MS: (M+H)⁺=613/615 (Cl)

R_(f)=0.50 (silica gel, DCM/MeOH 9:1)

15b) (R)-2-(4-amino-3-chloro-5-trifluoromethyl-phenyl)-1-carboxy-ethyl4-(7-methoxy-2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidine-1-carboxylate

A solution of 0.11 g (4.50 mmol) LiOH in 50 mL water was added to asolution of 1.80 g (2.94 mmol)(R)-2-(4-amino-3-chloro-5-trifluoromethyl-phenyl)-1-ethoxycarbonyl-ethyl4-(7-methoxy-2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidine-1-carboxylatein 50 mL THF and the reaction mixture was stirred for 3 h at RT. The THFwas eliminated i. vac., diluted with 100 mL water and acidified with 1 MHCl. The substance precipitated was suction filtered, washed with 50 mLwater and dried in the vacuum drying cupboard at 65° C.

Yield: 1.60 g (93% of theory)

ESI-MS: (M+H)⁺=585/587 (Cl)

15c)(R)-1-(4-amino-3-chloro-5-trifluoromethyl-benzyl)-2-(1′-ethoxycarbonylmethyl-4,4′-bipiperidinyl-1-yl)-2-oxo-ethyl4-(7-methoxy-2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidine-1-carboxylate

Prepared analogously to Example 9 from 100 mg (0.17 mmol)(R)-2-(4-amino-3-chloro-5-trifluoromethyl-phenyl)-1-carboxy-ethyl4-(7-methoxy-2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidine-1-carboxylateand 48 mg (0.19 mmol) ethyl[4,4′]bipiperidinyl-1-yl-acetate.

Yield: 58 mg (41% of theory)

ESI-MS: (M+H)⁺=821/823 (Cl)

Retention time (HPLC): 3.0 min (Method B)

EXAMPLE 15.1(R)-1-(4-amino-3-chloro-5-trifluoromethyl-benzyl)-2-(1′-carboxymethyl-4,4′-bipiperidinyl-1-yl)-2-oxo-ethyl4-(7-methoxy-2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidine-1-carboxylate

A solution of 1 mg (0.04 mmol) LiOH in 1 mL water was added to asolution of 20 mg (0.02 mmol)(R)-1-(4-amino-3-chloro-5-trifluoromethyl-benzyl)-2-(1′-ethoxycarbonylmethyl-4,4′-bipiperidinyl-1-yl)-2-oxo-ethyl4-(7-methoxy-2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidine-1-carboxylatein 1 mL THF and the reaction mixture was stirred overnight at RT. Tocomplete the reaction a solution of 1 mg LiOH in 1 mL water was againadded and the mixture was stirred for another 3 h at RT. The solventswere eliminated in a nitrogen stream, the residue was taken up in amixture of acetonitrile and water and the product was subjected tofreeze-drying.

Yield: 14 mg (72% of theory)

ESI-MS: (M+H)⁺=793/795 (Cl)

Retention time (HPLC): 2.6 min (Method B)

EXAMPLE 15.2(R)-1-(4-amino-3-chloro-5-trifluoromethyl-benzyl)-2-[1′-(2-morpholin-4-yl-ethoxycarbonyl-methyl)-4,4′-bipiperidinyl-1-yl]-2-oxo-ethyl4-(7-methoxy-2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidine-1-carboxylate

113 mg (0.35 mmol) TBTU, 84 μL (0.60 mmol) triethylamine and 39 mg (0.30mmol) 2-morpholin-4-yl-ethanol were added to a solution of 230 mg (0.29mmol)(R)-1-(4-amino-3-chloro-5-trifluoromethyl-benzyl)-2-(1′-carboxymethyl-4,4′-bipiperidinyl-1-yl)-2-oxo-ethyl4-(7-methoxy-2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidine-1-carboxylatein 5 mL DMF and the reaction mixture was stirred overnight at RT. Thereaction solution was poured onto a saturated NaHCO₃ solution, theproduct precipitated was suction filtered and dried at 40° C. The crudeproduct was dissolved in 25 mL dry isopropanol and precipitated with 0.5M HCl in isopropanol as the salt. The precipitate was filtered off,washed with 5 mL isopropanol and 30 mL DIPE and dried overnight in thevacuum drying cupboard at 30° C.

Yield: 90 mg (34% of theory)

ESI-MS: (M+H)⁺=906/908 (Cl)

Retention time (HPLC): 3.1 min (Method B)

EXAMPLE 16(R)-1-(4-amino-3-chloro-5-trifluoromethyl-benzyl)-2-[4-(4-ethoxycarbonylmethyl-piperazin-1-yl)-piperidin-1-yl]-2-oxo-ethyl4-(7-methoxy-2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidine-1-carboxylate

Prepared analogously to Example 9 from 100 mg (0.17 mmol)(R)-2-(4-amino-3-chloro-5-trifluoromethyl-phenyl)-1-carboxy-ethyl4-(7-methoxy-2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidine-1-carboxylateand 49 mg (0.19 mmol) ethyl(4-piperidin-4-yl-piperazin-1-yl)-acetate.

Yield: 62 mg (44% of theory)

ESI-MS: (M+H)⁺=822/824 (Cl)

Retention time (HPLC): 2.9 min (Method B)

EXAMPLE 16.1(R)-1-(4-amino-3-chloro-5-trifluoromethyl-benzyl)-2-[4-(4-carboxymethyl-piperazin-1-yl)-piperidin-1-yl]-2-oxo-ethyl4-(7-methoxy-2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidine-1-carboxylate

Prepared analogously to Example 15.1 from 20 mg (0.02 mmol)(R)-1-(4-amino-3-chloro-5-trifluoromethyl-benzyl)-2-[4-(4-ethoxycarbonylmethyl-piperazin-1-yl)-piperidin-1-yl]-2-oxo-ethyl4-(7-methoxy-2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidine-1-carboxylateand 2 mg (0.08 mmol) LiOH.

Yield: 19 mg (99% of theory)

ESI-MS: (M+H)⁺=794/796 (Cl)

Retention time (HPLC): 2.6 min (Method B)

EXAMPLE 17(R)-1-(4-amino-3-chloro-5-methyl-benzyl)-2-(1′-ethoxycarbonylmethyl-4,4′-bipiperidinyl-1-yl)-2-oxo-ethyl4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidine-1-carboxylate

17a)methyl(Z,E)-2-acetylamino-3-(4-amino-3-chloro-5-methyl-phenyl)-acrylateUnder a nitrogen atmosphere 15.4 g (49.1 mmol) tri-o-tolyl-phosphane and11.0 g (49.0 mmol) Pd(OAc)₂ were added to a mixture of 72.8 g (330 mmol)4-bromo-2-chloro-6-methyl-phenylamine and 58.0 g (397 mmol) methyl2-acetylamino-acrylate in 970 mL triethylamine and 1.2 L acetonitrileand the reaction mixture was stirred for 18 h at 80° C. After coolingthe reaction solution was filtered, evaporated down i. vac., the residuewas stirred with 350 mL water and 350 mL EtOAc. The solvents weredecanted off, the residue was again stirred with 300 mL EtOAc, suctionfiltered, washed with a little EtOAc and MTBE and dried at 60° C.

Yield: 40.6 g (44% of theory)

ESI-MS: (M+H)⁺=283/285 (Cl)

R_(f)=0.47 (silica gel, DCM/Cyc/MeOH/NH₃ 70:15:15:2)

17b) 3-(4-amino-3-chloro-5-methyl-phenyl)-2-oxo-propionic acid

Under a nitrogen atmosphere a solution of 28.0 g (99.0 mmol)methyl(Z,E)-2-acetylamino-3-(4-amino-3-chloro-5-methyl-phenyl)-acrylatein 250 mL 1,4-dioxane and 125 mL HCl (4 M) was stirred for 6 h at 80° C.The solvents were eliminated i. vac., the residue was triturated withisopropanol and DIPE, the precipitate was removed by suction filteringand dried at 60° C. The product was obtained as the hydrochloride salt,which was reacted further without purification.

Yield: 26.0 g (99% of theory)

ESI-MS: (M−H)⁻=226/228 (Cl)

R_(f)=0.15 (silica gel, DCM/Cyc/MeOH/NH₃ 70:15:15:2)

17c) methyl(R)-3-(4-amino-3-chloro-5-methyl-phenyl)-2-hydroxy-propionate

Under a nitrogen atmosphere a solution of 27.0 g (84.2 mmol)(1R)—B-chlorodiisopinocampheylborane in 75 mL THF was added dropwisewithin 15 min to a solution of 13.0 g (49.2 mmol)3-(4-amino-3-chloro-5-methyl-phenyl)-2-oxo-propionic acid and 17.0 mL(122.3 mmol) triethylamine in 175 mL THF cooled to about −30° C. Afterthe addition had ended the cooling bath was removed and the reactionmixture was stirred overnight at RT. 150 mL 1 M NaOH were added dropwiseto the reaction mixture while cooling with ice. 200 mL of EtOAc wereadded, the mixture was stirred for another 15 min, the aqueous phase wasseparated off and the organic phase was washed twice with 50 mL of 1 MNaOH, once with 40 mL water and acidified with 4 M HCl. The organicphase was separated off, dried over MgSO₄ and evaporated down i. vac.The residue was combined with 250 mL methanolic HCl (1.25 M) and stirredovernight at RT. The reaction mixture was evaporated down i. vac., theresidue was dissolved in a little PE and EtOAc, placed on silica gel andeluted with PE/EtOAc (2:1). The fractions containing the product werecombined and evaporated down.

Yield: 6.0 g (50% of theory)

ESI-MS: (M+H)⁺=244/246 (Cl)

R_(f)=0.74 (silica gel, DCM/Cyc/MeOH/NH₃ 70:15:15:2)

17d) (R)-2-(4-amino-3-chloro-5-methyl-phenyl)-1-carboxy-ethyl4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidine-1-carboxylate

Prepared analogously to Example 1e from 6.0 g (24.6 mmol)methyl(R)-3-(4-amino-3-chloro-5-methyl-phenyl)-2-hydroxy-propionate and6.1 g (24.9 mmol)3-piperidin-4-yl-1,3,4,5-tetrahydro-1,3-benzodiazepin-2-one. The crudemethyl ester product was dissolved in 100 mL THF and combined with asolution of 1.0 g (40.9 mmol) LiOH in 50 mL water. The reaction mixturewas stirred for 15 h at RT, diluted with water and the organic solventwas eliminated i. vac. The aqueous phase was washed with 60 mL EtOAc,acidified with 21 mL of 4 M HCl and stirred for 15 min at RT. Themixture was extracted three times with 150 mL of DCM and the combinedorganic phases were dried over MgSO₄. After elimination of the desiccantand solvent the residue was purified by chromatography (silica gel,gradient DCM to DCM/MeOH/NH₃ 70:27:3).

Yield: 0.88 g (7% of theory)

ESI-MS: (M+H)⁺=501/503 (Cl)

R_(f)=0.17 (silica gel, DCM/Cyc/MeOH/NH₃ 70:15:15:2)

17e)(R)-1-(4-amino-3-chloro-5-methyl-benzyl)-2-(1′-ethoxycarbonylmethyl-4,4′-bipiperidinyl-1-yl)-2-oxo-ethyl4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidine-1-carboxylate

Prepared analogously to Example 5 from 100 mg (0.20 mmol)(R)-2-(4-amino-3-chloro-5-methyl-phenyl)-1-carboxy-ethyl4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidine-1-carboxylateand 56 mg (0.22 mmol) ethyl [4,4′]bipiperidinyl-1-yl-acetate

Yield: 19 mg (13% of theory)

ESI-MS: (M+H)⁺=737/739 (Cl)

R_(f)=0.72 (silica gel, DCM/Cyc/MeOH/NH₃ 70:15:15:2)

EXAMPLE 17.1(R)-1-(4-amino-3-chloro-5-methyl-benzyl)-2-(1′-carboxymethyl-4,4′-bipiperidinyl-1-yl)-2-oxo-ethyl4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidine-1-carboxylate

A solution of 7.0 mg (0.29 mmol) LiOH in 5 mL water was added to asolution of 80 mg (0.11 mmol)(R)-1-(4-amino-3-chloro-5-methyl-benzyl)-2-(1′-ethoxycarbonyl-methyl-4,4′-bipiperidinyl-1-yl)-2-oxo-ethyl4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidine-1-carboxylatein 10 mL THF and the reaction mixture was stirred overnight at RT. TheTHF was eliminated i. vac., the aqueous residue was combined with 0.35mL of 1 M HCl and evaporated down i. vac. The residue was purified byHPLC. The fractions containing the product were combined andfreeze-dried.

Yield: 8 mg (10% of theory)

ESI-MS: (M+H)⁺=709/711 (Cl)

R_(f)=0.21 (silica gel, DCM/Cyc/MeOH/NH₃ 70:15:15:2)

EXAMPLE 18(R)-1-(3-chloro-4-hydroxy-5-methyl-benzyl)-2-(1′-ethoxycarbonylmethyl-4,4′-bipiperidinyl-1-yl)-2-oxo-ethyl4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidine-1-carboxylate

18a) 2-benzyloxy-5-bromo-1-chloro-3-methyl-benzene

7.0 mL (57.7 mmol) benzyl bromide were added to a suspension of 10.2 g(46.1 mmol) 4-bromo-2-chloro-6-methyl-phenol and 30.0 g (217 mmol) K₂CO₃in 130 mL DMF and the reaction mixture was stirred overnight at RT. Theinsoluble constituents were filtered off, the filtrate was evaporateddown i. vac., combined with water and extracted exhaustively with EtOAc.The combined organic phases were dried over Na₂SO₄, filtered andevaporated down. The product was reacted further without purification.

Yield: 14.0 g (98% of theory)

R_(f)=0.91 (silica gel, DCM/Cyc/MeOH/NH₃ 70:15:15:2)

18b)methyl(Z,E)-2-acetylamino-3-(4-benzyloxy-3-chloro-5-methyl-phenyl)-acrylate

Under a nitrogen atmosphere 4.4 g (14.0 mmol) tri-o-tolyl-phosphane and3.2 g (14.3 mmol) Pd(OAc)₂ were added to a mixture of 28.0 g (89.9 mmol)of 2-benzyl-oxy-5-bromo-1-chloro-3-methyl-benzene and 15.0 g (103 mmol)methyl 2-acetylamino-acrylate in 260 mL of triethylamine and 400 mLacetonitrile and the reaction mixture was stirred for 18 h at 80° C.After cooling the reaction solution was evaporated down i. vac., theresidue was stirred with 100 mL water, 50 mL EtOAc and 50 mL PE andfiltered to remove the insoluble components. The residue was taken up inDCM/MeOH (5:1), combined with activated charcoal, filtered andevaporated down i. vac. The crude product was reacted further withoutpurification.

Yield: 12.5 g (37% of theory)

ESI-MS: (M+H)⁺=374/376 (Cl)

R_(f)=0.67 (silica gel, DCM/Cyc/MeOH/NH₃ 70:15:15:2)

18c) 3-(4-benzyloxy-3-chloro-5-methyl-phenyl)-2-oxo-propionic acid

75 mL 4 M HCl were added to a solution of 18.4 g (49.2 mmol)methyl(Z,E)-2-acetylamino-3-(4-benzyloxy-3-chloro-5-methylphenyl)-acrylatein 150 mL 1,4-dioxane and the reaction mixture was refluxed overnight.The 1,4-dioxane was eliminated i. vac., the precipitated product wasfiltered off, dissolved again in DIPE and dried over MgSO₄. Afterelimination of the desiccant and solvent the residue was reacted furtherwithout purification.

Yield: 15.5 g (99% of theory)

ESI-MS: (M−H)⁻=317/319 (Cl)

R_(f)=0.20 (silica gel, DCM/Cyc/MeOH/NH₃ 70:15:15:2)

18d)methyl(R)-3-(4-benzyloxy-3-chloro-5-methyl-phenyl)-2-hydroxy-propionate

Under a nitrogen atmosphere a solution of 27.6 g (86.0 mmol)(1R)—B-chlorodiisopinocampheylborane in 100 mL THF was added dropwisewithin 15 min to a solution of 15.5 g (48.6 mmol)3-(4-benzyloxy-3-chloro-5-methyl-phenyl)-2-oxo-propionic acid and 9.2 mL(66.2 mmol) triethylamine in 200 mL THF cooled to about −30° C. Afterthe addition had ended the cooling bath was removed and the reactionmixture was stirred overnight at RT. 240 mL of 1 M NaOH were addeddropwise to the reaction mixture while cooling with ice. 400 mL EtOAcwere added, the mixture was stirred for 15 min, the aqueous phase wasseparated off and the organic phase was washed twice with 100 mL of 1 MNaOH and once with 100 mL water. The combined aqueous phases wereacidified with semi-concentrated HCl, extracted twice with 150 mL ofEtOAc and the combined organic phases were dried over MgSO₄. Afterelimination of the desiccant and solvent the oily residue was combinedwith 150 mL methanolic HCl (1.25 M) and the reaction mixture was stirredovernight at RT. It was evaporated down i. vac., the residue wascombined with 70 mL of 15% K₂CO₃ solution and extracted twice with 50 mLof EtOAc. The combined organic phases were dried over MgSO₄, filteredand evaporated down i. vac. The product was reacted further withoutpurification.

Yield: 7.0 g (43% of theory)

ESI-MS: (M+NH₄)⁺=352/354 (Cl)

R_(f)=0.87 (silica gel, DCM/Cyc/MeOH/NH₃ 70:15:15:2)

18e) (R)-2-(4-benzyloxy-3-chloro-5-methyl-phenyl)-1-carboxy-ethyl4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidine-1-carboxylate

Prepared analogously to Example 1e from 7.0 g (20.9 mmol)methyl(R)-3-(4-benzyloxy-3-chloro-5-methyl-phenyl)-2-hydroxy-propionateand 5.2 g (21.2 mmol)3-piperidin-4-yl-1,3,4,5-tetrahydro-1,3-benzodiazepin-2-one. The crudemethyl ester product was dissolved in 150 mL of THF and combined with asolution of 0.5 g (20.7 mmol) of LiOH in 50 mL water. The reactionmixture was stirred overnight at RT, diluted with water and the organicsolvent was eliminated i. vac. The aqueous phase was washed twice with60 mL EtOAc, acidified with 21 mL of 4 M HCl and the oil thus formed wasexhaustively extracted with EtOAc. The combined organic phases weredried over MgSO₄, filtered and the solvent was evaporated down i. vac.The residue was triturated with DIPE and suction filtered.

Yield: 3.3 g (26% of theory)

ESI-MS: (M+H)⁺=592/594 (Cl)

R_(f)=0.35 (silica gel, DCM/Cyc/MeOH/NH₃ 70:15:15:2)

18f) (R)-1-carboxy-2-(3-chloro-4-hydroxy-5-methyl-phenyl)-ethyl4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidine-1-carboxylate

A suspension of 2.75 g (4.65 mmol)(R)-2-(4-benzyloxy-3-chloro-5-methyl-phenyl)-1-carboxy-ethyl4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidine-1-carboxylateand 1.0 g rhodium on aluminium oxide in 150 mL MeOH was hydrogenated for18 h at 40° C. and 50 psi hydrogen pressure. To complete the reactionanother 0.5 g rhodium on aluminium oxide were added and the mixture washydrogenated for a further 6 h. The catalyst was removed by suctionfiltering and the filtrate was evaporated down i. vac. The residue,which was contaminated with about 50% of the corresponding methyl ester,was dissolved in 25 mL THF and combined with a solution of 250 mg (10.23mmol) LiOH in 15 mL water and the reaction mixture was stirred for 3 hat RT. The THF was eliminated i. vac., water and 10.5 mL of 1 M HCl wereadded, the product precipitated was suction filtered, then this waswashed with a little water and dried at 60° C.

Yield: 2.1 g (90% of theory)

ESI-MS: (M+H)⁺=502/504 (Cl)

R_(f)=0.12 (silica gel, DCM/Cyc/MeOH/NH₃ 70:15:15:2)

18g)(R)-1-(3-chloro-4-hydroxy-5-methyl-benzyl)-2-(1′-ethoxycarbonylmethyl-4,4′-bipiperidinyl-1-yl)-2-oxo-ethyl4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidine-1-carboxylate

Prepared analogously to Example 5 from 100 mg (0.20 mmol)(R)-1-carboxy-2-(3-chloro-4-hydroxy-5-methyl-phenyl)-ethyl and 51 mg(0.20 mmol) ethyl [4,4′]bipiperidinyl-1-yl-acetate

Yield: 14 mg (9% of theory)

ESI-MS: (M+H)⁺=738/740 (Cl)

Retention time (HPLC): 3.2 min (Method B)

EXAMPLE 18.1(R)-2-(1′-carboxymethyl-4,4′-bipiperidinyl-1-yl)-1-(3-chloro-4-hydroxy-5-methyl-benzyl)-2-oxo-ethyl4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidine-1-carboxylate

A solution of 2.0 mg (0.08 mmol) LiOH in 1 mL water was added to asolution of 38 mg (0.05 mmol)(R)-1-(3-chloro-4-hydroxy-5-methyl-benzyl)-2-(1′-ethoxy-carbonylmethyl-4,4′-bipiperidinyl-1-yl)-2-oxo-ethyl4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidine-1-carboxylatein 1 mL THF and the reaction mixture was shaken for 3 h at RT. Thereaction solution was acidified with 1 M HCl and purified by HPLC. Thefractions containing the product were combined and freeze-dried.

Yield: 30 mg (82% of theory)

ESI-MS: (M+H)⁺=710/712 (Cl)

R_(f)=0.20 (silica gel, DCM/Cyc/MeOH/NH₃ 70:15:15:2)

EXAMPLE 19(R)-1-(4-amino-3-chloro-5-trifluoromethyl-benzyl)-2-[4-(1-ethoxycarbonylmethyl-4-methyl-piperidin-4-yl)-piperazin-1-yl]-2-oxo-ethyl4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidine-1-carboxylate

0.25 mL (1.18 mmol) triethylamine were added to a mixture of 250 mg(0.45 mmol)(R)-2-(4-amino-3-chloro-5-trifluoromethyl-phenyl)-1-carboxy-ethyl4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidine-1-carboxylate(Example 1f), 250 mg (0.50 mmol)ethyl(4-methyl-4-piperazin-1-yl-piperidin-1-yl)-acetate (Example A7f)and 160 mg (0.50 mmol) TBTU in 2 mL DMF and the reaction mixture wasstirred for 4 h at RT. It was evaporated down i. vac. and the residuewas purified by HPLC; the fractions containing the product were combinedand lyophilised.

Yield: 225 mg (62% of theory)

ESI-MS: (M+H)⁺=806/808 (Cl)

Retention time (HPLC): 3.2 min (method B)

EXAMPLE 19.1(R)-1-(4-amino-3-chloro-5-trifluoromethyl-benzyl)-2-[4-(1-carboxymethyl-4-methyl-piperidin-4-yl)-piperazin-1-yl]-2-oxo-ethyl4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidine-1-carboxylate

A solution of 10.0 mg (0.42 mmol) LiOH in 5 mL water was added to 100 mg(0.12 mmol)(R)-1-(4-amino-3-chloro-5-trifluoromethyl-benzyl)-2-[4-(1-ethoxy-carbonyl-methyl-4-methyl-piperidin-4-yl)-piperazin-1-yl]-2-oxo-ethyl4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidine-1-carboxylatein 10 mL THF and the reaction mixture was stirred for 3 h at RT. 0.42 mL(0.42 mmol) 1 M HCl were added and the mixture was evaporated down i.vac. The residue was taken up in a little DCM/MeOH (1:1), filteredthrough a little silica gel and eluted with DCM/MeOH (1:1). The filtratewas evaporated down i. vac. and dried under a high vacuum.

Yield: 95 mg (98% of theory)

ESI-MS: (M+H)⁺=778/780 (Cl)

Retention time (HPLC): 2.9 min (method B)

EXAMPLE 20(R)-1-(4-amino-3-chloro-5-trifluoromethyl-benzyl)-2-[4-(4-ethoxycarbonylmethyl-piperazin-1-yl)-4-methyl-piperidin-1-yl]-2-oxo-ethyl4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidine-1-carboxylate

0.10 mL (0.72 mmol) triethylamine were added to a mixture of 250 mg(0.45 mmol)(R)-2-(4-amino-3-chloro-5-trifluoromethyl-phenyl)-1-carboxy-ethyl4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidine-1-carboxylate(Example 1f), 140 mg (0.49 mmol)ethyl[4-(4-methyl-piperidin-4-yl)-piperazin-1-yl]-acetate (Example A8b)and 160 mg (0.50 mmol) TBTU in 2 mL DMF and the reaction mixture wasstirred for 18 h at RT. It was evaporated down i. vac. and the residuewas purified by chromatography (Alox, gradient DCM/MeOH 40:1 nach 30:1).The fractions containing the product were combined, evaporated down i.vac. and purified by HPLC; the fractions containing the product werecombined and lyophilised.

Yield: 178 mg (49% of theory)

ESI-MS: (M+H)⁺=806/808 (Cl)

Retention time (HPLC): 3.8 min (method B)

EXAMPLE 20.1(R)-1-(4-amino-3-chloro-5-trifluoromethyl-benzyl)-2-[4-(4-carboxymethyl-piperazin-1-yl)-4-methyl-piperidin-1-yl]-2-oxo-ethyl4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidine-1-carboxylate

Prepared analogously to Example 19.1 from 100 mg (0.12 mmol)(R)-1-(4-amino-3-chloro-5-trifluoromethyl-benzyl)-2-[4-(4-ethoxycarbonylmethyl-piperazin-1-yl)-4-methyl-piperidin-1-yl]-2-oxo-ethyl4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidine-1-carboxylateand 10.0 mg (0.42 mmol) LiOH.

Yield: 42 mg (44% of theory)

ESI-MS: (M+H)⁺=778/780 (Cl)

Retention time (HPLC): 3.3 min (method B)

EXAMPLE 21Ethyl(S)-1-(1-{(R)-3-(4-amino-3-chloro-5-trifluoromethyl-phenyl)-2-[4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidine-1-carbonyloxy]-propionyl}-piperidin-4-yl)-4-methyl-piperazine-2-carboxylate

0.40 mL (2.88 mmol) triethylamine were added to a mixture of 260 mg(0.46 mmol)(R)-2-(4-amino-3-chloro-5-trifluoromethyl-phenyl)-1-carboxy-ethyl4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidine-1-carboxylate(Example 1f), 210 mg (0.58 mmol)ethyl(S)-4-methyl-1-piperidin-4-yl-piperazine-2-carboxylate (ExampleA9f) and 170 mg (0.53 mmol) TBTU in 2.4 mL DMF and the reaction mixturewas stirred for 18 h at RT. The reaction mixture was purified by HPLCwithout any further working up; the fractions containing the productwere combined and lyophilised.

Yield: 227 mg (61% of theory)

ESI-MS: (M+H)⁺=792/794 (Cl)

Retention time (HPLC): 3.4 min (method B)

EXAMPLE 21.1(S)-1-(1-{(R)-3-(4-amino-3-chloro-5-trifluoromethyl-phenyl)-2-[4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidine-1-carbonyloxy]-propionyl}-piperidin-4-yl)-4-methyl-piperazine-2-carboxylicacid

0.5 mL (1.00 mmol) 2 M LiOH solution were added to 80.0 mg (0.10 mmol)ethyl(S)-1-(1-{(R)-3-(4-amino-3-chloro-5-trifluoromethyl-phenyl)-2-[4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidine-1-carbonyloxy]-propionyl}-piperidin-4-yl)-4-methyl-piperazine-2-carboxylatein 1 mL THF and the reaction mixture was stirred for 20 h at RT. Thiswas purified by HPLC without working up; the fractions containing theproduct were combined and lyophilised.

Yield: 50 mg (65% of theory)

ESI-MS: (M+H)⁺=764/766 (Cl)

Retention time (HPLC): 3.0 min (method B)

EXAMPLE 22Ethyl(S)-4-{(R)-3-(4-amino-3-chloro-5-trifluoromethyl-phenyl)-2-[4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidine-1-carbonyloxy]-propionyl}-1-(1-methyl-piperidin-4-yl)-piperazine-2-carboxylate

0.25 mL (2.88 mmol) triethylamine were added to a mixture of 200 mg(0.36 mmol)(R)-2-(4-amino-3-chloro-5-trifluoromethyl-phenyl)-1-carboxy-ethyl4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidine-1-carboxylate(Example 1f), 150 mg (0.58 mmol)ethyl(S)-1-(1-methyl-piperidin-4-yl)-piperazine-2-carboxylate (ExampleA10c) and 140 mg (0.44 mmol) TBTU in 2.0 mL DMF and the reaction mixturewas stirred for 5 h at RT. This was purified by HPLC without any furtherworking up; the fractions containing the product were combined andlyophilised.

Yield: 84 mg (29% of theory)

ESI-MS: (M+H)⁺=792/794 (Cl)

Retention time (HPLC): 3.5 min (method B)

EXAMPLE 22.1(S)-4-{(R)-3-(4-amino-3-chloro-5-trifluoromethyl-phenyl)-2-[4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidine-1-carbonyloxy]-propionyl}-1-(1-methyl-piperidin-4-yl)-piperazine-2-carboxylicacid

0.26 mL (0.13 mmol) 0.5 M LiOH solution were added to 50.0 mg (0.06mmol)ethyl(S)-4-{(R)-3-(4-amino-3-chloro-5-trifluoromethyl-phenyl)-2-[4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidine-1-carbonyloxy]-propionyl}-1-(1-methyl-piperidin-4-yl)-piperazine-2-carboxylatein 0.8 mL THF and the reaction mixture was stirred overnight at RT. Tocomplete the reaction another 50 μL (0.1 mmol) 0.5 M LiOH solution wereadded, it was stirred for another 4 h at RT and then the reactionmixture was purified by HPLC without working up; the fractionscontaining the product were combined and lyophilised.

Yield: 22 mg (46% of theory)

ESI-MS: (M+H)⁺=764/766 (Cl)

Retention time (HPLC): 2.9 min (method B)

EXAMPLE 23Ethyl(S)-1-{(R)-3-(4-amino-3-chloro-5-trifluoromethyl-phenyl)-2-[4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidine-1-carbonyloxy]-propionyl}-4-(1-methyl-piperidin-4-yl)-piperazine-2-carboxylate

0.30 mL (2.16 mmol) triethylamine were added to a mixture of 700 mg(1.26 mmol)(R)-2-(4-amino-3-chloro-5-trifluoromethyl-phenyl)-1-carboxy-ethyl4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidine-1-carboxylate(Example 1f), 430 mg (1.41 mmol)ethyl(S)-4-(1-methyl-piperidin-4-yl)-piperazine-2-carboxylate (ExampleA11b) and 450 mg (1.40 mmol) TBTU in 7 mL DMF and the reaction mixturewas stirred for 18 h at RT. It was evaporated down i. vac., the residuewas stirred with saturated NaHCO₃ solution, extracted exhaustively withEtOAc and the combined organic phases were dried over Na₂SO₄. Afterelimination of the desiccant and solvent the residue was purified byHPLC; the fractions containing the product were combined andlyophilised.

Yield: 670 mg (67% of theory)

ESI-MS: (M+H)⁺=792/794 (Cl)

Retention time (HPLC): 3.4 min (method B)

EXAMPLE 23.1(S)-1-{(R)-3-(4-amino-3-chloro-5-trifluoromethyl-phenyl)-2-[4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidine-1-carbonyloxy]-propionyl}-4-(1-methyl-piperidin-4-yl)-piperazine-2-carboxylicacid

Prepared analogously to Example 22.1 from 80.0 mg (0.10 mmol)ethyl(S)-1-{(R)-3-(4-amino-3-chloro-5-trifluoromethyl-phenyl)-2-[4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidine-1-carbonyloxy]-propionyl}-4-(1-methyl-piperidin-4-yl)-piperazine-2-carboxylateand 0.46 mL (0.23 mmol) 0.5 M LiOH solution.

Yield: 53 mg (69% of theory)

ESI-MS: (M+H)⁺=764/766 (Cl)

Retention time (HPLC): 2.9 min (method B)

EXAMPLE 24(R)-1-(4-amino-3-chloro-5-trifluoromethyl-benzyl)-2-[4-(8-ethoxycarbonylmethyl-8-aza-bicyclo[3.2.1]oct-3-yl)-piperazin-1-yl]-2-oxo-ethyl4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidine-1-carboxylate

113 mg (0.40 mmol)ethyl(3-piperazin-1-yl-8-aza-bicyclo[3.2.1]oct-8-yl)-acetate (ExampleA12d) were added to a mixture of 200 mg (0.45 mmol)(R)-2-(4-amino-3-chloro-5-trifluoromethyl-phenyl)-1-carboxy-ethyl4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidine-1-carboxylate(Example 1f), 128 mg (0.40 mmol) TBTU and 56 μL (0.40 mmol)triethylamine in 2 mL DMF and the reaction mixture was stirred for 2 hat RT. This was purified by HPLC without any further working up; thefractions containing the product were combined and evaporated down i.vac.

Yield: 156 mg (53% of theory)

ESI-MS: (M+H)⁺=818/820 (Cl)

Retention time (HPLC): 3.1 min (method B)

EXAMPLE 24.1(R)-1-(4-amino-3-chloro-5-trifluoromethyl-benzyl)-2-[4-(8-carboxymethyl-8-aza-bicyclo[3.2.1]oct-3-yl)-piperazin-1-yl]-2-oxo-ethyl4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidine-1-carboxylate

A solution of 1.92 mg (0.08 mmol) LiOH in 1 mL water was added to 40.0mg (0.05 mmol)(R)-1-(4-amino-3-chloro-5-trifluoromethyl-benzyl)-2-[4-(8-ethoxycarbonyl-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-piperazin-1-yl]-2-oxo-ethyl4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidine-1-carboxylatein 1 mL THF and the reaction mixture was shaken overnight at RT. Thesolvents were eliminated in a nitrogen stream and the residue waspurified by HPLC; the fractions containing the product were combined andlyophilised.

Yield: 13 mg (34% of theory)

ESI-MS: (M+H)⁺=790/792 (Cl)

Retention time (HPLC): 2.7 min (method B)

EXAMPLE 25(R)-1-(4-amino-3-chloro-5-trifluoromethyl-benzyl)-2-(4-ethoxycarbonylmethoxy-1,4′-bipiperidinyl-1′-yl)-2-oxo-ethyl4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidine-1-carboxylate

0.30 mL (2.16 mmol) triethylamine were added to a mixture of 300 mg(0.54 mmol)(R)-2-(4-amino-3-chloro-5-trifluoromethyl-phenyl)-1-carboxy-ethyl4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidine-1-carboxylate(Example 1f), 220 mg (0.64 mmol)ethyl([1,4′]bipiperidinyl-4-yloxy)-acetate (Example A13c) and 200 mg(0.62 mmol) TBTU in 3 mL DMF and the reaction mixture was stirred for 4h at RT. Ice and saturated NaHCO₃ solution were added and theprecipitate was filtered off. This was taken up in DCM and a little EtOHand dried over Na₂SO₄. After elimination of the desiccant and solventthe residue was purified by HPLC; the fractions containing the productwere combined and lyophilised.

Yield: 170 mg (39% of theory)

ESI-MS: (M+H)⁺=807/809 (Cl)

Retention time (HPLC): 3.7 min (method B)

EXAMPLE 25.1(R)-1-(4-amino-3-chloro-5-trifluoromethyl-benzyl)-2-(4-carboxymethoxy-1,4′-bipiperidinyl-1′-yl)-2-oxo-ethyl4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidine-1-carboxylate

A solution of 8.00 mg (0.33 mmol) LiOH in 2.5 mL water was added to 100mg (0.12 mmol)(R)-1-(4-amino-3-chloro-5-trifluoromethyl-benzyl)-2-(4-ethoxycarbonyl-methoxy-1,4′-bipiperidinyl-1′-yl)-2-oxo-ethyl4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidine-1-carboxylatein 8 mL THF and the reaction mixture was stirred for 3 h at RT. 0.34 mL(0.34 mmol) 1 M HCl was added and the mixture was evaporated down i.vac. The residue was taken up in DCM/MeOH, filtered through a littlesilica gel and eluted with DCM/MeOH (7:3). It was evaporated down i.vac. and the residue was dried under a high vacuum.

Yield: 61 mg (63% of theory)

ESI-MS: (M+H)⁺=779/781 (Cl)

Retention time (HPLC): 3.2 min (method B)

EXAMPLE 26(R)-1-(4-amino-3-chloro-5-trifluoromethyl-benzyl)-2-(4-ethoxycarbonylmethyl-1,4′-bipiperidinyl-1′-yl)-2-oxo-ethyl4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidine-1-carboxylate

200 μL (1.43 mmol) triethylamine and 414 mg (1.29 mmol) TBTU were addedto 650 mg (1.17 mmol)(R)-2-(4-amino-3-chloro-5-trifluoromethyl-phenyl)-1-carboxy-ethyl4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidine-1-carboxylate(Example 1f) in 30 mL of THF and 5 mL of DMF and the reaction mixturewas stirred for 30 min at RT. Then 422 mg (1.29 mmol)ethyl[1,4′]bipiperidinyl-4-yl-acetate (A14b) and 330 μL (2.38 mmol)triethylamine in 10 mL DCM were added and the mixture was stirred for afurther 18 h at RT. 50 mL of semisaturated NaHCO₃ solution were added,the mixture was extracted twice with 50 mL EtOAc, the combined organicphases were washed with 50 mL saturated NaCl solution and dried overNa₂SO₄. After elimination of the desiccant and solvent the residue waspurified by chromatography (silica gel, EtOAc/MeOH/NH₃ 95:5:0.5). Thefractions containing the product were combined, evaporated down i. vac.,the residue was triturated with DIPE, suction filtered and dried.

Yield: 646 mg (70% of theory)

ESI-MS: (M+H)⁺=791/793 (Cl)

R_(f)=0.33 (silica gel, EtOAc/MeOH/NH₃ 90:10:1)

EXAMPLE 26.1(R)-1-(4-amino-3-chloro-5-trifluoromethyl-benzyl)-2-(4-carboxymethyl-1,4′-bipiperidinyl-1′-yl)-2-oxo-ethyl4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidine-1-carboxylate

A solution of 5.00 mg (0.21 mmol) LiOH in 3 mL water was added to 100 mg(0.13 mmol)(R)-1-(4-amino-3-chloro-5-trifluoromethyl-benzyl)-2-(4-ethoxycarbonyl-methyl-1,4′-bipiperidinyl-1′-yl)-2-oxo-ethyl4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidine-1-carboxylatein 10 mL THF and the reaction mixture was stirred for 2 days at RT. Themixture was evaporated to dryness i. vac., the residue was taken up in 1mL DMF and purified by HPLC; the fractions containing the product werecombined and lyophilised.

Yield: 22 mg (22% of theory)

ESI-MS: (M+H)⁺=763/765 (Cl)

Retention time (HPLC): 3.2 min (method B)

EXAMPLE 27(R)-1-(4-amino-3-chloro-5-trifluoromethyl-benzyl)-2-[4-(2-ethoxycarbonyl-ethyl)-1,4′-bipiperidinyl-1′-yl]-2-oxo-ethyl4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidine-1-carboxylate

Prepared analogously to Example 24 from 500 mg (0.90 mmol)(R)-2-(4-amino-3-chloro-5-trifluoromethyl-phenyl)-1-carboxy-ethyl4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidine-1-carboxylate(Example 1f) and 341 mg (1.00 mmol) ethyl3-[1,4′]bipiperidinyl-4-yl-propionate (Example A15b).

Yield: 340 mg (47% of theory)

ESI-MS: (M+H)⁺=805/807 (Cl)

Retention time (HPLC): 3.6 min (method B)

EXAMPLE 27.1(R)-1-(4-amino-3-chloro-5-trifluoromethyl-benzyl)-2-[4-(2-carboxy-ethyl)-1,4′-bipiperidinyl-1′-yl]-2-oxo-ethyl4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidine-1-carboxylate

A solution of 2.40 mg (0.10 mmol) LiOH in 1 mL water was added to 50 mg(0.06 mmol)(R)-1-(4-amino-3-chloro-5-trifluoromethyl-benzyl)-2-[4-(2-ethoxycarbonyl-ethyl)-1,4′-bipiperidinyl-1′-yl]-2-oxo-ethyl4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidine-1-carboxylatein 3 mL THF and the reaction mixture was stirred for 4 h at RT. THF waseliminated in a nitrogen stream, the residue was taken up in a littlewater and purified by HPLC; the fractions containing the product werecombined and lyophilised.

Yield: 38 mg (79% of theory)

ESI-MS: (M+H)⁺=777/779 (Cl)

Retention time (HPLC): 3.4 min (method B)

EXAMPLE 28(R)-1-(4-amino-3-chloro-5-trifluoromethyl-benzyl)-2-{4-[1-(3-ethoxycarbonyl-propyl)-piperidin-4-yl]-piperazin-1-yl}-2-oxo-ethyl4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidine-1-carboxylate

283 mg (1.00 mmol) ethyl 4-(4-piperazin-1-yl-piperidin-1-yl)-butyrate(Example A16b) were added to a mixture of 500 mg (0.90 mmol)(R)-2-(4-amino-3-chloro-5-trifluoromethyl-phenyl)-1-carboxy-ethyl4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidine-1-carboxylate(Example 1f), 321 mg (1.00 mmol) TBTU and 0.14 mL (1.00 mmol)triethylamine in 10 mL DMF and the reaction mixture was stirred for 2 hat RT. This was purified by HPLC without any further working up; thefractions containing the product were combined, evaporated down i. vac.,the residue was stirred with saturated NaHCO₃ solution, filtered anddried.

Yield: 165 mg (22% of theory)

ESI-MS: (M+H)⁺=820/822 (Cl)

Retention time (HPLC): 3.1 min (method B)

EXAMPLE 28.1(R)-1-(4-amino-3-chloro-5-trifluoromethyl-benzyl)-2-{4-[1-(3-carboxy-propyl)-piperidin-4-yl]-piperazin-1-yl}-2-oxo-ethyl4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidine-1-carboxylate

Prepared analogously to Example 27.1 from 50 mg (0.06 mmol)(R)-1-(4-amino-3-chloro-5-trifluoromethyl-benzyl)-2-{4-[1-(3-ethoxycarbonyl-propyl)-piperidin-4-yl]-piperazin-1-yl}-2-oxo-ethyl4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidine-1-carboxylateand 2.40 mg (0.10 mmol) LiOH.

Yield: 29 mg (60% of theory)

ESI-MS: (M+H)⁺=792/794 (Cl)

Retention time (HPLC): 3.0 min (method B)

EXAMPLE 29(R)-1-(4-amino-3-chloro-5-trifluoromethyl-benzyl)-2-{4-[1-(1-ethoxycarbonyl-ethyl)-piperidin-4-yl]-piperazin-1-yl}-2-oxo-ethyl4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidine-1-carboxylate

29a)(R)-1-(4-amino-3-chloro-5-trifluoromethyl-benzyl)-2-oxo-2-(4-piperidin-4-yl-piperazin-1-yl)-ethyl4-(2-oxo-1,2,45-tetrahydro-1,3-benzodiazepin-3-yl)-piperidine-1-carboxylate

A mixture of 1.00 g (1.80 mmol)(R)-2-(4-amino-3-chloro-5-trifluoromethyl-phenyl)-1-carboxy-ethyl4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidine-1-carboxylate(Example 1f), 546 mg (1.80 mmol) benzyl4-piperazin-1-yl-piperidine-1-carboxylate (Example A17b), 643 mg (2.00mmol) TBTU and 0.35 mL (2.50 mmol) triethylamine in 10 mL DMF wasstirred overnight at RT. This was combined with 150 mL of 15% K₂CO₃solution, the precipitate was removed by suction filtering, washed with30 mL water and the crude product was dried at 40° C. in the dryingcupboard.

Yield: 1.50 g (99% of theory)

ESI-MS: (M+H)⁺=840/842 (Cl)

Retention time (HPLC): 3.7 min (method B)

A suspension of 750 mg (0.89 mmol) of the above product and 600 mg Raneynickel in 50 mL MeOH was hydrogenated for 30 h at RT and 3447 hPa. Thecatalyst was removed by suction filtering, evaporated down i. vac. andthe residue was purified by HPLC. The fractions containing the productwere combined, evaporated down i. vac., the residue was made alkalinewith 15% K₂CO₃ solution, extracted with 100 mL EtOAc, the organic phasewas separated off and dried over Na₂SO₄. After elimination of thedesiccant and solvent the residue was triturated with 30 mL DIPE,suction filtered and dried.

Yield: 280 mg (44% of theory)

ESI-MS: (M+H)⁺=706/708 (Cl)

Retention time (HPLC): 2.8 min (method B)

29b)(R)-1-(4-amino-3-chloro-5-trifluoromethyl-benzyl)-2-{4-[1-(1-ethoxycarbonyl-ethyl)-piperidin-4-yl]-piperazin-1-yl}-2-oxo-ethyl4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidine-1-carboxylate

A mixture of 140 mg (0.20 mmol)(R)-1-(4-amino-3-chloro-5-trifluoromethyl-benzyl)-2-oxo-2-(4-piperidin-4-yl-piperazin-1-yl)-ethyl4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidine-1-carboxylate,60.8 mg (0.44 mmol) K₂CO₃ and 29 μL (0.22 mmol) ethyl 2-bromopropionatein 1.8 mL DMF was shaken for 2 h at 50° C. The reaction mixture waspurified by HPLC without working up; the fractions containing theproduct were combined and lyophilised.

Yield: 111 mg (69% of theory)

ESI-MS: (M+H)⁺=806/808 (Cl)

Retention time (HPLC): 3.1 min (method B)

EXAMPLE 29.1(R)-1-(4-amino-3-chloro-5-trifluoromethyl-benzyl)-2-{4-[1-(1-carboxy-ethyl)-piperidin-4-yl]-piperazin-1-yl}-2-oxo-ethyl4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidine-1-carboxylate

A solution of 2.4 mg (0.10 mmol) LiOH in 0.8 mL water was added to 50 mg(0.06 mmol)(R)-1-(4-amino-3-chloro-5-trifluoromethyl-benzyl)-2-{4-[1-(1-ethoxycarbonyl-ethyl)-piperidin-4-yl]-piperazin-1-yl}-2-oxo-ethyl4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidine-1-carboxylatein 1 mL THF and the reaction mixture was shaken for 2 h at RT and for 4h at 50° C. It was then purified by HPLC without working up; thefractions containing the product were combined and lyophilised.

Yield: 42 mg (87% of theory)

ESI-MS: (M+H)⁺=778/780 (Cl)

Retention time (HPLC): 3.0 min (method B)

EXAMPLE 30(R)-1-(4-amino-3-chloro-5-trifluoromethyl-benzyl)-2-{4-[1-(1-ethoxycarbonyl-1-methyl-ethyl)-piperidin-4-yl]-piperazin-1-yl}-2-oxo-ethyl4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidine-1-carboxylate

A mixture of 140 mg (0.20 mmol)(R)-1-(4-amino-3-chloro-5-trifluoromethyl-benzyl)-2-oxo-2-(4-piperidin-4-yl-piperazin-1-yl)-ethyl4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidine-1-carboxylate(Example 29a), 60.8 mg (0.44 mmol) K₂CO₃ and 45 μL (0.30 mmol) ethyl2-bromo-2-methyl-propionate in 1.8 mL DMF was shaken at 50° C. for 12 hand then for 48 h at RT. The precipitate was filtered off and thefiltrate was purified by HPLC without working up; the fractionscontaining the product were combined, evaporated down i. vac., theresidue was made alkaline with saturated NaHCO₃ solution, theprecipitate was suction filtered, washed with 20 mL water and dried at40° C.

Yield: 85 mg (52% of theory)

ESI-MS: (M+H)⁺=820/822 (Cl)

Retention time (HPLC): 3.0 min (method B)

EXAMPLE 31 Ethyl1′-{(R)-3-(4-amino-3-chloro-5-trifluoromethyl-phenyl)-2-[4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidine-1-carbonyloxy]-propionyl}-4-methyl-1,4′-bipiperidinyl-4-carboxylate

A mixture of 127 mg (0.20 mmol)(R)-1-(4-amino-3-chloro-5-trifluoromethyl-benzyl)-2-oxo-2-(4-oxo-piperidin-1-yl)-ethyl4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidine-1-carboxylate(Example 1g), 68.5 mg (0.40 mmol) ethyl4-methyl-piperidine-4-carboxylate and 11 μL (0.2 mmol) AcOH in 2 mL DCMwas stirred for 2 h at RT, cooled to 0° C., stirred for 2 h, then mixedwith 57.7 mg (0.26 mmol) sodium triacetoxyborohydride and stirredovernight at 0° C. The reaction mixture was purified by HPLC withoutworking up; the fractions containing the product were combined andlyophilised.

Yield: 85 mg (54% of theory)

ESI-MS: (M+H)⁺=791/793 (Cl)

Retention time (HPLC): 7.7 min (method C)

The following compounds were prepared analogously from in each case 127mg(R)-1-(4-amino-3-chloro-5-trifluoromethyl-benzyl)-2-oxo-2-(4-oxo-piperidin-1-yl)-ethyl4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidine-1-carboxylate(Example 1g) and the amount of amine component required in each case:

Re- tention time Ex- Yield Mass HPLC ample R (%) spectrum (method) 31.1

23 763/765 [M + H]⁺ 7.2 min (C) 31.2

74 763/765 [M + H]⁺ 7.1 min (C) 31.3

75 777/779 [M + H]⁺ 7.3 min (C) 31.4

72 777/779 [M + H]⁺ 7.3 min (C)

EXAMPLE 321′-{(R)-3-(4-amino-3-chloro-5-trifluoromethyl-phenyl)-2-[4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidine-1-carbonyloxy]-propionyl}-4-methyl-1,4′-bipiperidinyl-4-carboxylicacid

A solution of 2.00 mg (0.08 mmol) LiOH in 1 mL water was added to 40 mg(0.05 mmol) ethyl1′-{(R)-3-(4-amino-3-chloro-5-trifluoromethyl-phenyl)-2-[4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidine-1-carbonyloxy]-propionyl}-4-methyl-1,4′-bipiperidinyl-4-carboxylatein 0.8 mL THF and the reaction mixture was stirred for 1 h at RT and for8 h at 50° C. This was purified by HPLC without working up; thefractions containing the product were combined and lyophilised.

Yield: 18 mg (47% of theory)

ESI-MS: (M+H)⁺=763/765 (Cl)

Retention time (HPLC): 3.5 min (method B)

The following compounds were prepared analogously from in each case 40mg of the corresponding ethyl ester, the hydrolysis requiring only 1 hat RT:

Retention time Yield Mass HPLC Example R (%) spectrum (method) 32.1

93 735/737 [M + H]⁺ 3.3 min (B) 32.2

73 735/737 [M + H]⁺ 3.3 min (B) 32.3

73 749/751 [M + H]⁺ 3.3 min (B) 32.4

80 749/751 [M + H]⁺ 3.5 min (B)

EXAMPLE 33(R)-1-(4-amino-3-chloro-5-trifluoromethyl-benzyl)-2-{4-[1-(5-methyl-2-oxo-1,3-dioxol-4-ylmethoxycarbonylmethyl)-piperidin-4-yl]-piperazin-1-yl}-2-oxo-ethyl4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidine-1-carboxylate

A mixture of 185 mg (0.24 mmol)(R)-1-(4-amino-3-chloro-5-trifluoromethyl-benzyl)-2-[4-(1-carboxymethyl-piperidin-4-yl)-piperazin-1-yl]-2-oxo-ethyl4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidine-1-carboxylate(Example 4.1), 25 mg (0.25 mmol) KHCO₃ and 50 mg (0.26 mmol)4-bromomethyl-5-methyl-1,3-dioxol-2-one in 1 mL DMF was shaken overnightat RT. The reaction mixture was filtered through a syringe filter andpurified by HPLC; the fractions containing the product were combined andlyophilised.

Yield: 14 mg (7% of theory)

ESI-MS: (M+H)⁺=876/878 (Cl)

R_(f)=0.54 (silica gel, DCM/Cyc/MeOH/NH₃ 70:15:15:2)

EXAMPLE 33.1(R)-1-(4-amino-3-chloro-5-trifluoromethyl-benzyl)-2-[1′-(5-methyl-2-oxo-1,3-dioxol-4-ylmethoxycarbonylmethyl)-4,4′-bipiperidinyl-1-yl]-2-oxo-ethyl4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidine-1-carboxylate

Prepared analogously to Example 33 from 150 mg (0.20 mmol)(R)-1-(4-amino-3-chloro-5-trifluoromethyl-benzyl)-2-(1′-carboxymethyl-4,4′-bipiperidinyl-1-yl)-2-oxo-ethyl4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidine-1-carboxylate(Example 3.1) and 50 mg (0.26 mmol)4-bromomethyl-5-methyl-1,3-dioxol-2-one.

Yield: 8 mg (5% of theory)

ESI-MS: (M+H)⁺=875/877 (Cl)

R_(f)=0.74 (silica gel, DCM/Cyc/MeOH/NH₃ 70:15:15:2)

EXAMPLE 34(R)-1-(4-amino-3-chloro-5-trifluoromethyl-benzyl)-2-(4-{1-[2-(2-methoxy-ethoxy)-ethoxycarbonylmethyl]-piperidin-4-yl}-piperazin-1-yl)-2-oxo-ethyl4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidine-1-carboxylate

13 μL (0.11 mmol) 2-(2-methoxy-ethoxy)-ethanol were added to a mixtureof 75 mg (0.10 mmol) of(R)-1-(4-amino-3-chloro-5-trifluoromethyl-benzyl)-2-[4-(1-carboxymethyl-piperidin-4-yl)-piperazin-1-yl]-2-oxo-ethyl4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidine-1-carboxylate(Example 4.1), 35 mg (0.11 mmol) TBTU and 28 μL (0.20 mmol)triethylamine in 1 mL DMF and the reaction mixture was stirred for 1 hat RT. This was purified by HPLC without working up; the fractionscontaining the product were combined and lyophilised.

Yield: 22 mg (26% of theory)

ESI-MS: (M+H)⁺=866/868 (Cl)

Retention time (HPLC): 3.2 min (method B)

EXAMPLE 35(R)-1-(4-amino-3-chloro-5-trifluoromethyl-benzyl)-2-[1′-(2-morpholin-4-yl-ethoxycarbonylmethyl)-4,4′-bi piperidinyl-1-yl]-2-oxo-ethyl4-(7-methoxy-2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidine-1-carboxylate

A mixture of 230 mg (0.29 mmol)(R)-1-(4-amino-3-chloro-5-trifluoromethyl-benzyl)-2-(1′-carboxymethyl-4,4′-bipiperidinyl-1-yl)-2-oxo-ethyl4-(7-methoxy-2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidine-1-carboxylate(Example 15.1), 113 mg (0.35 mmol) TBTU, 84 μL (0.60 mmol) triethylamineand 39.3 mg (0.30 mmol) 2-morpholin-4-yl-ethanol in 5 mL DMF was stirredovernight at RT. The reaction mixture was poured onto saturated NaHCO₃solution, the product precipitated was suction filtered and dried at 40°C. This was dissolved in 25 mL of isopropanol and precipitated as thehydrochloride salt by the addition of 0.5 M HCl in isopropanol. This wassuction filtered, washed with 5 mL isopropanol and 30 mL DIPE and driedat 30° C. in the vacuum drying cupboard.

Yield: 90 mg (34% of theory)

ESI-MS: (M+H)⁺=906/908 (Cl)

Retention time (HPLC): 3.1 min (method B)

The Examples that follow describe the preparation of pharmaceuticalformulations which contain as active substance any desired compound ofgeneral formula I:

EXAMPLE I

Capsules for Powder Inhalation Containing 1 Mg of Active Ingredient

Composition:

1 capsule for powder inhalation contains: active ingredient 1.0 mglactose 20.0 mg hard gelatine capsules 50.0 mg 71.0 mgMethod of Preparation:

The active ingredient is ground to the particle size required forinhaled substances. The ground active ingredient is homogeneously mixedwith the lactose. The mixture is transferred into hard gelatinecapsules.

EXAMPLE II

Inhalable Solution for Respimat® Containing 1 Mg of Active Ingredient

Composition:

1 puff contains: active ingredient 1.0 mg benzalkonium chloride 0.002 mgdisodium edetate 0.0075 mg purified water ad 15.0 μlMethod of Preparation:

The active ingredient and benzalkonium chloride are dissolved in waterand transferred into Respimat® cartridges.

EXAMPLE III

Inhalable Solution for Nebulisers Containing 1 mg of Active Ingredient

Composition:

1 vial contains: active ingredient 0.1 g sodium chloride 0.18 gbenzalkonium chloride 0.002 g purified water ad 20.0 mlMethod of Preparation:

The active ingredient, sodium chloride and benzalkonium chloride aredissolved in water.

EXAMPLE IV

Propellant Gas-Operated Metering Aerosol Containing 1 mg of ActiveIngredient

Composition:

1 puff contains: active ingredient 1.0 mg lecithin 0.1% propellant gasad 50.0 μlMethod of Preparation:

The micronised active ingredient is homogeneously suspended in themixture of lecithin and propellant gas. The suspension is transferredinto a pressurised container with a metering valve.

EXAMPLE V

Nasal Spray Containing 1 mg of Active Ingredient

Composition:

active ingredient 1.0 mg sodium chloride 0.9 mg benzalkonium chloride0.025 mg disodium edetate 0.05 mg purified water ad 0.1 mlMethod of Preparation:

The active ingredient and the excipients are dissolved in water andtransferred into a suitable container.

EXAMPLE VI

Injectable Solution Containing 5 mg of Active Substance Per 5 Ml

Composition:

active substance 5 mg glucose 250 mg human serum albumin 10 mgglycofurol 250 mg water for injections ad 5 mlPreparation:

Glycofurol and glucose are dissolved in water for injections (Wfl);human serum albumin is added; active ingredient is dissolved withheating; made up to specified volume with Wfl; transferred into ampoulesunder nitrogen gas.

EXAMPLE VII

Injectable Solution Containing 100 mg of Active Substance Per 20 Ml

Composition:

active substance 100 mg monopotassium dihydrogen phosphate = KH₂PO₄ 12mg disodium hydrogen phosphate = Na₂HPO₄*2H₂O 2 mg sodium chloride 180mg human serum albumin 50 mg Polysorbate 80 20 mg water for injectionsad 20 mlPreparation:

Polysorbate 80, sodium chloride, monopotassium dihydrogen phosphate anddisodium hydrogen phosphate are dissolved in water for injections (Wfl);human serum albumin is added; active ingredient is dissolved withheating; made up to specified volume with Wfl; transferred intoampoules.

EXAMPLE VIII

Lyophilisate Containing 10 mg of Active Substance

Composition:

Active substance 10 mg Mannitol 300 mg human serum albumin 20 mg waterfor injections ad 2 mlPreparation:

Mannitol is dissolved in water for injections (Wfl); human serum albuminis added; active ingredient is dissolved with heating; made up tospecified volume with Wfl; transferred into vials; freeze-dried.

Solvent for Lyophilisate:

Polysorbate 80 = Tween 80 20 mg mannitol 200 mg water for injections ad10 mlPreparation:

Polysorbate 80 and mannitol are dissolved in water for injections (Wfl);transferred into ampoules.

EXAMPLE IX

Tablets Containing 20 mg of Active Substance

Composition:

active substance 20 mg lactose 120 mg corn starch 40 mg magnesiumstearate 2 mg Povidone K 25 18 mgPreparation:

Active substance, lactose and corn starch are homogeneously mixed;granulated with an aqueous solution of Povidone; mixed with magnesiumstearate; compressed in a tablet press; weight of tablet 200 mg.

EXAMPLE X

Capsules Containing 20 mg Active Substance

Composition:

active substance 20 mg corn starch 80 mg highly dispersed silica 5 mgmagnesium stearate 2.5 mgPreparation:

Active substance, corn starch and silica are homogeneously mixed; mixedwith magnesium stearate; the mixture is packed into size for 3 hardgelatine capsules in a capsule filling machine.

EXAMPLE XI

Suppositories Containing 50 mg of Active Substance

Composition:

active substance  50 mg hard fat (Adeps solidus) q.s. ad 1700 mgPreparation:

Hard fat is melted at about 38° C.; ground active substance ishomogeneously dispersed in the molten hard fat; after cooling to about35° C. it is poured into chilled moulds.

EXAMPLE XII

Injectable Solution Containing 10 mg of Active Substance Per 1 Ml

Composition:

active substance 10 mg mannitol 50 mg human serum albumin 10 mg waterfor injections ad 1 mlPreparation:

Mannitol is dissolved in water for injections (Wfl); human serum albuminis added; active ingredient is dissolved with heating; made up tospecified volume with Wfl; transferred into ampoules under nitrogen gas.

1. A compound of the formula I

wherein R¹ denotes a group of the formula

wherein R^(1.1) denotes H or H₃C—O, R² denotes a group selected from

R³ denotes a group of general formula II

wherein X denotes N or C, R^(3.1) denotes H, C₁₋₃-alkyl orR^(3.1.1)—O—C(O), R^(3.1.1) denotes H, C₁₋₆-alkyl, H₂N—C₂₋₄-alkylene,(C₁₋₃-alkyl)-NH—C₂₋₄-alkylene, (C₁₋₃-alkyl)₂N—C₂₋₄-alkylene,H₂N—C(O)—C₁₋₃-alkylene, (C₁₋₃-alkyl)-NH—C(O)—C₁₋₃-alkylene,(C₁₋₃-alkyl)₂N—C(O)—C₁₋₃-alkylene or R^(3.1.1.1)—C₂₋₄-alkylene,R^(3.1.1.1) denotes a group selected from

R^(3.2) denotes a pair of free electrons, if X=N, or R^(3.2) denotes H,C₁₋₃-alkyl or R^(3,2,1)—O—C(O), if X=C, R^(3,2,1) denotes H, C₁₋₆-alkyl,H₂N—C₂₋₄-alkylene, (C₁₋₃-alkyl)-NH—C₂₋₄-alkylene,(C₁₋₃-alkyl)₂N—C₂₋₄-alkylene, H₂N—C(O)—C₁₋₃-alkylene,(C₁₋₃-alkyl)-NH—C(O)—C₁₋₃-alkylene, (C₁₋₃-alkyl)₂N—C(O)—C₁₋₃-alkylene orR^(3,2,1.1)—C₂₋₄-alkylene, R^(3,2,1.1) denotes a group selected from

R⁴ denotes a group of general formulae III

wherein Y denotes C and R^(4.1) denotes H or C₁₋₃-alkyl, or Y denotes Nand R^(4.1) denotes a pair of free electrons, with the proviso that Xand Y do not simultaneously represent N, R^(4.2) denotes H, C₁₋₃-alkylor R^(4.2.1)—O—C(O), R^(4.2.1) denotes H, C₁₋₆-alkyl, H₂N—C₂₋₄-alkylene,(C₁₋₃-alkyl)-NH—C₂₋₄-alkylene, (C₁₋₃-alkyl)₂N—C₂₋₄-alkylene,H₂N—C(O)—C₁₋₃-alkylene, (C₁₋₃-alkyl)-NH—C(O)—C₁₋₃-alkylene,(C₁₋₃-alkyl)₂N—C(O)—C₁₋₃-alkylene or R^(4.2.1.1)—C₂₋₄-alkylene,R^(4.2.1.1) denotes a group selected from

R^(4.3) denotes H, C₁₋₆-alkyl, H₂N—C₂₋₄-alkylene,(C₁₋₃-alkyl)-NH—C₂₋₄-alkylene, (C₁₋₃-alkyl)₂N—C₂₋₄-alkylene,H₂N—C(O)—C₁₋₃-alkylene, (C₁₋₃-alkyl)-NH—C(O)—C₁₋₃-alkylene,(C₁₋₃-alkyl)₂N—C(O)—C₁₋₃-alkylene or R^(4.3.1)—C₂₋₄-alkylene- andR^(4.3.1) denotes a group selected from

R^(5.1) denotes H, C₁₋₃-alkyl, R^(5.1.1)—O—C(O),R^(5.1.1)—O—C(O)—C₁₋₃-alkylene-NH,R^(5.1.1)—O—C(O)—C₁₋₃-alkylene-N(C₁₋₃-alkyl),R^(5.1.1)—O—C(O)—C₁₋₃-alkylene-O, R^(5.1.1)—O—C(O)—C₁₋₃-alkylene,R^(5.1.1)—O—C(O)—C(O), R^(5.1.1)—O—C(O)—C(O)—O,R^(5.1.1)—O—C(O)—C₁₋₃-alkylene-C(O) orR^(5.1.1)—O—C(O)—C₁₋₃-alkylene-C(O)—O, R^(5.1.1) denotes H, C₁₋₈-alkyl,phenyl, indanyl, pyridyl-C₁₋₃-alkylene, HO—C₂₋₄-alkylene,C₁₋₆-alkyl-O—C₂₋₄-alkylene, H₂N—C₂₋₄-alkylene,(C₁₋₆-alkyl)-NH—C₂₋₄-alkylene, (C₁₋₆-alkyl)₂N—C₂₋₄-alkylene,H₂N—C(O)—C₁₋₃-alkylene, (C₁₋₆-alkyl)-NH—C(O)—C₁₋₃-alkylene,(C₁₋₆-alkyl)₂N—C(O)—C₁₋₃-alkylene, C₁₋₆-alkyl-C(O)—O—C₁₋₃-alkylene,C₁₋₆-alkyl-O—C(O)—O—C₁₋₃-alkylene, R^(5.1.1.1)—C(O)—C₁₋₃-alkylene orR^(5.1.1,2-)C₂₋₄-alkylene, R^(5.1.1.1) denotes a group selected from

R^(5.1.1.2) denotes a group selected from

R^(5.2) denotes H, C₁₋₃-alkyl, R^(5.2.1)—O—C(O)—C₁₋₃-alkylene-NH,R^(5.2.1)—O—C(O)—C₁₋₃-alkylene-O, R^(5.2.1)—O—C(O)—C₁₋₃-alkylene,R^(5.2.1)—O—C(O)—C(O) or R^(5.2.1)—O—C(O)—C₁₋₃-alkylene-C(O), R^(5.2.1)denotes H, C₁₋₈-alkyl, phenyl, indanyl, pyridyl-C₁₋₃-alkylene,HO—C₂₋₄-alkylene, C₁₋₆-alkyl-O—C₂₋₄-alkylene, C₁₋₆-alkyl-O—C₂₋₄-alkylene-O—C₂₋₄-alkylene, H₂N—C₂₋₄-alkylene, (C₁₋₆-alkyl)-NH—C₂₋₄-alkylene,(C₁₋₆-alkyl)₂N—C₂₋₄-alkylene, H₂N—C(O)—C₁₋₃-alkylene,(C₁₋₆-alkyl)-NH—C(O)—C₁₋₃-alkylene, (C₁₋₆-alkyl)₂N—C(O)—C₁₋₃-alkylene,C₁₋₆-alkyl-C(O)—O—C₁₋₃-alkylene, C₁₋₆-alkyl-O—C(O)—O—C₁₋₃-alkylene,R^(5.2.1.1)—C(O)—C₁₋₃-alkylene or R^(5.2.1,2-)C₂₋₄-alkylene, R^(5.2.1.1)denotes a group selected from

R^(5.2.1.2) denotes a group selected from

R^(5.2.1) denotes a group of formula

with the proviso that at least one of the groups R^(3.1), R^(3.2),R^(4.2), R^(5.1) or R^(5.2) denotes a group other than H or C₁₋₃-alkyl,or a tautomer or salt thereof.
 2. A compound of the formula I accordingto claim 1, wherein R¹ denotes a group of the formula

wherein R^(1.1) denotes H or H₃C—O, R² denotes a group selected from

R³ denotes a group of general formula II

wherein X denotes N or C, R^(3.1) denotes H, C₁₋₃-alkyl orR^(3.1.1)—(O)C, R^(3.1.1) denotes HO, C₁₋₆-alkyl-O, R^(3.2) denotes apair of free electrons, if X=N, or R^(3.2) denotes H or C₁₋₃-alkyl, ifX=C, R⁴ denotes a group of general formulae III

wherein Y denotes C and R^(4.1) denotes H or C₁₋₃-alkyl, or Y denotes Nand R^(4.1) denotes a pair of free electrons, with the proviso that Xand Y do not simultaneously represent N, R^(4.2) denotes H, C₁₋₃-alkylor R^(4.2.1)—(O)C, R^(4.2.1) denotes HO, C₁₋₆-alkyl-O, and R^(4.3)denotes H, C₁₋₆-alkyl, H₂N—C₂₋₄-alkylene, (C₁₋₃-alkyl)-NH—C₂₋₄-alkylene,(C₁₋₃-alkyl)₂N—C₂₋₄-alkylene, H₂N—C(O)—C₁₋₃-alkylene,(C₁₋₃-alkyl)-NH—C(O)—C₁₋₃-alkylene, (C₁₋₃-alkyl)₂N—C(O)—C₁₋₃-alkylene orR^(4.3.1)—C₂₋₄-alkylene, R^(4.3.1) denotes a group selected from

R^(5.1) denotes R^(5.1.1)—O—C(O), R^(5.1.1)—O—C(O)—C₁₋₃-alkylene-NH,R^(5.1.1)—O—C(O)—C₁₋₃-alkylene-O, R^(5.1.1)—O—C(O)—C₁₋₃-alkylene,R^(5.1.1)—O—C(O)—C(O) or R^(5.1.1)—O—C(O)—C₁₋₃-alkylene-C(O), R^(5.1.1)denotes H, C₁₋₈-alkyl, phenyl, indanyl, pyridyl-C₁₋₃-alkylene,HO—C₂₋₄-alkylene, C₁₋₆-alkyl-O—C₂₋₄-alkylene, H₂N—C₂₋₄-alkylene,(C₁₋₆-alkyl)-NH—C₂₋₄-alkylene, (C₁₋₆-alkyl)₂N—C₂₋₄-alkylene,H₂N—C(O)—C₁₋₃-alkylene, (C₁₋₆-alkyl)-NH—C(O)—C₁₋₃-alkylene,(C₁₋₆-alkyl)₂N—C(O)—C₁₋₃-alkylene, C₁₋₆-alkyl-C(O)—O—C₁₋₃-alkylene,C₁₋₆-alkyl-O—C(O)—O—C₁₋₃-alkylene, R^(5.1.1.1)—C(O)—C₁₋₃-alkylene orR^(5.1.1,2-)C₂₋₄-alkylene, R^(5.1.1.1) denotes a group selected from

R^(5.1.1.2) denotes a group selected from

R^(5.2) denotes R^(5.2.1)—O—C(O)—C₁₋₃-alkylene-NH,R^(5.2.1)—O—C(O)—C₁₋₃-alkylene-O, R^(5.2.1)—O—C(O)—C₁₋₃-alkylene,R^(5.2.1)—O—C(O)—C(O) or R^(5.2.1)—O—C(O)—C₁₋₃-alkylene-C(O), R^(5.2.1)denotes H, C₁₋₈-alkyl, phenyl, indanyl, pyridyl-C₁₋₃-alkylene,HO—C₂₋₄-alkylene, C₁₋₆-alkyl-O—C₂₋₄-alkylene, H₂N—C₂₋₄-alkylene,(C₁₋₆-alkyl)-NH—C₂₋₄-alkylene, (C₁₋₆-alkyl)₂N—C₂₋₄-alkylene,H₂N—C(O)—C₁₋₃-alkylene, (C₁₋₆-alkyl)-NH—C(O)—C₁₋₃-alkylene,(C₁₋₆-alkyl)₂N—C(O)—C₁₋₃-alkylene, C₁₋₆-alkyl-C(O)—O—C₁₋₃-alkylene,C₁₋₆-alkyl-O—C(O)—O—C₁₋₃-alkylene, R^(5.2.1.1)—C(O)—C₁₋₃-alkylene orR^(5.2.1,2-)C₂₋₄-alkylene, R^(5.2.1.1) denotes a group selected from

R^(5.2.1.2) denotes a group selected from

or a tautomer or salt thereof.
 3. A compound of the formula I accordingto claim 1, wherein R¹ denotes a group of the formula

wherein R^(1.1) denotes H or H₃C—O, R² denotes a group selected from

R³—R⁴ together denote a group of general formulae IV

wherein R^(3.1) denotes H, H₃C or R^(3.1.1)—O—C(O), R^(3.1.1) denotes H,C₁₋₆-alkyl, (C₁₋₃-alkyl)₂N—C₂₋₄-alkylene,(C₁₋₃-alkyl)₂N—C(O)—C₁₋₃-alkylene or R^(3.1.1.1)—C₂₋₄-alkylene,R^(3.1.1.1) denotes a group selected from

R^(3.2) denotes H, C₁₋₃-alkyl or R^(3,2,1)—O—C(O), R^(3,2,1) denotes H,C₁₋₆-alkyl, (C₁₋₃-alkyl)₂N—C₂₋₄-alkylene,(C₁₋₃-alkyl)₂N—C(O)—C₁₋₃-alkylene or R^(3,2,1.1)—C₂₋₄-alkylene,R^(3,2,1.1) denotes a group selected from

R^(4.1) denotes H or C₁₋₃-alkyl, R^(4.2) denotes H, C₁₋₃-alkyl orR^(4.2.1)—O—C(O), R^(4.2.1) denotes H, C₁₋₆-alkyl,(C₁₋₃-alkyl)₂N—C₂₋₄-alkylene, (C₁₋₃-alkyl)₂N—C(O)—C₁₋₃-alkylene orR^(4.2.1.1)—C₂₋₄-alkylene, R^(4.2.1.1) denotes a group selected from

R^(4.3) denotes H, C₁₋₆-alkyl, H₂N—C₂₋₄-alkylene,(C₁₋₃-alkyl)-NH—C₂₋₄-alkylene, (C₁₋₃-alkyl)₂N—C₂₋₄-alkylene,H₂N—C(O)—C₁₋₃-alkylene, (C₁₋₃-alkyl)-NH—C(O)—C₁₋₃-alkylene,(C₁₋₃-alkyl)₂N—C(O)—C₁₋₃-alkylene or R^(4.3.1)—C₂₋₄-alkylene, andR^(4.3.1) denotes a group selected from

R^(5.1) denotes H, H₃C, R^(5.1.1)—O—C(O),R^(5.1.1)—O—C(O)—C₁₋₃-alkylene-NH,R^(5.1.1)—O—C(O)—C₁₋₃-alkylene-N(C₁₋₃-alkyl),R^(5.1.1)—O—C(O)—C₁₋₃-alkylene-O, R^(5.1.1)—O—C(O)—C₁₋₃-alkylene,R^(5.1.1)—O—C(O)—C(O), R^(5.1.1)—O—C(O)—C(O)—O,R^(5.1.1)—O—C(O)—C₁₋₃-alkylene-C(O) orR^(5.1.1)—O—C(O)—C₁₋₃-alkylene-C(O)—O, R^(5.1.1) denotes H, C₁₋₈-alkyl,phenyl, indanyl, pyridyl-CH₂, HO—C₂₋₄-alkylene,C₁₋₆-alkyl-O—C₂₋₄-alkylene, H₂N—C₂₋₄-alkylene,(C₁₋₆-alkyl)-NH—C₂₋₄-alkylene, (C₁₋₆-alkyl)₂N—C₂₋₄-alkylene,H₂N—C(O)—C₁₋₃-alkylene, (C₁₋₆-alkyl)-NH—C(O)—C₁₋₃-alkylene,(C₁₋₆-alkyl)₂N—C(O)—C₁₋₃-alkylene, C₁₋₆-alkyl-C(O)—O—C₁₋₃-alkylene,C₁₋₆-alkyl-O—C(O)—O—C₁₋₃-alkylene, R^(5.1.1.1)—C(O)—C₁₋₃-alkylene orR^(5.1.1,2-)C₂₋₄-alkylene, R^(5.1.1.1) denotes a group selected from

R^(5.1.1.2) denotes a group selected from

R^(5.2) denotes H, H₃C, R^(5.2.1)—O—C(O)—C₁₋₃-alkylene-NH,R^(5.2.1)—O—C(O)—C₁₋₃-alkylene-O, R^(5.2.1)—O—C(O)—C₁₋₃-alkylene,R^(5.2.1)—O—C(O)—C(O) or R^(5.2.1)—O—C(O)—C₁₋₃-alkylene-C(O), R^(5.2.1)denotes H, C₁₋₈-alkyl, phenyl, indanyl, pyridyl-CH₂, HO—C₂₋₄-alkylene,C₁₋₆-alkyl-O—C₂₋₄-alkylene, C₁₋₆-alkyl-O—C₂₋₄-alkylene-O—C₂₋₄-alkylene,H₂N—C₂₋₄-alkylene, (C₁₋₆-alkyl)-NH—C₂₋₄-alkylene,(C₁₋₆-alkyl)₂N—C₂₋₄-alkylene, H₂N—C(O)—C₁₋₃-alkylene,(C₁₋₆-alkyl)-NH—C(O)—C₁₋₃-alkylene, (C₁₋₆-alkyl)₂N—C(O)—C₁₋₃-alkylene,C₁₋₆-alkyl-C(O)—O—C₁₋₃-alkylene, C₁₋₆-alkyl-O—C(O)—O—C₁₋₃-alkylene,R^(5.2.1.1)—C(O)—C₁₋₃-alkylene or R^(5.2.1,2-)C₂₋₄-alkylene, R^(5.2.1.1)denotes a group selected from

R^(5.2.1.2) denotes a group selected from

R^(5.2.1) denotes a group of formula

with the proviso that at least one of the groups R^(3.1), R^(3.2),R^(4.2), R^(5.1) or R^(5.2) denotes a group other than H or C₁₋₃-alkyl,or a tautomer or salt thereof.
 4. A compound of the formula I accordingto claim 1, wherein R¹ denotes a group of the formula

wherein R^(1.1) denotes H or H₃C—O, R² denotes a group selected from

R³-R⁴ together denote a group of general formulae IV

wherein R^(3.1) denotes H, R^(3.2) denotes H or C₁₋₃-alkyl, R^(4.1)denotes H or C₁₋₃-alkyl, R^(4.2) denotes H, R^(4.3) denotes H,C₁₋₆-alkyl, H₂N—C₂₋₄-alkylene, (C₁₋₃-alkyl)-NH—C₂₋₄-alkylene,(C₁₋₃-alkyl)₂N—C₂₋₄-alkylene, H₂N—C(O)—C₁₋₃-alkylene,(C₁₋₃-alkyl)-NH—C(O)—C₁₋₃-alkylene, (C₁₋₃-alkyl)₂N—C(O)—C₁₋₃-alkylene orR^(4.3.1)—C₂₋₄-alkylene, R^(4.3.1) denotes a group selected from

R^(5.1) denotes R^(5.1.1)—O—C(O), R^(5.1.1)—O—C(O)—C₁₋₃-alkylene-NH,R^(5.1.1)—O—C(O)—C₁₋₃-alkylene-O, R^(5.1.1)—O—C(O)—C₁₋₃-alkylene,R^(5.1.1)—O—C(O)C(O)—C(O) or R^(5.1.1)—O—C(O)—C₁₋₃-alkylene-C(O),R^(5.1.1) denotes H, C₁₋₈-alkyl, phenyl, indanyl, pyridyl-C₁₋₃-alkylene,HO—C₂₋₄-alkylene, C₁₋₆-alkyl-O—C₂₋₄-alkylene, H₂N—C₂₋₄-alkylene,(C₁₋₆-alkyl)-NH—C₂₋₄-alkylene, (C₁₋₆-alkyl)₂N—C₂₋₄-alkylene,H₂N—C(O)—C₁₋₃-alkylene, (C₁₋₆-alkyl)-NH—C(O)—C₁₋₃-alkylene,(C₁₋₆-alkyl)₂N—C(O)—C₁₋₃-alkylene, C₁₋₆-alkyl-C(O)—O—C₁₋₃-alkylene,C₁₋₆-alkyl-O—C(O)—O—C₁₋₃-alkylene, R^(5.1.1.1)—C(O)—C₁₋₃-alkylene orR^(5.1.1,2-)C₂₋₄-alkylene, R^(5.1.1.1) denotes a group selected from

R^(5.1.1.2) denotes a group selected from

R^(5.2) denotes R^(5.2.1)—O—C(O)—C₁₋₃-alkylene-NH,R^(5.2.1)—O—C(O)—C₁₋₃-alkylene-O, R^(5.2.1)—O—C(O)—C₁₋₃-alkylene,R^(5.2.1)—O—C(O)—C(O) or R^(5.2.1)—O—C(O)—C₁₋₃-alkylene-C(O), R^(5.2.1)denotes H, C₁₋₈-alkyl, phenyl, indanyl, pyridyl-C₁₋₃-alkylene,HO—C₂₋₄-alkylene, C₁₋₆-alkyl-O—C₂₋₄-alkylene, H₂N—C₂₋₄-alkylene,(C₁₋₆-alkyl)-NH—C₂₋₄-alkylene, (C₁₋₆-alkyl)₂N—C₂₋₄-alkylene,H₂N—C(O)—C₁₋₃-alkylene, (C₁₋₆-alkyl)-NH—C(O)—C₁₋₃-alkylene,(C₁₋₆-alkyl)₂N—C(O)—C₁₋₃-alkylene, C₁₋₆-alkyl-C(O)—O—C₁₋₃-alkylene,C₁₋₆-alkyl-O—C(O)—O—C₁₋₃-alkylene, R^(5.2.1.1)—C(O)—C₁₋₃-alkylene orR^(5.2.1,2-)C₂₋₄-alkylene, R^(5.2.1.1) denotes a group selected from

R^(5.2.1.2) denotes a group selected from

or a tautomer or salt thereof.
 5. A compound of the formula I accordingto claim 1, wherein R¹ denotes a group of the formula

wherein R^(1.1) denotes H or H₃C—O, R² denotes a group selected from

R³-R⁴ together denote a group of general formulae IV

wherein R^(3.1) denotes H or R^(3.1.1)—O—C(O), R^(3.1.1) denotes H,C₁₋₆-alkyl, (C₁₋₃-alkyl)₂N—C₂₋₄-alkylene,(C₁₋₃-alkyl)₂N—C(O)—C₁₋₃-alkylene or R^(3.1.1.1)—C₂₋₄-alkylene,R^(3.1.1.1) denotes a group

R^(3.2) denotes H, H₃C or R^(3,2,1)—O—C(O), R^(3,2,1) denotes H,C₁₋₆-alkyl, (C₁₋₃-alkyl)₂N—C₂₋₄-alkylene,(C₁₋₃-alkyl)₂N—C(O)—C₁₋₃-alkylene or R^(3,2,1.1)—C₂₋₄-alkylene,R^(3,2,1.1) denotes a group

R^(4.2) denotes H or H₃C, R^(4.3) denotes H, C₁₋₆-alkyl,(C₁₋₃-alkyl)₂N—C₂₋₄-alkylene, (C₁₋₃-alkyl)₂N—C(O)—C₁₋₃-alkylene orR^(4.3.1)—C₂₋₄-alkylene, and R^(4.3.1) denotes a group selected from

R^(5.1) denotes H, H₃C, R^(5.1.1)—O—C(O),R^(5.1.1)—O—C(O)—C₁₋₃-alkylene-NH,R^(5.1.1)—O—C(O)—C₁₋₃-alkylene-N(C₁₋₃-alkyl),R^(5.1.1)—O—C(O)—C₁₋₃-alkylene-O, R^(5.1.1)—O—C(O)—C₁₋₃-alkylene,R^(5.1.1)—O—C(O)—C(O),R^(5.1.1)—O—C(O)—C(O)—O—R^(5.1.1)—O—C(O)—C₁₋₃-alkylene-C(O) orR^(5.1.1)—O—C(O)—C₁₋₃-alkylene-C(O)—O, R^(5.1.1) denotes H, C₁₋₈-alkyl,phenyl, indanyl, pyridyl-methyl, HO—C₂₋₄-alkylene,C₁₋₆-alkyl-O—C₂₋₄-alkylene, H₂N—C₂₋₄-alkylene,(C₁₋₆-alkyl)-NH—C₂₋₄-alkylene, (C₁₋₆-alkyl)₂N—C₂₋₄-alkylene,H₂N—C(O)—C₁₋₃-alkylene, (C₁₋₆-alkyl)-NH—C(O)—C₁₋₃-alkylene,(C₁₋₆-alkyl)₂N—C(O)—C₁₋₃-alkylene, C₁₋₆-alkyl-C(O)—O—C₁₋₃-alkylene,C₁₋₆-alkyl-O—C(O)—O—C₁₋₃-alkylene, R^(5.1.1.1)—C(O)—C₁₋₃-alkylene orR^(5.1.1,2-)C₂₋₄-alkylene, R^(5.1.1.1) denotes a group selected from

R^(5.1.1.2) denotes a group selected from

R^(5.2) denotes H, H₃C, R^(5.2.1)—O—C(O)—C₁₋₃-alkylene,R^(5.2.1)—O—C(O)—C(O) or R^(5.2.1)—O—C(O)—C₁₋₃-alkylene-C(O), R^(5.2.1)denotes H, C₁₋₈-alkyl, phenyl, indanyl, pyridyl-methyl,HO—C₂₋₄-alkylene, C₁₋₆-alkyl-O—C₂₋₄-alkylene,C₁₋₆-alkyl-O—C₂₋₄-alkylene-O—C₂₋₄-alkylene, H₂N—C₂₋₄-alkylene,(C₁₋₆-alkyl)-NH—C₂₋₄-alkylene, (C₁₋₆-alkyl)₂N—C₂₋₄-alkylene,H₂N—C(O)—C₁₋₃-alkylene, (C₁₋₆-alkyl)-NH—C(O)—C₁₋₃-alkylene,(C₁₋₆-alkyl)₂N—C(O)—C₁₋₃-alkylene, C₁₋₆-alkyl-C(O)—O—C₁₋₃-alkylene,C₁₋₆-alkyl-O—C(O)—O—C₁₋₃-alkylene, R^(5.2.1.1)—C(O)—C₁₋₃-alkylene orR^(5.2.1,2-)C₂₋₄-alkylene, R^(5.2.1.1) denotes a group selected from

R^(5.2.1.2) denotes a group selected from

R^(5.2.1) denotes a group of formula

with the proviso that at least one of the groups R^(3.1), R^(3.2),R^(4.2), R^(5.1) or R^(5.2) denotes a group other than H, H₃C orC₁₋₃-alkyl, or a tautomer or salt thereof.
 6. A compound of the formulaI according to claim 1, wherein R¹ denotes a group of the formula

wherein R^(1.1) denotes H or H₃C—O, R² denotes a group selected from

R³-R⁴ together denote a group of general formulae IV

wherein R^(4.3) denotes H, C₁₋₆-alkyl, (C₁₋₃-alkyl)₂N—C₂₋₄-alkylene,(C₁₋₃-alkyl)₂N—C(O)—C₁₋₃-alkylene or R^(4.3.1)—C₂₋₄-alkylene, R^(4.3.1)denotes a group selected from

R^(5.1) denotes R^(5.1.1)—O—C(O), R^(5.1.1)—O—C(O)—C₁₋₃-alkylenl-NH,R^(5.1.1)—O—C(O)—C₁₋₃-alkylene-O, R^(5.1.1)—O—C(O)—C₁₋₃-alkylene,R^(5.1.1)—O—C(O)—C(O) or R^(5.1.1)—O—C(O)—C₁₋₃-alkylene-C(O), R^(5.1.1)denotes H, C₁₋₈-alkyl, phenyl, indanyl, pyridyl-CH₂, HO—C₂₋₄-alkylene,C₁₋₆-alkyl-O—C₂₋₄-alkylene, H₂N—C₂₋₄-alkylene,(C₁₋₆-alkyl)-NH—C₂₋₄-alkylene, (C₁₋₆-alkyl)₂N—C₂₋₄-alkylene,H₂N—C(O)—C₁₋₃-alkylene, (C₁₋₆-alkyl)-NH—C(O)—C₁₋₃-alkylene,(C₁₋₆-alkyl)₂N—C(O)—C₁₋₃-alkylene, C₁₋₆-alkyl-C(O)—O—C₁₋₃-alkylene,C₁₋₆-alkyl-O—C(O)—O—C₁₋₃-alkylene, R^(5.1.1.1)—C(O)—C₁₋₃-alkylene orR^(5.1.1,2-)C₂₋₄-alkylene, R^(5.1.1.1) denotes a group selected from

R^(5.1.1.2) denotes a group selected from

R^(5.2) denotes R^(5.2.1)—O—C(O)—C₁₋₃-alkylene, R^(5.2.1)—O—C(O)—C(O) orR^(5.2.1)—O—C(O)—C₁₋₃-alkylene-C(O), R^(5.2.1) denotes H, C₁₋₈-alkyl,phenyl, indanyl, pyridyl-CH₂, HO—C₂₋₄-alkylene,C₁₋₆-alkyl-O—C₂₋₄-alkylene, H₂N—C₂₋₄-alkylene,(C₁₋₆-alkyl)-NH—C₂₋₄-alkylene, (C₁₋₆-alkyl)₂N—C₂₋₄-alkylene,H₂N—C(O)—C₁₋₃-alkylene, (C₁₋₆-alkyl)-NH—C(O)—C₁₋₃-alkylene,(C₁₋₆-alkyl)₂N—C(O)—C₁₋₃-alkylene, C₁₋₆-alkyl-C(O)—O—C₁₋₃-alkylene,C₁₋₆-alkyl-O—C(O)—O—C₁₋₃-alkylene, R^(5.2.1.1)—C(O)—C₁₋₃-alkylene orR^(5.2.1,2)—C₂₋₄-alkylene, R^(5.2.1.1) denotes a group selected from

R^(5.2.1.2) denotes a group selected from

or a tautomer or salt thereof.
 7. A compound of the formula I accordingto claim 1, wherein R¹ denotes a group of the formula

wherein R^(1.1) denotes H or H₃C—O, R² denotes a group selected from

R³-R⁴ together denote a group of formulae IV

or a tautomer or salt thereof.
 8. A compound of the formula I accordingto claim 1, selected from the group consisting of: No. Structure (1)

(2)

(3)

(4)

(5)

(6)

(7)

(8)

(9)

(10)

(11)

(12)

(13)

(14)

(15)

(16)

(17)

(18)

(19)

(20)

(21)

(22)

(23)

(24)

(25)

(26)

(27)

(28)

(29)

(32)

(33)

(34)

(35)

(36)

(37)

(40)

(41)

(42)

(43)

(44)

(45)

(46)

(47)

(48)

(49)

(50)

(51)

(52)

(53)

(54)

(55)

(56)

(57)

(58)

(59)

(60)

(61)

(62)

(63)

(64)

(65)

(66)

(67)

(68)

(69)

(70)

(71)

(72)

(73)

(74)

(75)

(76)

(77)

(78)

(79)

(80)

(81)

(82)

(83)

(84)

(85)

(86)

(87)

(88)

(89)

(90)

(91)

(92)

(93)

(94)

(95)

(96)

(97)

(98)

(99)

(100)

(101)

(102)

(103)

(104)

(105)

(106)

(107)

(108)

(109)

(110)

(111)

(112)

(113)

(114)

(115)

(116)

(117)

(118)

(119)

(120)

(121)

(122)

(123)

(124)

(125)

(126)

(127)

(128)

(129)

(130)

(131)

(132)

(133)

(134)

(135)

(136)

(137)

(138)

(139)

(140)

(141)

(142)

(143)

(144)

(145)

(146)

(147)

(148)

(149)

(150)

(151)

(152)

(153)

(154)

(155)

(156)

(157)

(158)

(159)

(160)

(161)

(162)

(163)

(164)

(165)

(166)

(167)

(168)

(169)

(170)

(171)

(172)

(173)

(174)

(175)

(176)

(177)

(178)

(179)

(180)

(181)

(182)

(183)

(184)

(185)

(186)

(187)

(188)

(189)

(190)

(191)

(192)

(193)

(194)

(195)

(196)

(197)

(198)

(199)

(200)

(201)

(202)

(203)

(204)

(205)

(206)

(207)

(208)

(209)

(210)

(211)

(212)

(213)

(214)

(215)

(216)

(217)

(218)

(219)

(220)

(221)

(222)

(223)

(224)

(225)

(226)

(227)

(228)

(229)

(230)

(231)

(232)

(233)

(234)

(235)

(236)

(237)

(238)

(239)

(240)

(241)

(242)

(243)

(244)

(245)

(246)

(247)

(248)

(249)

(250)

(251)

(252)

(253)

(254)

(255)

(256)

(257)

(258)

(259)

(260)

(261)

(262)

(263)

(264)

(265)

(266)

(267)

(268)

(269)

(270)

(271)

(272)

(273)

(274)

(275)

(276)

(277)

(278)

(279)

(280)

(281)

(282)

(283)

(284)

(285)

(286)

(287)

(288)

(289)

(290)

(291)

(292)

(293)

(294)

(295)

(296)

(297)

(298)

(299)

(300)

(301)

(302)

(303)

(304)

(305)

(306)

(307)

(308)

(309)

(310)

(311)

(312)

(313)

(314)

(315)

(316)

(317)

(318)

(319)

(320)

(321)

(322)

(323)

(324)

(325)

(326)

(327)

(328)

(329)

(330)

(331)

(332)

(333)

(334)

(335)

(336)

(337)

(338)

(339)

(340)

(341)

(342)

(343)

(344)

(345)

(346)

(347)

(348)

(349)

(386)

(387)

(388)

(389)

(390)

(391)

(392)

(393)

(394)

(395)

(396)

(397)

(398)

(399)

(400)

(401)

(402)

(403)

(404)

(405)

(406)

(407)

(408)

(409)

(410)

(411)

(412)

(413)

(414)

(415)

(416)

(417)

(418)

(419)

(420)

(421)

(422)

(423)

(424)

(425)

(426)

(427)

(428)

(429)

(430)

(431)

(432)

(433)

(434)

(435)

(436)

(437)

(438)

(439)

(440)

(441)

(442)

(443)

(444)

(445)

(446)

(447)

(448)

(449)

(450)

(451)

(452)

(453)

(454)

(455)

(456)

(457)

(458)

(459)

(460)

(461)

(462)

(463)

(464)

(465)

(466)

(467)

(468)

(469)

(470)

(471)

(472)

(473)

(474)

(475)

(476)

(477)

(478)

(479)

(480)

(481)

(482)

(483)

(484)

(485)

(486)

(487)

(488)

(489)

(490)

(491)

(492)

(493)

(494)

(495)

(496)

(497)

(498)

(499)

(500)

(501)

(502)

(503)

(504)

(505)

(506)

(507)

(508)

(509)

(510)

(511)

(512)

(513)

(514)

(515)

(516)

(517)

(518)

(519)

(520)

(521)

(522)

(523)

(524)

(525)

(526)

(527)

(528)

(529)

(530)

(531)

(532)

(533)

(534)

(535)

(536)

(537)

(538)

(539)

(540)

(541)

(542)

(543)

(544)

(545)

(546)

(547)

(548)

(549)

(550)

(551)

(552)

(553)

(554)

(555)

(556)

(557)

or a tautomer or salt thereof.
 9. A compound of the formula I accordingto claim 1, selected from the group consisting of: No. Structure  (3)

 (4)

 (7)

 (59)

(112)

(113)

(462)

(463)

or a tautomer or salt thereof.
 10. The following compound of the formulaI according to claim 1: (3)

or a tautomer or salt thereof.
 11. The following compound of the formulaI according to claim 1: (4)

or a tautomer or salt thereof.
 12. The following compound of the formulaI according to claim 1: (7)

or a tautomer or salt thereof.
 13. The following compound of the formulaI according to claim 1: (59)

or a tautomer or salt thereof.
 14. The following compound of the formulaI according to claim 1: (112)

or a tautomer or salt thereof.
 15. The following compound of the formulaI according to claim 1: (113)

or a tautomer or salt thereof.
 16. The following compound of the formulaI according to claim 1: (462)

or a tautomer or salt thereof.
 17. The following compound of the formulaI according to claim 1: (463)

or a tautomer or salt thereof.
 18. A physiologically acceptable salt ofa compound according to claim 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14,15, 16 or
 17. 19. A pharmaceutical composition, containing a compoundaccording to claim 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14, 15, 16 or17, or a pharmaceutically acceptable salt thereof, together with one ormore inert carriers and/or diluents.
 20. A method for treating acondition selected from the group consisting of migraine, clusterheadaches and tension headaches, which method comprises administering atherapeutically effective amount of a compound according to claim 1, 2,3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14, 15, 16 or 17, or a pharmaceuticallyacceptable salt thereof.
 21. A method for treating non-insulin-dependentdiabetes mellitus (NIDDM), which method comprises administering atherapeutically effective amount of a compound according to claim 1, 2,3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14, 15, 16 or 17, or a pharmaceuticallyacceptable salt thereof.
 22. A method for treating irritable bowelsyndrome (IBS), which method comprises administering a therapeuticallyeffective amount of a compound according to claim 1, 2, 3, 4, 5, 6, 7,8, 9, 10, 11, 12, 14, 15, 16 or 17, or a pharmaceutically acceptablesalt thereof.
 23. A method for treating hot flushes in anoestrogen-deficient woman, which method comprises administering atherapeutically effective amount of a compound according to claim 1, 2,3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14, 15, 16 or 17, or a pharmaceuticallyacceptable salt thereof.